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Abstract 
 
Alzheimer’s disease (AD) is a devastating neurodegenerative disease characterized histopathologically by 
the accumulation of amyloid-β (Aβ) and hyperphosphorylation of tau protein. These two key proteins 
are major contributors to neuronal toxicity and disease progression; however, the causal factors 
initiating this toxic cascade in sporadic disease are unknown. We hypothesize that the specific 
degeneration of basal forebrain cholinergic neurons (BFCNs) and a decrease in neurotrophin 
availability - which occur coincidentally with the disease - are key regulators of aberrant Aβ 
accumulation and tau hyperphosphorylation, and could constitute the molecular basis of AD pathology 
in sporadic disease.  	  
Here we show that loss of BFCN innervation to the hippocampus of two pre-symptomatic mouse lines 
modelling the disease (APP/PS1 and pR5 (P301L) mice) causes a reduction in hippocampal and nerve 
growth factor (NGF) protein and/or brain-derived neurotrophic factor (BDNF). In APP/PS1 mice this 
correlates with memory and learning deficits in a Morris water maze task, which is not observed in 
unlesioned transgenic controls and wildtype littermates – indicating an exacerbation of the disease. Loss 
of BFCN hippocampal innervation in APP/PS1 mice also increases the amount of total 
Aβ in the hippocampus, but has no additional effects on levels of tau hyperphosphorylation. In 
contrast, memory deficits are not observed in pR5 tau transgenic mice following an equivalent loss of 
BFCN hippocampal innervation and reduction of neurotrophin levels. Moreover, hippocampal levels of 
tau and hyperphosphorylated tau were comparable to that of control pR5 tau transgenic mice. The role 
of neurotrophins in Aβ pathology in APP/PS1 mice was further assessed through viral knockdown of 
BDNF protein in the hippocampus, and treatment with a neurotrophic c29 peptide following loss of 
basal forebrain cholinergic neurons. Although reduction of BDNF did not cause increased Aβ levels, 
and treatment with c29 peptide did not reduce Aβ load in the hippocampus of APP/PS1 mice 
following loss of BFCN, c29 peptide was able to rescue behavioural deficits of aged unlesioned 
APP/PS1 mice. 
 
This work demonstrates that early cholinergic denervation of the hippocampus can trigger some 
features of Alzheimer’s disease, namely reduced neurotrophin expression and increased Aβ production, 
but does not alone cause tau hyperphosphorylation and aggregation. These results are consistent with 
the idea that tau pathology in AD may be downstream of Aβ pathology, and highlights the possibility 
that cholinergic dysfunction might be a major upstream contributing factor of sporadic Alzheimer’s 
disease. Although we show that neurotrophin dysfunction is insufficient by itself to induce or prevent 
	  	  
Aβ accumulation, enhancing neurotrophic signalling to provide cognitive benefit may be a viable 
treatment strategy. 
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1.1     Overview 	  
In Alzheimer’s disease (AD), the accumulation of amyloid beta (Aβ) protein into plaques and the 
hyperphosphorylation and aggregation of tau protein represent the main pathological hallmarks (Hardy 
and Selkoe, 2002). However, decades prior to cognitive symptoms and these pathological changes 
arising, a selective, prodromal loss of basal forebrain cholinergic neurons occurs (Whitehouse et al., 
1982). This selective dysfunction and the subsequent degeneration of these neurons underpins the 
cholinergic hypothesis of Alzheimer’s disease, and is the rationale behind current therapeutic 
treatments, which aim to rescue the loss of cholinergic signalling, and thereby improve cognitive 
function. 
 
Although the loss of basal forebrain cholinergic neurons correlate with cognitive deficits and brain 
amyloid and tau burden, whether these features are causally linked or merely molecular processes 
occurring in parallel is only now being addressed. One candidate by which the degeneration of the 
cholinergic system may be linked to AD pathology, are the family of growth factors called 
neurotrophins. The neurotrophins are required for cell survival and maintenance in the adult and 
developing nervous system, and a decline in or loss of neurotrophic signalling in the brain is associated 
with a range of neurodegenerative diseases, including AD (Kaplan and Miller, 2000, Tapia-Arancibia et 
al., 2008). 
 
This chapter presents an overview of AD, focusing on the pathological post-translational modifications 
of Aβ and tau protein, and an examination of the current transgenic mouse lines which model the 
disease. In particular, we focus on the cholinergic hypothesis and the loss of neurotrophic signalling that 
coincide with the pathological features of AD are discussed, with an emphasis on the potential 
mechanisms by which cholinergic and neurotrophic dysfunction might cause and/or exacerbate 
Alzheimer’s disease pathology.  
 
1.2     Alzheimer’s disease 
 
AD is a chronic, progressive neurodegenerative disease, and the most common form of dementia. It is 
characterized clinically by cognitive dysfunction including memory loss, psychiatric and behavioural 
disturbances such as depression (termed non-cognitive symptoms), and difficulties with activities of 
daily life (Burns, 2009). Although progression of the disease varies amongst individuals, average life 
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expectancy following diagnosis is between three to nine years (Querfurth and LaFerla, 2010). There is 
presently no cure for the disease, with current therapies treating only the symptoms, and disease-
modifying treatments remaining on the horizon. 
 
Around 1% of AD cases are a result of genetic heritability (familial AD) and the rest are idiopathic in 
origin and thus termed sporadic AD (Hardy and Selkoe, 2002). Familial AD is attributed to mutations 
in one of three genes involved in the production of Aβ protein: the amyloid precursor protein (APP) 
gene and the presenilin (PS) 1 and 2 genes (Hardy and Selkoe, 2002, Waring and Rosenberg, 2008). 
While age is the principle risk factor for the more prevalent, sporadic, form of the disease, the cause is 
still unknown. Many genetic and environmental risk factors have been identified with the best 
characterized of these being the ε4 allele of the apolipoprotein E (APOE) gene (Mahley and Huang, 
2006), which increases the risk of disease by a factor of just under three for each additional APOE ε4 
allele expressed (Corder et al., 1993, Blennow et al., 2006). However, regardless of origin, AD remains 
a devastating neurodegenerative disease with no cure. 	  
1.2.1     Alzheimer’s disease pathology  
AD is characterized by gross neuronal atrophy and degeneration, with corresponding enlargement of 
the cerebral ventricles in the brain. On a neuropathological level, dense insoluble protein deposits 
composed of Aβ protein can be observed in the extracellular space surrounding neurons. 
Hyperphosphorylated tau aggregates in the somal and dendritic compartments forming neurofibrillary 
tangles, and in distal dendrites as neuropil threads.  Post-translational modifications of these two key 
proteins, Aβ and tau, are the major focus of current research as they are widely considered the foremost 
contributors to the progressive synaptic loss that is characteristic of the disease.  
 
Aβ plaques are the classic, histopathological hallmark of AD. They consist of aggregated Aβ peptide 
formed from sequential cleavage of the transmembrane amyloid precursor protein (APP). APP is 
processed in two different pathways; the non-amyloidogenic pathway and the amyloidogenic pathway. 
In the non-amyloidogenic pathway, cleavage by α-secretase cleaves APP in half in the first step of 
formation of the non-toxic peptide, p3, followed by γ-secretase cleavage. This is the principle pathway 
in physiologically normal conditions and precludes the formation of toxic Aβ peptide. In the 
amyloidogenic pathway, β-secretase cleaves APP in lieu of α-secretase and is followed by γ-secretase 
cleavage to release 38-42 amino acid length Aβ peptides into the extracellular space (Wilquet and  	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Figure 1.1     Amyloidogenic and non-amyloidogenic proteolytic cleavage of the amyloid 
precursor protein 
Non-amyloidogenic and amyloidogenic processing of the amyloid precursor protein (APP). Cleavage of 
the transmembrane APP in the non-amyloidogenic pathway by #-secretase results in the release of 
secreted ectodomain of APP# (APPs#) followed by cleavage of the #-carboxy terminal fragment (CTF) 
by $-secretase to release the APP intracellular domain (AICD) and the non-toxic p3 fragment. In 
contrast, !-secretase cleavage in lieu of #-secretase cleavage results in APPs! fragment release and 
cleavage of the remaining membrane bound !-CTF, releasing toxic amyloid-! (A!) protein and AICD. 
Figure adapted from Wilquet and Strooper (2004). 
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Strooper, 2004; Figure 1.1). The normally less abundant form, Aβ42, is produced under pathological 
conditions and is more likely to oligomerise when released, forming fibrils which accumulate into  
amyloid plaques. In familial AD, mutations in the presenilins, the catalytic subunit of the β-secretase 
complex, drives the over-production of toxic Aβ peptide from its precursor APP through amyloidogenic 
processing (Waring and Rosenberg, 2008), however, little is known about what drives proteolytic 
cleavage and formation of toxic Aβ preferentially over the non-toxic processing of APP in sporadic AD, 
with an emerging idea being that sporadic AD is due to failed clearance of Aβ rather than 
overproduction (Hickman et al., 2008, Kurz and Perneczky, 2011).  	  
Tau is a microtubule-associated protein that binds to, and enhances the stability of microtubules 
(Reszka et al., 1995), and is consequently involved in vesicle transport and actin cytoskeleton 
organization. Additional roles in signal transduction and anchoring of phosphatases and kinases 
functions have also been attributed to tau protein (Ebneth et al., 1998, Jenkins and Johnson, 1998, 
Sontag et al., 1999, Maas et al., 2000). Tau protein consists of a projection domain, including an acidic 
and a proline-rich region, which interacts with cytoskeletal elements to determine the spacing between 
microtubules in axons, and an N-terminal part, involved in signal transduction pathways by interacting 
with proteins such as phopholipase C-γ (PLC-γ) and Src-kinases. The C-terminal part, referred to as 
the microtubule-binding domain, regulates the rate of microtubule polymerization and is involved in 
binding with functional proteins such as protein phosphatase 2A (PP2A) or PS1 (Sontag et al., 1999) 
(Figure 1.2). As it is just one member of a family of microtubule-associated proteins, knock out of tau 
in mice does not result in abnormalities and mice can reproduce normally (Tucker et al., 2001).  
 
Under physiological conditions tau is a phosphorylated protein, however, in AD, tau is phosphorylated 
to a higher degree at physiological sites and also at further ‘pathological’ residues, this is referred to as 
hyperphosphorylation of tau (Buee et al., 2000). This hyperphosphorylation of tau protein at specific 
residues leads to conformational changes from its natively unfolded, flexible shape into a more rigid 
compact state and causes tau to dissociate from microtubules, disrupting its role in their stabilisation. 
Dissociation from microtubules results in an increase in soluble tau that may lead to the assembly of tau 
filaments (Lichtenberg et al., 1988, Schweers et al., 1994, Goedert et al., 1995, Mandelkow et al., 
1996, Buee et al., 2000, Chen et al., 2004a). Hyperphosphorylated tau translocates from the axons and 
dendrites where it stabilizes microtubules, to somal and nuclear compartments. In these intracellular 
spaces, tau aggregates and forms abnormal tangles of paired-helical filaments (PHFs) that can be 
observed histologically (Medeiros et al., 2011). PHF-tau is a reliable marker of neurofibrillary tangles 
(NFTs) and correlates with dementia severity of AD patients (Bierer et al., 1995).  
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Figure 1.2     Schematic representation of tau protein and its functional domains  
Schematic representation of the functional domains of the largest tau human isoform (441 amino 
acids). The projection domain, including an acidic and a proline-rich region, interacts with cytoskeletal 
elements to determine the spacing between microtubules in axons. The N-terminal part is also involved 
in signal transduction pathways by interacting with proteins such as PLC-! and Src-kinases. The C-
terminal part, referred to as the microtubule-binding domain, regulates the rate of microtubule 
polymerization and is involved in binding with functional proteins such as protein phosphatase 2A or 
PS1.  
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Both Aβ and tau are critical in causing neuronal toxicity (Ittner and Gotz, 2011), however, the key 
factors that initiate these pathogenic events, the mechanisms regulating their neurotoxicity, and the 
involvement of other effector or intermediary proteins are still poorly understood. Gaining a better 
understanding of these triggering events would provide more specific targets on which we could focus 
for disease modifying therapeutic interventions. 
 
1.2.2      Mouse models of Alzheimer’s disease 
To better understand the etiological roles of amyloid plaques and tau NFTs, and to study specific, AD-
relevant neurodegenerative pathways, single, double, and triple transgenic mice modelling particular 
aspects of AD have been produced. These AD mouse models carry mutations in genes involved in the 
overproduction of Aβ and/or hyperphosphorylation and aggregation of tau protein. However it is 
important to note that no human AD patients have recorded mutations in the microtubule associated 
protein tau (MAPT) gene, thus mouse models that produce AD-like tau pathogenic changes are from 
other human diseases in which tau pathology is present, such as fronto-temporal dementia (FTD; Gotz, 
2001). As with all modelling of human diseases, the complexity of pathology and behavioural readout is 
limited, only recapitulating certain features of the disease in mice, and thus use of these models must be 
undertaken only with understanding of the caveats and limitations of these models.  
  
Single transgenic lines modeling just the amyloid component of AD, such as the Tg2576 and APP23 
mouse lines, express the familial APP Swedish mutation under different promoters and both show 
major deposition of Aβ and behavioural deficits in the Morris water maze (MWM) paradigm (Hsiao et 
al., 1996, Sturchler-Pierrat et al., 1997, Stalder et al., 1999). The identification of pathogenic 
mutations in the presenilin genes in AD led to the development of combinatorial transgenic mice with 
familial mutations in both human APP and PS1 transgenes expressed together - although this 
combination does not exist in human AD (Gotz et al., 2004). These mice showed a greater elevation in 
Aβ levels than single transgenic mice, and learning and memory deficits appear at an earlier age 
(Borchelt et al., 1996, Holcomb et al., 1998, Edwards et al., 2014). These single and double transgenic 
mice provide researchers with models suited to test therapeutic strategies aimed at reducing amyloid 
pathology, however these mice tend to not reproduce AD-relevant tau pathology. Transgenic mice 
expressing both mutant tau alone or mutant APP and tau, have been generated following the 
identification of pathogenic mutations in tau in FTDP-17 (FTD with Parkinsonism). These mice 
model aspects of tau pathology similar to that of human AD, such as tau hyperphosphorylation and 
NFT formation (Lewis et al., 2000, Lewis et al., 2001, Tanemura et al., 2001). Additionally, triple 
transgenic AD mice (3xTg-AD) expressing mutant APP, PS1 and tau have also been developed which 
	   9 
develop age-related neuropathology including plaques and tangles (Oddo et al., 2003). 
 
However, regardless of transgene expression, the majority of these mouse models do not present with 
the marked loss of basal forebrain cholinergic neurons (BFCNs), which is a major feature of the disease. 
Although a small but significant cortical cholinergic deficit have been reported in APP23 mice and a 
small reduction in cholinergic cells in the basal forebrain of aged 3xTg-AD mice, there is no frank, 
prodromal degeneration of BFCNs as is observed in human AD patients (Boncristiano et al., 2002, 
Perez et al., 2011). Thus, mouse models of AD which present with the triad of Aβ plaques, tau tangles 
and a cholinergic phenotype, has posed a challenge until recently. As I will discuss later on in this thesis, 
selective immunolesioning of the cholinergic basal forebrain in amyloid and tau transgenic AD mouse 
models has allowed several groups, including our own, to more completely reproduce the AD triad 
(Gil-Bea et al., 2012; Laursen et al., 2013; Ramos-Rodriguez et al., 2013) and investigate links between 
the cholinergic hypothesis and the amyloid and tau hypothesis of AD aetiology.  
 
1.3     The cholinergic hypothesis 
 
The cholinergic hypothesis of AD is the original hypothesis proposed to explain AD and the one on 
which current drug therapies are based. It emerged from the hope that a defined neurochemical change 
could be observed in AD patients and later lead to targets in which therapeutics could test. Reports that 
levels of choline acetyltransferase (ChAT), the enzyme involved in synthesis of acetylcholine (ACh), 
were reduced in the neocortex of AD patients (Perry et al., 1977, Bowen et al., 1982) as well as reduced 
levels of choline uptake (Rylett et al., 1983), decreased efflux of ACh (Nilsson et al., 1986) and the loss 
of cholinergic neurons from the basal forebrain (Whitehouse et al., 1982), placed disrupted cholinergic 
signalling at the forefront. During this period, ACh’s essential role in learning and memory was 
emerging and this combined with the observed loss of cholinergic activity in the brains of AD patients 
led to the development of the cholinergic hypothesis of AD (Bartus et al., 1982). 	  
Current therapeutic strategies are aimed at restoring the loss of cholinergic signalling by inhibiting the 
breakdown of ACh by acetylcholine esterase (AChE) in the synaptic cleft, with targeted 
acetylcholinesterase inhibitors (AChEI) such as donepezil, rivastigmine and galantamine (Pohanka, 
2011). However, although small improvements in measures of cognition and functionality are 
improved, 2 years on overall progression of the disease is equivalent to placebo treated controls 
(Courtney et al., 2004, Birks and Harvey, 2006). Moreover, AD patients demonstrate divergent 
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responses to the effects of AChEIs, with the underlying reasons behind ‘responders’ and ‘non-
responders’ still unclear (Connelly et al., 2005). 	  
1.3.1     The cholinergic basal forebrain 
The cholinergic system is one of the most extensive and widely dispersed neurotransmitter systems in 
the brain. The basal forebrain, a collection of anatomical structures located ventral to the striatum, 
contains a heterogeneous mixture of cell types including the brain’s largest cholinergic neuron 
population. Cholinergic neurons are identified by the presence of the neurotransmitter ACh and the 
enzyme choline acetyltransferase (ChAT), responsible for the catalysis of acetyl coenzyme A and choline 
into ACh. The cholinergic basal forebrain is divided into distinct areas including the medial septum 
(MS), vertical (VDB) and horizontal (HDB) limbs of the diagonal band of Broca and the nucleus 
basalis (NB), which encompasses the substantia innominata (SI) (Baxter and Chiba, 1999, Zaborszky et 
al., 1999). 
 
Basal forebrain cholinergic neurons (BFCNs) are the major source of cholinergic projections to regions 
throughout the brain, including the hippocampus and cortex (Figure 1.3). More specifically, tracing 
studies mainly in rats, have established that projection patterns from the basal forebrain are 
topographically organized in roughly mediolateral and anteroposterior planes. For instance, the 
hippocampus receives afferents from the MS/VDB, 35-45% of which are cholinergic, and provide the 
major cholinergic innervation of the hippocampus via the septohippocampal pathway (Rye et al., 1984, 
Bloem et al., 2014). Alternatively, the SI-NB complex primarily innervates the cortex, of which 80-
90% of projections are cholinergic (Rye et al., 1984). Projecting BFCNs have gained particular 
attention since their role in mediating cognitive functions such as attention, memory and information 
processing have been characterised (Baxter and Chiba, 1999). This has been supported by work in 
animals with selective lesioning of BFCNs, resulting in disruptions of various forms of attentional 
processing in rodents (Waite et al., 1999, Risbrough et al., 2002) and learning and memory deficits in 
primates (Fine et al., 1997, Ridley et al., 1999).  	  
Many groups have detailed the connection between the cholinergic basal forebrain and the 
hippocampus in relation to learning and memory, with the release of ACh being one of the factors 
mediating this interaction. ACh is implicated in higher functions such as associative learning and 
memory (Hasselmo, 2006), and its release is observed in the hippocampus during spatial memory 
formation (Giovannini et al., 1998). ACh mediates hippocampal learning and memory through 
regulation of long-term potentiation (LTP) and synaptic consolidation (Auerbach and Segal, 1994,  
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Figure 1.3     Basal forebrain cholinergic neuron projections in the murine brain 
Diagram of a representative sagittal section of a mouse brain showing projections of the basal forebrain 
cholinergic system. The basal forebrain is located ventral to the striatum and consists of distinct nuclei: 
the medial septum (MS), vertical (VDB) and horizontal diagonal band of Brocas (HDB), nucleus 
basalis (NB), and substantia innominata (SI). The MS, VDB and HDB project to the olfactory bulb, 
cortex and hippocampus and the NB and SI project mainly to the cortex. Figure adapted from Woolf 
(1991).
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Ovsepian et al., 2004, Drever et al., 2011). Moreover, ACh is a presynaptic modulator of hippocampal 
excitatory transmission, promoting long-term synaptic plasticity and upregulating brain-derived 
neurotrophic factor (BDNF) protein and Arc expression in the hippocampus, which are involved in 
synaptic consolidation (Fernandez de Sevilla et al., 2008, Gil-Bea et al., 2011). Thus ACh signalling 
from the cholinergic basal forebrain to the hippocampus is vital for hippocampal function and normal 
cognition, and deterioration of this brain structure in human disease, not surprisingly, has devastating 
consequences. 
 
1.3.2     Cholinergic hypofunction in Alzheimer’s disease 
As a result of their involvement in cognitive functions, deterioration of BFCN projections have 
consequences on mental function. An association between cognitive impairment and alterations in 
BFCNs is seen in normal aging; aged mice have fewer and smaller cholinergic cells in the basal 
forebrain which is correlated with poorer performances in learning and memory tasks compared to their 
younger counterparts (Gallagher and Colombo, 1995). Consistent with this, abnormalities in 
cholinergic innervation have been associated with age-associated cognitive disorders such as Alzheimer’s 
disease (AD) and senile dementia (Whitehouse et al., 1982) in which degeneration in these pathological 
states is elevated compared to normal aging. Gaykema et al., (1992) reported a severe reduction in 
cholinergic fibers in the cortex and abnormalities, such as large globular swellings, in surviving 
cholinergic fibers in autopsy brains of AD patients. Moreover, the decline in cholinergic neuron 
number that occurs in AD has been correlated with the degree of cognitive impairment seen in the 
disease (Perry et al., 1977), and similarly, ACh deficits in the cortex and hippocampus are correlated 
with dementia severity (Shinotoh et al., 2000). However, recent evidence stresses neuronal atrophy 
rather than cell death as the underpinning feature of AD.  
 
More recent findings using magnetic resonance imaging (MRI) confirm these finding, demonstrating 
significant basal forebrain loss in AD and mild cognitively impaired (MCI) patients compared to age-
matched controls (Hall et al., 2008, Muth et al., 2010, Grothe et al., 2013), that is greater than the rate 
of atrophy associated with normal aging (Grothe et al., 2012). Moreover, collaborative efforts such as 
the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Australian Imaging, Biomarker & 
Lifestyle Flagship Study of Ageing (AIBL) initiative along with the use of Aβ biomarkers such as 
Pittsburg compound B (PiB) have further demonstrated an association between basal forebrain atrophy 
and Aβ burden in AD (Grothe et al., 2014, Teipel et al., 2014, Kerbler et al., 2015). 	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Loss of cholinergic signalling in AD is a primary contributor to memory impairments, however the 
exact mechanisms remain to be defined. The net result of loss of ACh signalling has been addressed 
through loss of function studies, where deletion of muscarinic ACh receptors in transgenic AD mice 
resulted in an exacerbation of cognitive impairment. However it also resulted in an increase in plaque 
and tangle levels, and changes in glycogen synthase kinase-3β (GSK3β) and protein kinase C activity 
(Medeiros, 2011; Davis, 2010). Along with the expected consequences of reduced ACh on memory 
mechanisms, such as changes in synaptic plasticity and consolidation in the hippocampus, impaired 
cholinergic function also directly regulates AD-related signalling mechanisms. Reduced cholinergic 
signalling has been shown to affect the expression and processing of APP, for example loss of subcortical 
cholinergic innervation induces cortical APP mRNA and increased levels of secreted APP into the 
cerebrospinal fluid (CSF) (Wallace and Haroutunian, 1993, Schliebs, 2005). Futhermore, induced 
cholinergic hypofunction results in downregulation of BDNF (Gil-Bea et al., 2011), a member of the 
neurotrophin family which has been shown to be directly involved in the regulation of AD pathology. 
 
1.4     Neurotrophins 
 
1.4.1     Neurotrophins and their receptors 
Neurotrophins are the classical growth factors that regulate neuronal survival, maintenance and cell 
death during both development and adulthood (Kaplan and Miller, 2000). They belong to a family of 
small homodimeric proteins that are synthesized as active precursors, or proneurotrophins, before 
conversion to a mature processed form (Seidah et al., 1996). The prototypic neurotrophin, nerve 
growth factor (NGF), was identified by Rita Levi-Montalcini and Stanley Cohen in their seminal work 
(Levi-Montalcini, 1987) which led to their receipt of the 1986 Nobel Prize in Physiology or Medicine. 
In the 1980’s a functionally similar neurotrophin was identified; BDNF, followed closely by the 
cloning of neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4) (Friedman and Greene, 1999). 
 
Two classes of transmembrane glycoproteins are responsible for the regulation of cellular responses to 
neurotrophins: the Trk members of the tropomyosin-related kinase superfamily (Soppet et al., 1991) 
and the pan-neurotrophin receptor, p75NTR (Johnson et al., 1986, Radeke et al., 1987). Trk receptor 
subtypes show preferential binding affinity to specific neurotrophins: TrkA with NGF, TrkB with 
BDNF and NT-4 and TrkC with NT-3, while p75NTR can bind all neurotrophins (Chao, 2003). 
Neurotrophins bind to their respective Trk receptors as dimers which promotes receptor dimerization 
and the transphosphorylation of tyrosine residues within the intracellular domain. This leads to the 
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formation of docking sites to which different adaptor proteins and signalling enzymes can bind to and 
initiate signal transduction cascades (Huang and Reichardt, 2003). Trk receptor activation promotes 
the transcription of prosurvival and pro-differentiation genes through activated Raf and the extracellular 
signal-regulated kinase (ERK) pathway as well as phosphatidyl inositol-3 kinase (PI3K) and its 
serine/threonine kinase target, Akt. Activation of these signalling proteins is commonly used as readouts 
for Trk receptor signalling. Synaptic plasticity is regulated through binding of BDNF to its TrkB 
receptor which promotes the activation of PLC-γ1 and subsequent stimulation of Ca2+- and PLC-
regulated pathways (Reichardt, 2006). 
 
The pan-neurotrophin receptor p75NTR is a type I transmembrane receptor of the tumor necrosis factor 
(TNF) receptor superfamily (Reichardt, 2006). Structurally, p75NTR consists of an extracellular domain 
(ECD) comprising of four tandemly arranged cysteine rich domains, characteristic of the TNF family, 
which are responsible for the binding of neurotrophins (Baldwin et al., 1992). The intracellular domain 
(ICD), although lacking any catalytic activity, encompasses a death domain (Liepinsh et al., 1997) and 
several sites available for protein phosphorylation and interaction with downstream signalling molecules 
(Grob et al., 1985, Roux and Barker, 2002). Neurotrophin binding to p75NTR can trigger three 
alternate pathways; activation of NF-κB which leads to transcription of prosurvival genes; initiation of 
the Jun kinase pathway which directs transcription of proapoptotic genes; and regulation of Rho which 
controls growth cone motility (Reichardt, 2006). Importantly, p75NTR can also augment or diminish 
Trk responsiveness to the neurotrophins, either through direct interaction with the receptor or through 
influence on downstream Trk signalling pathways (Roux and Barker, 2002, Nykjaer et al., 2005). 	  
1.4.2     Neurotrophic function in the hippocampus 
Neurotrophins have been identified as key regulators in many aspects of neuronal formation and 
function as well as synapse development and function (Reichardt, 2006, Park and Poo, 2013). A clear 
role for BDNF in synapse formation, function and plasticity in the mature brain has also been 
demonstrated. BDNF is found throughout the brain pre- or post-synaptically in axonal and dendritic 
compartments and throughout cerebellar, hippocampal and cortical regions (Vicario-Abejon et al., 
2002). Pro-BDNF is released through either constitutive secretion or activity-dependent release, 
suggesting that the mature form of the homodimeric BDNF arises mainly from extracellular cleavage 
within the synapse (Lessmann and Brigadski, 2009).  In a healthy brain, continued ACh release from 
BFCNs onto excitatory neurons of the hippocampus maintains activity-dependent BDNF synthesis and 
release (Hartmann et al., 2001). This BDNF acts in an autocrine manner through its receptor, TrkB, to 
trigger synthesis of dendritic proteins and modulate LTP, thus impacting on the molecular machinery 
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of memory consolidation in the hippocampus (Hartmann et al., 2001, Gil-Bea et al., 2011). In a mouse 
model of cholinergic hypofunction, the loss of BFCN projections that stimulate activity-dependent 
neurotrophin release contributes to the selective decrease in BDNF protein and consequent 
dysregulation of downstream signalling in the hippocampus (Gil-Bea et al., 2011). 	  
1.4.3     Neurotrophins and the regulation of AD pathology 
The involvement of neurotrophins and their cognate receptors in a range of pathophysiological 
conditions of the nervous system provides us with strong motivation to investigate, and further 
understand, the nuances in these signalling pathways. In particular, dysregulation of neurotrophin 
signalling may contribute to neurodegenerative conditions such as AD, and neurological conditions 
including mood disorders (Dawbarn and Allen, 2003, Kruttgen et al., 2003, Bronfman et al., 2007).  
 
In AD patients specifically, levels of neurotrophins and their receptors generally decline during the 
progression of the disease. Both BDNF mRNA and protein have been shown to be selectively decreased 
in the hippocampus and cortex compared to normal aged controls (Phillips et al., 1991), and levels of 
proNGF, the NGF precursor, have been shown to be elevated in the parietal cortex, possibly indicating 
a role for disturbances in synthesis of NGF in AD (Fahnestock et al., 2001). Moreover, the levels of 
TrkA gene expression and TrkA receptor expression is decreased in the basal forebrain and cortex 
(Mufson et al., 1996, Hock et al., 1998), and TrkB receptor undergoes a similar declining profile in 
AD (Ferrer et al., 1999, Ginsberg et al., 2006). In contrast, levels of p75NTR are increased in AD patient 
brains (Apelt et al., 2002, Hu et al., 2002, Ginsberg et al., 2006), which may allow it to mediate Aβ 
signalling and toxicity of the basal forebrain (Yaar et al., 1997, Sotthibundhu et al., 2008, Coulson et 
al., 2009). As neurotrophins are responsible for the continued survival and phenotypic maintenance of 
mature neurons, it is suggested that a reduction in neurotrophin availability in the central nervous 
system may contribute to, or trigger, the pathocascade of AD. 	  
The relationship between neurotrophins and AD pathology has been demonstrated in vitro where 
stimulation of cultured neurons with BDNF causes a rapid decrease in tau phosphorylation through 
activation of phosphoinositide 3-kinase (PI3K) and GSK3β pathways following activation of TrkB 
(Elliott et al., 2005). Direct regulation of APP secretion by neurotrophins has been shown in vitro 
following TrkA receptor stimulation and mediated by the MAP kinase pathway (Rossner et al., 1999). 
Moreover, BDNF-TrkB signalling has been shown to have a protective effect against Aβ-induced 
neurotoxicity in cultured cortical neurons (Arancibia et al., 2008). Neurotrophin deprivation of 
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neuron-like PC12 cells or cultured rat hippocampal neurons results in overproduction of Aβ protein 
and concomitant apoptotic cell death (Matrone et al., 2008a, Matrone et al., 2008b). Changes in tau 
phosphorylation state have also been shown to be temporally related to aberrant Aβ generation in 
neurotrophin-starved rat hippocampal neurons, a process that occurs through the Akt-GSK3β 
signalling pathway (Amadoro et al., 2011). In addition, Aβ antibodies or GSK3β inhibitors reduce the 
axonal transport defects induced by neurotrophin withdrawal (Amadoro et al., 2011). Thus, 
neurotrophin-mediated pathways have the potential to regulate Aβ and tau pathology. Understanding 
whether these mechanisms are in play in vivo, and deciphering whether loss of neurotrophic signalling 
is causative, rather than merely occurring in parallel, or in response, to AD pathology, would contribute 
significantly to our understanding of the aetiology of AD. 
 
1.5     Project rationale 
 
As discussed in this introduction, Alzheimer’s disease is a devastating neurodegenerative disease in 
which the causal factors that initiate the toxic accumulation of Aβ and tau protein pathology are 
unknown. The persisting hypothesis of cholinergic degeneration underpinning cognitive impairment is 
expanding to encompass the possibility that cholinergic hypofunction also triggers other disease 
mechanisms such as the loss of neurotrophin expression and induction of Aβ and/or tau pathology. 
Support for this widening of the hypothesis has come not only from in vitro studies but also by 
inducing BFCN degeneration in AD mouse models. However, there remain pathways and mechanisms 
that are yet to be investigated, such as the impact of cholinergic dysfunction on tau pathology alone, 
without the influence of amyloid pathology. Moreover the precise mechanisms and the involvement of 
the neurotrophin family and its regulation of pathology in these cholinergic hypofunction AD models 
remain yet to be fully explored. 	  
These questions address the fundamentals of Alzheimer’s disease progression, and bring the role of 
neurotrophic regulation of pathology to the forefront. Direct manipulation of cholinergic signalling and 
of neurotrophic factor expression in these mouse models, will lead to greater understanding of disease 
mechanisms. 
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1.6     Aims and hypothesis 	  
1.6.1      Aim 
The overarching aim of this project is to gain a better understanding of the molecular mechanisms 
underpinning AD progression by resolving the interaction between basal forebrain cholinergic neuron 
degeneration, reduction in neurotrophin availability and the initiation or exacerbation of AD 
pathology. 	  
1.6.2      Hypothesis 
We hypothesize that loss of BFCNs in genetically susceptible mice will cause an acceleration in the 
development of AD pathology. Moreover, we hypothesize the involvement of the neurotrophin family 
in this exacerbation, with a reduction in neurotrophic signalling resulting in an increase in pathology. 
When neurotrophic signalling is enhanced or reduced experimentally, we expect a consequent 
reduction or elevation of pathology, respectively. 	  
1.6.3      Questions 
1. Does cholinergic hypofunction trigger early amyloid pathology and cognitive deficits in 
presymptomatic amyloid transgenic mice? 
 
2. Does cholinergic hypofunction trigger early tau pathology and cognitive deficits in presymptomatic 
tau transgenic mice? 	  
3. Does a selective reduction in hippocampal BDNF levels directly affect amyloid pathology and 
cognitive deficits in susceptible amyloid transgenic mice? 	  
4. Does enhancement of neurotrophic signalling rescue amyloid pathology or cognitive deficits in 
amyloid transgenic mice with basal forebrain cholinergic neuron degeneration? 	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2.1     Antibodies  
 
2.1.1     Primary antibodies 
Antibody	   Species/Class	   Supplier	   Use	   Dilution	   Incubation	  
β-amyloid (amino 
acid residues 1-16) Mouse/mAb 
Covance 
Signaling IHC 1:500 
Overnight, room 
temperature 
Akt Mouse/mAb Cell Signaling WB 1:1000 Overnight, 4˚C 
p-Akt (Ser473) Rabbit/mAb Cell Signaling WB 1:1000 Overnight, 4˚C 
AT8 (pTau, 
pSer202/pThr205) Mouse/mAb 
Thermo 
Scientific WB 1:1000 Overnight, 4˚C 
AT100 (pTau, 
pSer212/pThr214) Mouse/mAb 
Thermo 
Scientific WB 1:1000 Overnight, 4˚C 
AT180 (pTau, 
pThr231) Mouse/mAb 
Thermo 
Scientific WB 1:1000 Overnight, 4˚C 
AT270 (pTau, 
pThr181) Mouse/mAb 
Thermo 
Scientific WB 1:1000 Overnight, 4˚C 
ChAT Goat/pAb Millipore WB IHC 1:1000 Overnight, 4˚C 
ERK (p44/42 
MAPK) Rabbit/pAb Cell Signaling WB 1:1000 Overnight, 4˚C 
p-ERK (phospho-
p44/42 MAPK) Rabbit/pAb Cell Signaling WB 1:1000 Overnight, 4˚C 
GAPDH Rabbit and Mouse/mAb Cell Signaling WB 1:4000 Overnight, 4˚C 
GFAP Rabbit/mAb Dako WB 1:1000  Overnight, 4˚C 
GFP Rabbit/mAb Rabbit IHC 1:1000 Overnight, room temperature 
GSK3β Rabbit/mAb Cell Signaling WB 1:1000 Overnight, 4˚C 
p-GSK3β (Ser9) Rabbit/mAb Cell Signaling WB 1:1000 Overnight, 4˚C 
HT7 (pan-Tau, 
residues 159-163) Mouse/mAb 
Thermo 
Scientific WB 1:1000 Overnight, 4˚C 
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Parvalbumin Mouse/mAb Millipore IHC 1:1000 Overnight, room temperature 
pSer235 (pTau) Rabbit/pAb Thermo Scientific WB 1:1000 Overnight, 4˚C 
pSer262 (pTau) Rabbit/pAb Thermo Scientific WB 1:1000 Overnight, 4˚C 
pSer422 (pTau) Rabbit/pAb Thermo Scientific WB 1:1000 Overnight, 4˚C 
Synaptophysin Mouse Dako WB 1:1000 Overnight, 4˚C 
Tau5 Mouse/mAb Merck Millipore WB 1:1000 Overnight, 4˚C 
Tyr18 Mouse/mAb MédiMabs WB 1:5000 Overnight, 4˚C 
  
 
2.1.2     Secondary antibodies 
Antibody	   Supplier	   Use	   Dilution	   Incubation	  
Donkey anti-rabbit  
Alexa Fluor 488 Life Technologies IHC 1:1000 
2 hours, room 
temperature 
Donkey anti-mouse 
Alexa Fluor 647 Life Technologies IHC 1:1000 
2 hours, room 
temperature 
Donkey anti-goat Alexa 
Fluor 488 Life Technologies IHC 1:1000 
2 hours, room 
temperature 
Donkey anti-rabbit 680 Molecular Probes WB 1:50,000 2 hours, room temperature 
Donkey anti-mouse 800 Molecular Probes WB 1:50,000 2 hours, room temperature 
Biotinylated donkey 
anti-goat 
Jackson 
ImmunoResearch IHC 1:1000 
24 hours, room 
temperature 
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2.2     Animals 
 
All animal experiments were performed within the guidelines of, and approved by, the institutional 
Animal Ethics Committee. Mice were housed in the Queensland Brain Institute (QBI) Specific 
Pathogen Free (SPF) Facility on a 12-hour dark/light cycle with water and standard chow available ad 
libitum. Genotyping for each strain was performed by the Australian Equine Genetics Research Centre 
(AEGRC).  
 
2.2.1     APP/PS1 amyloid transgenic mice 
The APPswe/PSIΔE9 mice (Jax Mice Database strain B6C3-Tg(APPswe,PSEN1dE9)85Dbo/J; stock 
number #004462) are double transgenic mice which express human APP695 with Swedish mutations 
(K595N and M596L) and mutant human presenilin 1 carrying the exon-9-deleted variant (Jankowsky 
et al 2001; Jankowsky 2004). These transgenes are under control of independent mouse prion protein  
promoter elements, thus expression is restricted to the CNS. These mutations are associated with early-
onset Alzheimer’s disease and are accordingly characterised by increased deposition of amyloid-
β deposits and deficits in spatial learning and memory. Transgenic mice were obtained from a colony 
housed within the QBI animal facility, a specific pathogen free environment. For our research, 
hemizygous transgenic males aged 6 months were used, with age and gender matched non-transgenic 
littermate controls. 
 
2.2.2     pR5 (P301L) tau transgenic mice 
The pR5 (P301L) tau transgenic mice were generated as previously described (Gotz et al., 2001). These 
mice harbor the longest human tau isoform containing the hereditary FTD with parkinsonism (FTDP) 
P301L mutation under the control of the neuron-specific mouse Thy1.2 promoter (Luthi et al., 1997). 
Transgenic mice were acquired from a colony maintained in the QBI SPF facility. For our research, 
hemizygous transgenic males and females aged 3 and 7 months were used, with age and gender 
matched non-transgenic littermates used as controls. Results from males and females were quantified 
separately; however as no significant differences were found between the sexes, data were pooled and 
further analyses were conducted as mixed gender cohorts. 
 
2.2.3     Tau knockout mice (Tau KO; Mapttm1(EGFP)Klt) 
The tau knockout mice (Tau KO; Jax Mice Database strain Mapttm1(EGFP)Klt; stock number #004779) 
were generated as previously described (Gotz et al., 2001). Briefly, these mice have a knock in of the 
EGFP (enhanced green fluorescent protein) coding sequence into exon 1 which disrupts expression of 
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the Mapt (microtubule associated protein tau) gene and expression of cytoplasmic EGFP fused to the 
first 31 amino acids (Tucker et al., 2001). Western blot analysis of lysates confirms the absence of tau 
protein. The Götz Lab maintains these tau KO transgenic mice in the QBI animal facility. For our 
research, a single homozygotic male was used as a negative control for tau expression in Western 
blotting experiments.  
 
2.2.4    BDNF2lox transgenic mice 
The BDNF2lox mice (Jax Mice Database strain Bdnftm3Jae; stock number #004339) possess loxP sites 
flanking exon 5 of the BDNF gene. The strain originated on a mixed C.129S4 background, and has 
been maintained as a homozygote on a mixed C57BL/6, C.129S4, BALB/c background. Transgenic 
mice were obtained from a colony maintained in the QBI SPF facility. For our experiments 
heterozygous and homozygous males aged 9 months were used to test the efficacy of the adeno-
associated virus (AAV)-Synapsin-Cre-GFP in bilateral hippocampal infusions.  	  
2.2.5     APP/PS1 x BDNF2lox transgenic mice 
Transgenic APP/PS1 mice were obtained from a colony maintained in the QBI SPF facility and were 
bred with BDNF2lox mice producing APP/PS1 x BDNF2lox (heterozygous) or APP/PS1 transgene 
negative x BDNF2lox (heterozygous) mice. For our experiments, BDNF2lox (heterozygous) x APP/PS1 
male mice were used with age, gender and genotype-matched littermates as controls. Mice were used at 
7 and 9 months of age and results were quantified separately; however as no significant differences were 
found between the ages, data were pooled and further analyses were conducted as mixed age cohorts.  
In the results chapters, BDNF2lox (heterozygous) mice are referred to as BDNF fl/wt mice and BDNF2lox 
(homozygous) mice are referred to as BDNF fl/fl. 
 
2.3     Surgical techniques 
 
2.3.1     Anaesthetics, analgesics and antibiotics  
Mice weighing under 35 g were anesthetized for surgery by an intraperitoneal (i.p.) injection of 
ketamine (100 mg/kg; Provet) and the muscle relaxant xylazine (10 mg/kg). For mice over 35 g, a 
combination of zoletil (40 mg/kg) and xylazine (10 mg/kg) were used. Immediately after surgery and 24 
hours post-surgery, mice were injected subcutaneously with the analgesic torbugesic (2 mg/kg), and the 
antibiotic Baytril (5 mg/kg; Bayer Corporation).  
 
2.3.2     Stereotaxic surgery: basal forebrain lesion 
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To lesion basal forebrain cholinergic neurons via stereotaxic injection of p75-saporin, mice were placed 
in a stereotaxic frame (David Kopf Instruments), with the skull in a flat position. The skin around the 
incision site was cleaned with Betadine before a 1 cm cut was made sagitally along the head exposing 
the skull and allowing Bregma to be seen. After drilling through the skull with a handheld drill, a single 
infusion of murine p75-saporin (0.4 mg/ml; Advanced Targeting Systems) or control rabbit IgG-
saporin (0.4 mg/ml) was measured using a 30G needle attached to a 5 ml Hamilton syringe and pump 
(World Precision Instruments). The needle was lowered into the medial septum (A-P 0.9 mm; M-L 0 
mm; D-V 4.2 mm from Bregma) (Franklin and Paxinos, 2007), and the toxin was infused at a rate of 
0.400µl/min (1.5µl total volume). The needle was then left in place for 5 minutes to allow for 
diffusion. Post surgery, mice were placed in a temperature controlled chamber (28˚C) until awake, then 
transferred into single animal housing units. 
 
2.3.3     Stereotaxic surgery: hippocampal AAV-Synapsin-Cre-GFP injection 
To knockdown BDNF gene expression in the hippocampus via stereotaxic injection of AAV-Synapsin-
Cre-GFP (SignaGen Laboratories), mice were placed in a stereotaxic frame (David Kopf Instruments), 
with the skull in a flat position (Figure 2.1A). The skin around the incision site was cleaned with 
Betadine before a 1.5 cm cut was made sagitally along the head above Bregma. After drilling through 
the skull with a handheld drill, a single infusion of AAV-Synapsin-Cre-GFP (Serotype 8; 1x1013 
genome copies/ml; SignaGen Laboratories) was measured using a 30G needle attached to a 5 ml 
Hamilton syringe and pump (World Precision Instruments). In the initial pilot study, the needle was 
lowered into the hippocampus at A-P -2 mm; M-L ±1.3 mm; D-V 2 mm from Bregma, and this was 
amended in further experiments to A-P -2 mm; M-L ±1.3 mm; D-V 1.8 mm (Franklin and Paxinos, 
2007), and the virus was infused at a rate of 0.400 µl/min (2 µl total volume). The needle was then left 
in place for 5 minutes to allow for diffusion of the virus in the hippocampus. The same protocol was 
followed to infuse AAV-Synapsin-Cre-GFP into the hippocampus of the contralateral hemisphere in 
the same mice (Figure 2.1B). As with basal forebrain lesioning, mice were placed in a temperature 
controlled chamber (28˚C) post surgery until awake, then transferred into single animal housing units. 	  
2.3.4     c29 peptide  
c29 peptide (KRWNSCKQNKQGANSRPVNQTPPPEGEKL; MW: 3752) and its randomly 
scrambled peptide control, SC (scrambled; SKGQVCRNQPGQNKPEPANKSWKETPLRN) were 
synthesized by James I. Elliott (W. M. Keck Biotechnology Facility, Yale University). c29 peptide is a 
soluble peptide consisting of a 29 amino acid residue peptide of the juxtamembrane intracellular  
domain sequence of p75NTR (Coulson et al., 2000, Matusica et al., 2013). The peptides are linked to a  
!26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1    Stereotaxic frame set up and injection into the hippocampus   
(A) Photo of the stereotaxic frame and microscope set up used for stereotaxic surgery. The mouse is 
placed on a heating pad with ear bars to keep the head aligned and still.  The needle and tubing in 
which the virus is delivered can be identified over the mouse’s head. (B) Photo taken through a 
microscope lens showing the bared mouse’s skull with two drill holes. A needle into the right drill hole 
descends into the hippocampus. 
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biotin tag and a TAT-4 non-naturally occurring protein transduction domain peptide sequence 
(YARAAARNARA) at the amino terminus to render the peptide membrane permeable (Ho et al., 
2001) (Figure 2.2). 	  
2.3.5     Osmotic pump implantation and peptide delivery 
To treat animals systemically with peptide, c29 peptide and its SC control were delivered 
subcutaneously by osmotic pump (0.11 µl/hour flow; Alzet) at a 5 mg/kg/day peptide dose for 28 days. 
Osmotic pumps were filled with 100 µl of peptide dissolved in PBS then incubated overnight in PBS at 
37˚C to activate the pump. At the end of surgery to infuse p75- and IgG-saporin into the basal 
forebrain, pumps were placed subcutaneously along the mouse’s back, using the original incision to 
gain access. Alternatively, an i.p. 5 mg/kg dose of c29 or SC peptide(dissolved in sterile saline) was 
given everyday of Morris water maze testing, 30 minutes prior to being placed in the maze. 
 
2.3.6     Animal sacrifice and tissue preparation  
Mice were sacrificed by different methods dependent on the type of tissue analysis required. 
When only histological analysis was required, mice were perfused transcardially under deep anaesthesia 
(3 µl/g body weight; Lethabarb, Virbac). Briefly, the heart and major vessels were exposed by opening 
the thorax and a cannula inserted into the ascending aorta through the left ventricle. A small puncture 
was made to the right atrium allowing the efflux of return circulation. Blood was removed from the 
body by pumping the vasodilator sodium nitrite (1% in phosphate buffered saline (PBS)) through the 
heart and body until efflux was clear. This was followed by fixation with 30 ml of 4% 
paraformaldehyde (PFA) in PBS. Brains were removed, postfixed for 2 hours at room temperature 
followed by incubation overnight at 4˚C. The following day, brains were rinsed in PBS then transferred 
to a 30% sucrose solution for 24 hours at 4˚C. Brains were then embedded in Frozen Section 
Compound (FSC22; Leica) before requisite brain regions were cut in the coronal plane (40 µm) using a 
sliding microtome (SM2000r, Leica). All sections intended to be used for comparative analysis were 
processed, stained and analyzed together.  
 
Where brain tissue was used for biochemical analysis and/or histology, mice were sacrificed by cervical 
dislocation. All mice that underwent basal forebrain lesioning required histological analysis of the basal 
forebrain for neuronal counts. Therefore, the brain was divided into three portions: the anterior portion 
of the brain containing the basal forebrain, and the remaining two hemispheres containing the 
hippocampus and cortex. The basal forebrain portion of the brain, was removed and fixed in 4% PFA 
for 3 hours at room temperature, then post-fixed overnight at 4˚C. Following this, basal forebrain  
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Figure 2.2     C29 and SC peptide sequence  
Graphical representation of c29 peptide and its scrambled (SC) peptide control. Each peptide is linked 
to a biotin tag and a TAT-4 protein transduction domain at its amino terminus. The c29 peptide 
sequence corresponds to the first 29 amino acids of the juxtamembrane intracellular domain sequence 
of p75NTR, and the SC peptide is a randomly scrambled sequence of these amino acids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TAT-4Biotin R NAGQKNQKCSNWK LKEGEPPPTQNVPRS
274 302
Biotin K KNQGPQNRCVQGS NRLPTEKWSKNAPEP
C29 peptide:
SC peptide:
p75NTR juxtamembrane intracellular domain sequence
TAT-4
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portions were transferred to a 30% sucrose solution as described above, and embedded and sectioned. 
The posterior brain portions reserved for biochemical analysis were cut in half sagitally and the 
hippocampi and cortex were dissected and snap-frozen in liquid nitrogen. Tissue was stored at -80˚C 
until further processing. 
 
2.4     Animal behavioural testing 
 
2.4.1     Activity tracking 
In order to assess movement and exploratory behaviour, we placed our mice into an automated activity 
monitoring chamber (MED Associates, Inc). The chamber consists of a 27 cm x 27 cm x 20.3 cm open 
field arena where animal movement is tracked by three 16 beam infrared (IR) arrays. The IR beams are 
located on the X and Y axes for positional tracking and the Z axis for rearing detection. Mice were 
transferred to the behavioural room 30 minutes prior to starting and the arena was wiped clean with 
ethanol in between mice. The mice were placed into the activity chamber for 20 minutes and a range of 
behaviours including rearing, time at rest, velocity, time spent in center zone and time spent along the 
edge of the chamber were recorded and analysed. 
 
2.4.2     Y-maze paradigm 
To measure short-term spatial working memory we tested our mice in a two-trial forced Y-maze 
paradigm (Dember and Fowler, 1959). The Y-maze consists of an elevated Y-shaped maze constructed 
in-house from clear plexiglass with 40 cm long, 9 cm wide and 21 cm high arms. A removable ‘barrier’ 
provided us with the ability to shut off a maze arm of choice. Extra-maze visual cues were placed 
around the room to guide directionality and the maze was wiped with ethanol after every trial in order 
to remove odour cues (Figure 2.4). Mice were transferred to the behavioural room 30 minutes prior to 
starting. 
 
The test was divided into two phases; a 5 minute habituation phase, a 20 minute inter-phase interval, 
then another 5 minute test phase. Prior to the start of the habituation phase, the left or the right arm of 
the maze (alternating between mice) was closed off to the mouse with the clear plexiglass ‘barrier.’ The 
mice were placed into the maze in the home arm and allowed to move freely around the remaining two 
arms for 5 minutes. The mice were then removed from the maze for a 20 minute inter-phase interval in 
which the mice were placed back in to their original housing. Before placing the mice back in the home 
arm for the 5 minute test phase, the barrier closing off one of the maze arms was removed. Mice were 
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now able to freely explore all arms of the maze, either entering the previously explored arm or entering 
the novel, unexplored arm from which it had previously been prohibited from entering. This test relies 
on the innate tendency of mice to explore novel places, and tests their short-term spatial working 
memory. During the test phase, time spent in the ‘old’ and ‘novel’ arm, and overall distance travelled 
was recorded and analysed. 	  
2.4.3     Elevated Plus Maze paradigm 
To measure anxiety in our mice, we subjected mice to an Elevated Plus Maze paradigm. The arena 
consists of a plus-shaped maze with two open arms and two enclosed arms, elevated from the floor. The 
paradigm is based on a mouse’s aversion to open spaces and a preference to remain near to a vertical 
surface. Thus a mouse that shows preference for the closed arms by restricting movement to within the 
enclosed arms of the maze, is rated as being more anxious.  
 
Mice were transferred to the behavioural room 30 minutes prior to starting and the arena was wiped 
clean with ethanol in between mice in order to remove odour cues. Mice were placed onto the open 
arm of the maze and allowed to freely explore the maze over a period of 10 minutes. The time spent in 
either the closed or open arms, number of arm entries and average velocity was assessed. 
 
2.4.1     Morris water maze (MWM) paradigm 
To measure learning and spatial reference memory, mice were subjected to the Morris water (Morris, 
1984). Mice were trained in a 100 cm diameter circular pool made of gray plastic and filled with room 
temperature water. White non-toxic paint was added to the water in order to make it opaque (Figure 
2.3A). Visual cues were placed around the room for navigation and a small circular (10 cm diameter) 
platform was hidden 1.5 cm below the water surface in the north-east quadrant (Figure 2.3B). Mice 
were transferred to the behavioural room 30 minutes prior to starting.  
 
Three starting positions were predetermined (south, west and north) and mice were placed into the 
pool facing the pool perimeter. The mice were placed in sequential order of starting positions with an 
approximately 20 minute inter-trial interval. Timing begun as soon as the mouse was in the water, and 
they were allowed to swim for a maximum of 60 seconds or until they were sitting on the platform. 
Finding the platform was defined as remaining on the platform for a total of 10 seconds. If the mice 
swam off the platform prior to this time, time on the platform was restarted once they returned. If the 
mice exceeded the 60 seconds in the arena, they were collected and placed on the platform for a total of  
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Figure 2.3     Y-maze paradigm  
(A) Photo of Y-maze test set up with 3 arms: home, left and right, and visual cues on the walls 
surrounding the maze. (B) Y-maze paradigm represented graphically. The home arm in which the 
mouse is placed at the bottom of the image and one arm is shut off (alternating between left and right 
and represented by gray shading) during the habituation phase of test, then all arms are opened for the 
test phase. Visual cues are represented by the large black and white squares found at the top and left of 
the image. (C) Test protocol represented graphically. Mice are placed inside the maze (with one arm 
closed off) for a 5 minute habituation period, followed by a 20 minute interval where there are returned 
to their nesting box. Mice are then placed back into the maze where all arms are open for exploration 
for a 5 minute testing period. 
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10 seconds. After removal from the arena, mice were dried with a paper towel and placed under a heat 
lamp to warm up. 
 
The MWM test was divided into two phases, a 5-day acquisition phase (3 start positions/day) followed 
by a probe trial for spatial retention on the sixth day (Figure 2.3C), and a 2-day memory updating 
phase (3 trials/day) followed by another probe trial on day 9 (Figure 2.3D). During acquisition and 
memory updating, escape latency and swim speed were analysed. During probe trials (when platform 
was removed from the arena), latency to platform zone, time spent in target quadrant and platform 
zone crossing frequency were recorded and analysed. For data analysis, trials were averaged per day and 
are presented as escape latency in seconds per day. 	  
2.4.5     Video tracking and data analysis 
All animal movements in the Morris water maze, Y-maze and Elevated Plus Maze were tracked with an 
electronic imaging system (EthoVision XT, Noldus Information Technology). Raw data were 
transferred to Graphpad Prism 6 where statistical analysis was performed. Between-group comparisons 
were analyzed using a one-way analysis of variance (ANOVA) or a two-way ANOVA with repeated 
measures. Significant effects with the appropriate post hoc test and are reported in figure legends. All 
data are represented as mean ± SEM with a statistical significance given at p<0.05. 
 
2.5     Histology and microscopy 
 
2.5.1     Free-floating fluorescence immunohistochemistry  
In order to block non-specific binding sites, 40 µm thick brain tissue sections were placed into blocking 
solution (5% horse serum (HS) in PBS-Triton X (0.1% Triton X-100 in PBS)) in 12-well plates 
(Falcon) for 1 hour at room temperature. Sections were then transferred into blocking solution with 
various primary antibodies overnight at room temperature. The next day, sections were washed for 1 
hour in PBS-Triton X followed by a two hour incubation at room temperature with the appropriate 
fluorescent secondary antibody and DAPI (4',6-diamidino-2-phenylindole; 1:4000; Thermo Scientific) 
which labels nuclei. After a final one hour wash in PBS-Triton X, sections were mounted onto 
Superfrost Plus slides (Thermo Scientific) and allowed to dry. The slides were coverslipped with Dako 
Fluorescence Mounting Medium and stored at 4˚C before scanning. 	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Figure 2.4     Morris water maze paradigm  
(A) Morris water maze set up represented schematically. Arena measures 100 cm x 100 cm, with a 
hidden platform in the NE quadrant represented by a gray shaded circle. The dotted black line 
indicates quadrants. (B) Hidden platform position and starting points for 5-day training paradigm and 
probe trial. Trials 1 to 3 with different start locations (black triangle) are performed once sequentially 
everyday, for 5 days. On the probe trial (Day 6) the platform is removed and mice are placed in the 
arena at the first starting location. (C) Memory updating and second probe trial paradigm. As with the 
5-day training paradigm, mice are placed in the arena in 3 sequential starting positions, however 
platform location has been changed and mice are trained over 2 days.  	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2.5.2     Free-floating Ni-DAB histochemistry  
As with free-floating fluorescence staining, 40 µm thick brain tissue sections were used. Sections were 
placed into phosphate buffer (PB) solution (0.2 M NaH2PO4, 0.25 M Na2HPO4) for 30 minutes at 
room temperature, followed by 30 minutes in 25% ethanol, 30 minutes in 25% ethanol with 3% 
H2O2, then blocked for 30 minutes in 5% HS in PB solution. Sections were then incubated for 24 
hours at room temperature 5% HS in PB solution with 0.1% Triton X-100 and goat anti-ChAT 
(Millipore). The following day, sections were washed for 30 minutes in PB solution then incubated in 
the biotinylated anti-goat secondary antibody and PB solution with 0.1% Triton X-100 for 2 hours at 
room temperature. Sections were washed for 1 hour in PB solution before being incubated in a 1:1 
avidin-biotin complex (ABC; Thermo Scientific) followed by another 1-hour wash in PB solution. 
After a 20 minute incubation in sodium acetate buffer (0.1 M C2H3NaO2, pH 6.0), sections were 
placed in a Ni-DAB (Nickel-3,3’-diaminobenzidine) solution (0.1 M C2H3NaO2, 2% NiSO4, 11 mM 
D-glucose, 7.5 mM ammonium chloride, 1.17 mM DAB) for 15 minutes at room temperature, 
followed by Ni-DAB solution with the addition of 0.2 µl/ml glucose oxidase. Sections were monitored 
carefully under a brightfield microscope (Zeiss) until the colorimetric reaction clearly labeled neurons, 
then the reaction was halted by transferring sections into sodium acetate buffer. Finally, sections were 
washed for 1 hour in PB solution before being mounted onto Superfrost Plus slides (Thermo Scientific) 
and allowed to dry overnight. The following day, slides were placed vertically into a slide holder and 
dehydrated and defatted by washing twice in 100% ethanol for 5 minutes each followed by two washes 
in Xylene (Fisher Chemical) for 3 minutes each. Slides were coverslipped with DPX neutral mounting 
medium (Ajax Finechem) and left lying flat overnight. 
 
2.5.3    Thioflavin-S staining   
Hippocampal and cortical Aβ plaques were identified by Thioflavin-S staining which binds to the β-
pleated sheet structure that is characteristic of senile plaques. Sections were incubated at room 
temperature in PBS-Triton X with DAPI (1:4000; Thermo Scientific), then washed for 30 minutes in 
PBS-Triton X. The sections were mounted onto Superfrost Plus slides (Thermo Scientific) and allowed 
to dry completely by leaving them overnight. The following day, mounted sections on glass slides were 
placed vertically in a slide holder and rehydrated by placing them into distilled water for 10 minutes 
then in 70% ethanol for 5 minutes. The slides were then incubated in the dark for 5 minutes in twice-
filtered 0.1% Thioflavin-S solution. Slides were washed in 70% ethanol followed by distilled water to 
remove excess stain, and allowed to dry before being coverslipped with Dako Fluorescence Mounting 
Medium. Slides were left lying flat overnight and stored at 4˚C. 
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2.5.4     Slide Scanner and Imaris Image Analysis 
All fluorescence and bright field microscopy and image acquisition were performed using a fluorescence 
slide scanner (Axio, Zeiss) and bright field slide scanner (Axio, Zeiss), respectively. 
 
Quantification of ChAT- and parvalbumin-positive neurons in the basal forebrain was performed as per 
Boskovic et al. (2014). For each animal, every third basal forebrain section (10 sections per animal) was 
counted starting from the beginning of the medial septum (1.18 mm anterior to Bregma). 
Identification of the medial septum/diagonal band of Broca areas was made using the Mouse Brain 
Atlas (Franklin and Paxinos, 2007). All measurements and analyses were performed using Imaris 7.2.3 
software (Bitplane). 
Quantification and measurements of Thioflavin S-positive plaques were calculated using CellProfiler 
and hippocampal area were calculated in Fiji (Image J). For each animal, every third hippocampal 
section (10 sections per animal) was counted starting from the beginning of the hippocampus (1.06 
mm posterior to Bregma). 
 
2.6     Enzyme-linked immunosorbent assays (ELISAs) 
 
2.6.1     Acid extraction and homogenization for NGF and BDNF  
Hippocampal neurotrophin levels were measured by ELISA (Biosensis) in supernatant prepared from 
hippocampal homogenates. Soluble proteins were extracted using an acid extraction protocol as per the 
manufacturer’s instructions. Briefly, hippocampi were suspended in 10 volume/weight extraction buffer 
(0.05 M sodium acetate, 1 M sodium chloride, 1% Triton-X, pH to 4 with acetic acid and Roche 
complete inhibitor cocktail tablet) and homogenized on ice with the Bullet Blender Storm (Next 
Advance). Samples were then centrifuged for 30 minutes at 20, 000 xg at 4˚C. Supernatant was 
collected and a bicinchoninic acid assay (BCA; Thermo Scientific) to measure total protein content was 
performed. Samples were stored at -80˚C until required.  
 
2.6.2     BDNF and NGF sandwich ELISAs 
ELISAs for the individual neurotrophins were performed according to the manufacturer’s instructions 
(Biosensis) and all reagents and antibodies were provided in the kit. Briefly, BDNF and NGF standard 
curves were generated with lyophilized antigen standard and brain tissue sample diluent (1:3 ratio of 
extraction buffer and neutralization buffer (0.1 M phosphate buffer: 0.1 M KH2PO4 + 0.1 M 
Na2HPO4)). Standard curves and hippocampal tissue diluted in brain tissue sample diluent were loaded 
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into pre-coated mouse monoclonal anti-BDNF or anti-NGF capture antibody microplate wells. The 
plate was sealed and incubated on a shaker for 45 minutes at room temperature. Following 5 washes 
with Wash Buffer (provided in kit), biotinylated anti-BDNF or anti-NGF detection antibody was 
added to each well and the plate was again sealed and incubated on the shaker for 30 minutes. The 
solution inside the wells was discarded and washed 5 times with wash buffer followed by the addition of 
HRP-conjugated streptavidin for a 30 minute incubation. Following the final wash sequence, the 
addition of a substrate (3,3’,5,5’-tetramethylbenzidine, TMB) for 5 minutes in the dark, yields a 
coloured reaction product (reaction is stopped with Stop Solution) which is directly proportional to the 
concentration of BDNF or NGF present in samples and protein standards. Plates were read at 450 nm 
using the FLUOstar OPTIMA plate reader (BMG LABTECH) and the resulting measurements (pg) 
were calculated from a log curve of the protein standards and were normalized to per mg of total 
soluble protein from the BCA assay results. 
 
2.6.3    Extraction and homogenization for soluble Aβ 
Hippocampal Aβ levels were measured by ELISA (Invitrogen) in supernatant prepared from 
hippocampal homogenates. Briefly, soluble protein was extracted in an 8x volume/weight hippocampal 
suspension of cold 5 M guanidine HCl and 50 mM Tris HCl (pH 8.0) as per the manufacturer’s 
instructions and homogenized on ice with the Bullet Blender Storm (Next Advance). Homogenate was 
then mixed at room temperature for 4 hours and diluted 1:50 with cold Reaction Buffer (0.2 g/L KCl, 
0.2 g/L KH2PO4, 8.0 g/L NaCl, 1.150 g/L Na2HPO4, 5% BSA, 0.03% Tween-20, pH to 7.4). 
Homogenate was collected for a bicinchoninic acid assay (BCA; Thermo Scientific) to measure total 
protein content was performed. Samples were stored at -80˚C until required.  
 
2.6.4     Aβ sandwich ELISA 
An ELISA for Aβ levels in the hippocampus of APP/PS1 mice was performed according to the 
manufacturer’s instructions (Invitrogen) using reagents and antibodies provided in the kit. Briefly, an 
Aβ standard curve were generated with lyophilized antigen standard and Standard Reconstitution 
Buffer (55 mM sodium biocarbonate, pH 9.0 with sodium hydroxide). Standard curves and 
hippocampal samples were loaded into pre-coated monoclonal anti-Aβ (NH2 terminus region) capture 
antibody microplate wells. Aβ42 Detection Antibody was added to every well and the plate was sealed 
and incubated on a shaker for 3 hours at room temperature. Following 4 washes with Wash Buffer 
(provided in kit), HRP anti-rabbit antibody was added to the wells and incubated on the shaker for 30 
minutes. The solution inside the wells was discarded and washed 5 more times with wash buffer 
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followed by the addition of Stabilized Chromagen for 30 minutes at room temperature in the dark. 
Stop Solution is added to every well and plates were read at 450 nm using the FLUOstar OPTIMA 
plate reader (BMG LABTECH). The resulting measurements (pg) were calculated from a log curve of 
the protein standards and were normalized to per mg of total soluble protein from the BCA assay 
results. 
 
2.7     Western blotting  
 
2.7.1     General lysis and protein extraction from mouse brain tissue 
To measure the levels of proteins of interest, brain tissue was dissected, and protein was extracted as 
follows: hippocampi/cortices were suspended in lysis buffer (15-20 mg tissue/1 ml lysis buffer; 150 mM 
NaCl, 50 mM Tris-HCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 
mM sodium orthovanadate, 1 mM PMSF, 1 µM BB94 (Betimastat), 20 mM NaF, 1% (v/v) Complete 
Inhibitor Cocktail (Roche) and 1% (v/v) PhosSTOP Phosphatase Inhibitor Cocktail (Roche), pH 7.0) 
and homogenized on ice with the Bullet Blender Storm (Next Advance). Homogenates were 
centrifuged at 12, 000 xg for 20 minutes at 4˚C and pellets discarded. A BCA assay (Thermo Scientific) 
to measure the total protein content of each sample was performed and the supernatant was stored at -
80˚C until required. 
 
2.7.2     Sequential tau extraction from mouse brain tissue 
To measure the levels of tau and hyperphosphorylated tau epitopes, soluble (RAB) and insoluble 
(RIPA) fractions of hippocampal or cortical homogenate were sequentially extracted as previously 
described (Probst et al., 2000). Hippocampi/cortices were suspended in 10 volume/weight ice-cold 
RAB buffer (0.01 M MES, 1 mM EGTA, 0.5 mM MgSO4, 0.75 M NaCl, 0.02 M NaF, 1 mM 
Na3VO4, 1 mM PMSF) containing Complete EDTA-free Protease Inhibitor Cocktail (Roche) and 
PhosSTOP Phosphatase Inhibitor Cocktail (Roche), and homogenized. Samples were kept on ice for 
30 minutes, and then centrifuged at 21,000 g for 90 minutes at 4˚C. Supernatant was extracted and 
stored as the RAB fraction at -80˚C. The remaining pellet was resuspended and homogenized in the 
same volume of ice-cold RIPA buffer (Cell Signaling) with 0.02 M NaF, 1 mM Na3VO4, 1 mM PMSF, 
Complete EDTA-free Protease Inhibitor Cocktail (Roche) and PhosSTOP Phosphatase Inhibitor 
Cocktail (Roche). Samples were allowed to stand on ice for 30 minutes before being centrifuged at 
21,000 g for 90 minutes at 4˚C. The supernatant was extracted and stored at -80˚C as the RIPA 
fraction. A BCA assay (Thermo Scientific) to measure the total protein content for each sample from 
each fraction was performed to ensure that changes in tau were comparable across samples. 
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2.7.2     Western blotting  
Proteins of interest in their naïve or phosphorylated states were quantified from hippocampal or cortical 
homogenate by western blot analysis. For total tau and hyperphosphorylated tau epitopes, protein was 
quantified from the soluble and insoluble fractions of hippocampal or cortical homogenate. 
Homogenate was denatured in SDS-PAGE loading buffer (80mM Tris, pH 6.8, 2% SDS, 10% 
glycerol, 5 mg/ml bromophenol blue) with 0.1 M dithiothreiol (DTT) and heated for 10 minutes at 
90˚C followed by a 5-minute spin at 4, 500 rpm in a desktop centrifuge. Equal amounts of protein (20 
µg, unless otherwise indicated) were separated by SDS-PAGE using precast NuPage Novex 4-12% Bis-
Tris Protein Gels (Life Technologies). Gels were run for 90 minutes at 130 V in NuPage MOPS-SDS 
Running Buffer (20x; Life Technologies; 50 mM MOPS, 50 mM Tris Base, 0.1% sodium dodecyl 
sulphate (SDS), 1 mM EDTA, pH 7.7) then proteins were electrophoretically transferred onto a 
polyvinlidene difluoride membrane (PVDF), Immobilon-FL transfer membrane (Millipore) in transfer 
buffer (25 mM Tris, 192 mM glycine, 20% methanol) on ice for 90 minutes at 90 V. In order to block 
non-specific binding sites, membranes were incubated in 5% bovine serum albumin (BSA) in 
phosphate buffered saline with 0.1% Tween-20 (PBS-T) for 1 hour at room. Membranes were probed 
with various antibodies in 5% BSA in PBS-T overnight at 4˚C. Membranes were washed three times 
for 10 minutes in PBS-T then incubated with the appropriate secondary antibody (1:50,000; see 
Appendix 1) for two hours at room temperature. Membranes were washed thoroughly before protein 
bands were imaged using an Odyssey Imaging System (LI-COR Biosciences). Image Studio software 
(LI-COR Biosciences) was used for quantification of Western blots. 
 
2.7.5     Stripping and re-probing of PVDF membranes 
When use of the same membrane was required (i.e. to control for total protein levels of phosphorylated 
protein, e.g. pERK/ERK), membranes were stripped and re-probed. PVDF membranes were incubated 
in stripping buffer (62 mM Tris base, 2% SDS, 7% 2-mercaptoethanol, pH 6.7) for 30 minutes at 
50˚C in a Hybaid oven. The membrane was then washed 3x for 10 minutes each in PBS-T and blocked 
for 1 hour at room temperature in 5% BSA in PBS-T before incubation in primary antibody (as 
described above). 
 
2.7.6     Quantification and analysis of western blots 
Image Studio software (LI-COR Biosciences) was used for quantification of Western blots. Briefly, 
bands were identified using the ‘Add Rectangle’ tool which quantified the signal into a density value. 
These values were normalized to the density values of their corresponding loading controls in Excel 
(Microsoft) and graphs and statistical tests were preformed in Graphpad Prism 6. 
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2.8     Statistical analysis 
 
All data are expressed as mean ± SEM. Statistical tests performed for each result are reported in figure 
legends. Significance threshold was set at p<0.05 and analyses were performed using Graphpad Prism 6. 	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3.1     Introduction 
 
3.1.1     Chapter overview 
The aim of this chapter was to investigate the effect of loss of cholinergic signalling on triggering the 
development of pathology and cognitive impairment in an AD mouse model consisting of a partial 
cholinergic neuron lesion in presymptomatic Aβ producing transgenic mice. Establishment of a robust 
cholinergic-lesioned AD mouse model will allow us to further test the role of potential mechanisms 
underlying sporadic AD, such as dysfunction in neurotrophic signalling, as well as provide a model with 
which to test a therapeutic peptide developed in our lab that enhances trophic signalling, a later aim of 
this thesis. 	  
3.1.2     BFCN loss by p75-saporin selective immunolesioning 
Multiple animal models have been developed in an effort to study the etiology, progression and 
therapeutic avenues of AD. However, in these mouse models of AD, no prodromal, pathological loss of 
cholinergic neurons has been reported, although some impairment in cholinergic function is observed 
in aged AD transgenic mouse lines (Apelt et al., 2002, Boncristiano et al., 2002, Perez et al., 2011). As 
there is a strong correlation between the regions of the brain where amyloid plaque load is high, such as 
the hippocampus and the cortex (Schliebs, 2005), and degeneration of the innervating BFCNs, the 
suggestion is that cholinergic dysfunction is the driver of pathology. However, there was no 
comprehensive animal model that reproduces the complexity of AD by presenting with an early 
cholinergic degeneration phenotype along with Aβ plaques and tau tangles, until the recent 
introduction of p75-saporin to induce cholinergic degeneration in mouse AD models in order to 
investigate this relationship. 
 
Experimental cholinergic degeneration of the mouse basal forebrain through a specific immunotoxin, 
murine p75-saporin, or its rat equivalent 192IgG-saporin, has been robustly used in rodent models to 
explore cholinergic function (Wiley et al., 1991, Berger-Sweeney et al., 2001, Moreau et al., 2008). 
Developed by Wiley and colleagues in the 1990’s (Wiley et al., 1991, Book et al., 1992), 
intracerebroventricular infusion of the selective toxin resulted in loss of basal forebrain cholinergic 
neurons in rats and highlighted the use of anti-neuronal immunotoxins as a powerful tool to answer 
questions in neurobiology. In the murine equivalent, saporin, a ribosome-inactivating protein, is 
disulfide coupled to a monoclonal antibody against the mouse p75NTR receptor and is effective both in 
vitro and in vivo at killing p75NTR-expressing cells (Berger-Sweeney et al., 2001, Moreau et al., 2008). 
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In the basal forebrain, p75NTR expression is restricted to cholinergic neurons and endocytosis of the 
saporin-receptor complex induces cell death.  Previous work has established that ICV injection of p75-
saporin results in a decrease in hippocampal and cortical ChAT activity without inducing changes in 
glutamic acid decarboxylase (GAD) activity. Furthermore, a selective, dose-dependent loss of 
cholinergic neurons in the basal forebrain with no effect on non-cholinergic neurons is reported. 
Importantly, other neurons that express p75NTR, such as cerebellar Purkinje cells which are remote from 
the ICV injection site, are unaffected by the injected p75-saporin (Berger-Sweeney et al., 2001). 
Behavioral analysis performed on mice following infusion of p75-saporin indicates deficits in spatial 
learning in Morris water maze and place avoidance tasks (Berger-Sweeney et al., 2001, Hamlin et al., 
2013). Moreover, no adverse effects such as abnormal loss of weight or disruption of sensorimotor 
coordination were reported following surgery and a 100% postsurgical survival rate was observed 
(Moreau et al., 2008). 	  
This lesioning technique has permitted extensive experimental examination of the neuroanatomical 
connections of basal forebrain and continues to be used in neuroanatomical, neurochemical and 
behavioural investigations. 	  
3.1.3     Cholinergic basal forebrain degeneration in AD transgenic mice 
The Coulson lab therefore aimed to test what affect BFCN lesions had on AD pathology, with 
preliminary data supporting a causal link between lesioning and deposition of Aβ (Sharma, 2013). 
However not long after I began this aspect of my project, an investigation of the affects of induced 
cholinergic degeneration on aged 6-8 month old Tg2576 transgenic mice that overexpress the Swedish 
mutation of human APP was published (Gil-Bea et al., 2012). ICV injection of p75-saporin resulted in 
a significant decrease in BFCNs and a concomitant increase in cortical soluble Aβ42 and hippocampal 
atrophy, exemplified by degenerating neurons and reduced levels of the presynaptic protein 
synaptophysin in the CA1-3 pyramidal layers (Gil-Bea et al., 2012). Moreover, these effects could be 
rescued following administration of the cholinergic agonist, carbachol, indicating direct involvement of 
cholinergic signalling in the development of this pathology (Gil-Bea et al., 2012). Other groups rapidly 
repeated aspects of these experiments using ICV administration of the toxin into AD transgenic mice, 
reporting a similar exacerbation of Aβ deposition and plaque burden in the hippocampus and cortex 
and in some cases also tau pathology following cholinergic denervation (Laursen et al., 2013, Ramos-
Rodriguez et al., 2013, Hartig et al., 2014). Futhermore, memory impairments in a T-maze continuous 
alternation task and place recognition maze (Laursen et al., 2013), new object discrimination tests and a 
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Morris water maze task (Ramos-Rodriguez et al., 2013) have been reported in these lesioned AD mice 
(where cognitive impairments were not apparent in AD only mice) (summarized in Table 3.1). 
 
These results suggest that cholinergic denervation may trigger the production and/or deposition and/or 
reduced clearance, of Aβ protein, the hyperphosphorylation of tau protein, and synergistically 
underwrite cognitive impairment in AD. However, the exact pathways by which this exacerbation of 
pathology is mediated, remain unclear. 
 
3.1.4     APP/PS1 transgenic mice as a model of AD  
In this chapter, we used double transgenic APP/PS1 mice which express a chimeric mouse/human 
amyloid precursor protein (Mo/HuAPP695swe) and a mutant human presenilin 1 (PS1-dE9) both 
expressed within CNS neurons (Jankowsky et al., 2004). Both of these mutations are associated with 
early-onset Alzheimer's disease. The APP transgene allows the mice to produce elevated levels of the 
human Aβ peptide by favoring processing through the β-secretase pathway, resulting in the 
development of amyloid deposits in the brain by six to seven months of age (Jankowsky et al., 2004). 
Moreover, by seven months, these mice show a spatial learning deficit in a hidden-target version of the 
Barnes and Morris water mazes (Harrison et al., 2006, Edwards et al., 2014). 	  
Thus, these mice provide us with a useful tool to study AD-specific changes in the brain such as 
amyloid plaque formation and associated cognitive deficits. The results in this chapter are based on this 
APP/PS1 mouse model in which we have induced cholinergic degeneration with the immunotoxin, 
p75-saporin. We aimed to reproduce a robust partial loss of cholinergic neurons to determine if 
cholinergic degeneration in young, presymptomatic mice was able to trigger early pathogenic changes 
and impact learning and memory. If successful, this method would provide us with an in vivo AD 
model of very early disease processes in which to further investigate the underlying mechanisms, such as 
dysfunction neurotrophic signalling, which may underpin AD disease progression. 
 
 
 
 
 
 
 
 
Table 3.1     Comparison of previously published cholinergic lesioned AD mouse models  
A comparison of recent literature in which cholinergic hypofunction was induced in a range of AD transgenic mouse models. Comparison of mouse line, 
method of toxin deliver, age of mice (at the time of lesion and testing), observation of amyloid and tau pathology and comparison of behavioural testing 
performed. ICV: Intracerebral ventricle. 
Author and Year 
of paper 
Transgenic 
AD mouse 
line 
Method 
of toxin 
delivery 
Mouse age 
at time of 
lesion 
Mouse age at time of 
testing 
Increase in 
amyloid 
pathology 
observed? 
Increase 
in tau 
pathology 
observed? 
Behavioural testing?  
If yes, what test? 
Gil-Bea et al., 2012 	   Tg2576 Single bilateral 
ICV 
infusion 
6-8 months 9 months Yes - No 
Laursen et al., 2013 APP/PS1 Single 
bilateral 
ICV 
infusion 
6 months 8 months Yes - Yes, T-maze continuous alternation 
and place recognition maze 
Ramos-Rodriguez 
et al., 2013 
APP/PS1 Single 
bilateral 
ICV 
infusion 
3 and 7 
months 
Short term:  
7 days post lesion (3 
month and 7 months old) 
Long term:  
4 months post 
lesion (7 months 
old) 
Yes 
 
Yes 
Yes 
 
Yes 
Yes, novel object discrimination 
test and Morris water maze 
paradigm (but not in probe trial) 
Yes, novel object discrimination 
test and Morris water maze 
paradigm  
Laursen et al., 2014 Tg2576 Single 
bilateral 
ICV 
infusion 
3 months 9 months - - Yes, T-maze continuous alternation 
and place recognition maze 
Härtig et al., 2014 	   3xTg-AD Single bilateral 
ICV 
infusion 
12 months 16 months Yes Yes No 
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3.2    Results 	  
3.2.1     p75-saporin injection selectively lesions basal forebrain cholinergic neurons without 
affecting parvalbumin-positive neurons 
In order to test whether cholinergic neuron degeneration triggers or accelerates amyloid pathology in 
genetically susceptible mice, we lesioned BFCNs in 5-month-old pre-symptomatic APP/PS1 amyloid 
transgenic mice using the toxin murine p75-saporin. At this age, mice have very little amyloid plaque 
pathology in the hippocampus. Control transgenic mice were injected with the non-specific IgG-
saporin. After one month, behavioral, histological and biochemical analyses were performed. Stereotaxic 
injection of p75-saporin into the medial septal area of the basal forebrain resulted in a decrease in the 
number of ChAT-positive neurons compared to IgG-saporin injected mice (Figure 3.1A-C). This 
lesion consequently resulted in denervation of the BFCN projections to the hippocampus represented 
by a decrease in hippocampal ChAT levels (Figure 3.1E). The number of parvalbumin-positive 
neurons in the basal forebrain was unchanged following p75-saporin injection compared to control 
(Figure 3.1D), confirming the specificity of the lesion.  
 
3.2.2     Levels of hippocampal BDNF protein, but not NGF protein, are significantly reduced 
following loss of basal forebrain cholinergic neurons  
To determine whether loss of cholinergic innervation to the hippocampus resulting from loss of BFCNs 
had an effect on the levels of neurotrophins in the hippocampus, we measured the amount of NGF and 
BDNF protein in hippocampal homogenates following p75-saporin- and IgG-saporin-injection into 
the MS of APP/PS1 amyloid transgenic mice, and their naïve wildtype age- and gender-matched 
littermates. IgG-saporin-injected animals had equivalent levels of NGF protein levels to their wildtype 
littermates. Similarly, levels of NGF protein in the hippocampus of p75-saporin injected mice had 
equivalent levels of NGF following lesion compared to unlesioned transgenic control levels and naïve 
wildtype levels (Figure 3.2A). This indicates that BFCN projections to the hippocampus are not 
involved in regulation of NGF protein. In contrast, loss of BFCN projections to the hippocampus in 
p75-saporin injected mice resulted in a significant decrease in BDNF levels in the hippocampus. IgG-
saporin-injected control animals had equivalent levels of BDNF protein levels to their wildtype 
littermates (Figure 3.2B). 	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Figure 3.1     p75-saporin injection selectively lesions basal forebrain cholinergic neurons 
without affecting parvalbumin-positive neurons  
(A) Representative schematics of a murine brain in the sagittal plane (left) with a red box indicating the 
location of the basal forebrain and in the coronal plane (right) indicating the location of the p75-
saporin or IgG-saporin injection location into the medial septum region of the basal forebrain. 
(B) Representative photomicrographs of coronal brain sections at the level of the basal forebrain, 
immunostained for a cholinergic neuron marker (anti-ChAT) 1 month after microinjection of IgG-
saporin (control) or p75-saporin (lesion) into the medial septum. Quantification of (C) ChAT- and (D) 
parvalbumin (PARV)-positive neuronal numbers in the basal forebrain, demonstrating a selective loss of 
ChAT-positive neurons following p75-saporin lesion with parvalbumin-positive neuron numbers being 
unchanged. Data are presented as mean ± SEM. The number of animals per condition is indicated 
within the bars of the graphs. * p<0.05, unpaired t-test. (E) Representative western blots of 
hippocampal homogenates from naïve, control (IgG-saporin) and lesioned (p75-saporin) APP/PS1 
amyloid transgenic mice probed for the enzyme ChAT. Loss of basal forebrain cholinergic neurons 
results in a decrease in ChAT protein in the hippocampus. 
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Figure 3.2     Levels of hippocampal BDNF protein, but not NGF protein, are significantly 
reduced following loss of basal forebrain cholinergic neurons  
Quantification of (A) NGF and (B) BDNF protein levels (pg protein/mg wet tissue) in hippocampal 
homogenates by ELISA in p75-saporin (lesion) and IgG-saporin (control) injected APP/PS1 amyloid 
transgenic mice and their wildtype littermates. Loss of basal forebrain cholinergic neurons resulted in a 
decrease in hippocampal BDNF levels but not NGF levels compared to control transgenic mice and 
naïve wildtype littermates. Data are presented as mean ± SEM. The number of animals per condition is 
indicated within the bars of the graphs. One-way ANOVA with Tukey’s multiple comparisons test, ***  
p<0.001.  
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3.2.3     No memory impairment in a Y-maze paradigm following basal forebrain cholinergic 
neuron loss in APP/PS1 mice 
Previous work from our lab has demonstrated short-term spatial navigation deficits in a Y-maze task in 
aged (12-15 month old) APP/PS1 mice (Qian, unpublished); moreover, impairments in a Y-maze  
paradigm are one of the earliest behavioural changes reported in APP/PS1 mice (Holcomb et al., 1998). 
Therefore, to determine whether loss of BFCN innervation to the hippocampus together with any 
downstream effects had an impact on short-term spatial working memory, we tested BFCN lesioned 
and control unlesioned APP/PS1 mice in a Y-maze paradigm. Mice were placed in the maze for a 5 
minute habituation period with one of the maze arms closed, followed by a 20 minute interphase 
interval and finally a 5 minute testing period, where all arms of the maze were open for exploration. 
The Y-maze paradigm takes advantage of a mouse’s innate tendency to explore novel places to test their 
short-term spatial working memory, therefore comparisons of time spent in familiar and novel arms 
and the number of arm entries made were made.  
 
APP/PS1 mice spent equivalent proportions of time in familiar and novel arms regardless of BFCN 
status (Figure 3.3A). Consistent with this, neither group of mice showed a preference for any arm, 
regardless of novelty. However, compared to control transgenic mice, the BFCN lesioned APP/PS1 
mice made significantly fewer entries into each of the arms (Figure 3.3B). Following this result, we 
analysed movement patterns for each of the groups. We found the APP/PS1 amyloid transgenic mice 
with lesioned BFCNs travelled less and at a slower velocity during the testing phase than control 
APP/PS1 mice, however, they spent the same proportion of time immobile (Figure 3.3C-F). The 
APP/PS1 mice therefore did not appear to be significantly impaired in the spatial memory aspect of this 
test. 
 
3.2.4     Impairment in memory retention in a hippocampal-dependent spatial navigation 
Morris water maze task following loss of basal forebrain cholinergic neurons in APP/PS1 mice  
To determine whether loss of BFCN innervation to the hippocampus together with any downstream 
effects was sufficient to induce a deficit in longer-term spatial memory function, lesioned and non-
lesioned control APP/PS1 amyloid transgenic mice, together with their age- and gender-matched 
lesioned, non-lesioned controls and naïve wildtype littermates, were tested in a Morris water maze 
hippocampal-dependent learning and memory paradigm. Animals underwent an 8 day learning 
schedule including a probe trial on the sixth day. The platform location was changed on the seventh 
day and mice had to relearn or ‘update’ their memory over the seventh and eighth day of testing; this 
reversal test is sensitive to BFCN dysfunction (Catts et al., 2008). All groups of mice travelled  
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Figure 3.3     No memory impairment in a Y-maze paradigm following basal forebrain 
cholinergic neuron loss in APP/PS1 mice  
(A) Graph of the percentage of total time that basal forebrain lesioned and non-lesioned APP/PS1 mice 
spent in familiar and novel arms of the Y-maze. Loss of basal forebrain cholinergic neurons did not 
affect the proportion of time spent in the novel or familiar arms of the Y-maze compared to transgenic 
controls. (B) Total number of arm entries made by lesioned and non-lesioned APP/PS1 mice into the 
home, familiar and novel arms. Both groups of mice showed no preference for any arm, regardless of 
novelty, however, overall made significantly fewer entries into each of the arms compared to control 
transgenic mice. Two-way ANOVA with Tukey’s post hoc, *=p<0.05. Quantification of (C) distance 
travelled in meters (m), (D) average velocity (centimeters per second), (E) velocity per minute and (F) 
percentage time spent immobile. Basal forebrain lesioned mice travel significantly smaller distances 
during testing, and have a significantly slower velocity compared to transgenic controls, however there 
is no difference observed in the time spent immobile. Data are presented as mean ± SEM with sample 
size indicated in the bars. Unpaired t-test, *=p<0.05. 
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equivalent distances and velocity in the maze arena (Figure 3.4F) and no mouse displayed obvious 
motor difficulties. No significant differences in escape latency between any of the groups were observed 
over the first 5 days, however following a change in platform location on the seventh day, lesioned  
APP/PS1 and wildtype mice both demonstrated deficits in finding the platform location compared to 
APP/PS1 and wildtype controls and naïve wildtype mice (Figure 3.4A, B). As the deficit occurred in 
both APP/PS1 and wildtype BFCN lesioned mice, we conclude that this impairment is a result of the 
loss of BFCNs and not due to acceleration in pathology. 
 
In the probe trial on the sixth day when the hidden platform was removed from the arena, the time 
spent in the target quadrant, latency to the platform quadrant and platform crossing frequency were 
assessed. In lesioned, control and naïve wildtype mice, no differences were observed between groups. In 
contrast, p75-saporin lesioned APP/PS1 mice displayed significantly less time in the target quadrant  
and crossed the platform less frequently (Figure 3.4C and E). Although not significant, BFCN 
lesioned APP/PS1 also appeared to take longer to research the platform (Figure 3.4D). These deficits 
in the probe trial between BFCN lesioned and control APP/PS1 mice compared to BFCN lesioned and 
control wildtype mice, indicate a disease specific deficit in allocentric navigation learning and memory 
in susceptible AD mice induced by a loss of BFCNs.  
 
3.2.5     Increase in total Aβ42 levels in the hippocampus but not Aβ plaque number and size 
following loss of basal forebrain cholinergic neurons 
It has previously been reported that APP/PS1 amyloid transgenic mice with a loss of BFCNs have 
exacerbated amyloid pathology in older (symptomatic) mice (Laursen et al., 2013, Ramos-Rodriguez et 
al., 2013). To determine if an equivalent loss of BFCNs in young, presymptomatic mice could induce 
an increase Aβ levels, we analysed Aβ plaque load and total levels of Aβ in the hippocampus. No 
difference in the number of Aβ plaques per square mm or plaque size was observed between transgenic 
mice one month after IgG-saporin or p75-saporin injection (Figure 3.5A-C). However, total Aβ levels 
in hippocampal homogenates of APP/PS1 mice with lesioned BFCNs (as measured by ELISA) were 
significantly higher than that of control-injected APP/PS1 mice (Figure 3.5D). This indicates that a 
loss of cholinergic innervation to the hippocampus of presymptomatic, susceptible AD mice can 
accelerate the production/accumulation of Aβ peptide. 
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Figure 3.4     Impairment in memory retention in a hippocampal-dependent spatial navigation 
Morris water maze task following loss of basal forebrain cholinergic neurons in APP/PS1 mice  
(A and B) Graph of the escape latency (time to find the hidden platform) averaged per day in a 8 day 
Morris water maze task of spatial learning of (A) basal forebrain lesioned (p75-saporin) APP/PS1 mice 
and their non-lesioned (IgG-saporin) transgenic controls, and (B) basal forebrain lesioned (p75-saporin) 
wildtype mice, their non-lesioned (IgG-saporin) controls and naïve wildtypes of the same age.  No 
significant differences between basal forebrain lesioned APP/PS1 transgenic mice or wildtype mice and 
their non-lesioned controls were observed during the initial 5-day learning schedule. Following a 
change in platform location on day 7, basal forebrain lesioned transgenic and wildtype mice both take 
longer to find and remain on the platform. On the following day (day 8) this deficit in escape latency is 
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no longer observed. Two-way ANOVA with Tukey’s post-hoc test, *p<0.05. 
Quantification of time spent in seconds (s) in target quadrant (C), latency to platform (D) and 
platform crossing frequency (E) during the probe trial on day 6, between basal forebrain lesioned and 
non-lesioned transgenic mice, basal forebrain lesioned and non-lesioned wildtype mice and naïve 
wildtype controls. Basal forebrain lesioned APP/PS1 spend significantly less time in the target quadrant 
and make significantly fewer platform crosses than transgenic and wildtype non-lesioned controls, and 
wildtype mice with equivalent basal forebrain loss. Data are presented as mean ± SEM with sample size 
indicated in the bars. One-way ANOVA with Tukey’s post-hoc, *=p<0.05. 
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3.2.6     Hippocampal synaptophysin and GFAP are unchanged following loss of basal 
forebrain cholinergic neurons 
To determine whether a loss of cholinergic innervation to the hippocampus, the reduction in 
hippocampal BDNF and the consequent increase in Aβ protein had an effect on other features of AD, 
such as synapse loss and reactive astrogliosis, we measured levels of synaptophysin, a presynaptic 
protein, and glial fibrillary acidic protein (GFAP) a marker of astrocytes, in hippocampal homogenates. 
This analysis revealed no differences in total synaptophysin or GFAP levels in the hippocampus 
following loss of BFCNs in APP/PS1 mice compared to transgenic controls (Figure 3.6A-B). As these 
features of AD are most tightly linked with plaques and plaque load, the results are consistent with the 
above finding of increase Aβ in lysates but not an increase in Aβ plaque. 	  
3.2.7     No change in levels of hyperphosphorylated tau epitopes in the hippocampus and 
cortex of basal forebrain lesioned APP/PS1 mice  
Ramos-Rodriguez and colleagues (2013) have previously demonstrated that loss of BFCNs exacerbates 
tau pathology in symptomatic APP/PS1, however this was measured by the increase in phosphorylation 
of a single hyperphosphorylated epitope in the cortex by western blot analysis. In most circumstances, 
hyperphosphorylation of several epitopes is used to determine pathological changes in tau. Therefore, to 
determine whether loss of BFCNs in our presymptomatic mice was able to precipitate pathological 
hyperphosphorylation of tau, we measured the extent of phosphorylation of tau in a range of epitopes 
that are considered to be markers of pathological hyperphosphorylation and which are found in disease 
states. We assessed the phosphorylation of tau in hippocampal and cortical lysates from BFCN lesioned 
APP/PS1 transgenic mice. However, no differences were found in the levels of total tau or the level of 
phosphorylation at any of the phospho-tau epitopes investigated, in either the soluble (Figure 3.7A,B) 
or insoluble (Figure 3.8) hippocampal lysate fractions, between p75-saporin and IgG-saporin injected 
mice. Furthermore, no change in total tau or phospho-tau in the soluble cortical lysate fraction was 
induced by loss of BFCNs (Figure 3.9). This suggests that loss of BFCNs, neurotrophic dysregulation 
and increased Aβ levels were insufficient to induce tau phosphorylation in the hippocampus or cortex 
of young APP/PS1 transgenic mice. 
 
3.2.8     Trophic signalling and levels of the tau kinase, GSK3β, are unaffected by loss of basal 
forebrain cholinergic neurons and a reduction in hippocampal BDNF levels 
To determine whether the loss of BDNF in the hippocampus of lesioned mice resulted in a decrease in 
local downstream signalling one month following the loss of BFCNs, we measured levels of the total 
and phosphorylated forms of the downstream signalling proteins, ERK1/2 and Akt, in the  
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hippocampus. No differences in phosphorylated ERK1/2 or Akt, nor any changes in total ERK1/2 or 
Akt were found by western blot (Figure 3.10A-D). Similarly, and consistent with the lack of change in 
phosphorylated Akt (a kinase upstream of GSK3β) and phospho-tau in the hippocampus, western blot 
analysis revealed no change in either phospho-GSK3β levels or total GSK3β in the hippocampus of 
lesioned mice compared to transgenic controls (Figure 3.10E,F). 	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Figure 3.5     Increase in total A!42 levels in the hippocampus but not A! plaque number and size 
following loss of basal forebrain cholinergic neurons  
(A) Representative fluorescent images of amyloid plaques (visualized with Thioflavin S staining) in the 
hippocampus of a control (IgG-saporin, left) and a basal forebrain lesioned (p75-saporin, right) 
APP/PS1 amyloid transgenic mouse. Plaques are indicated by white arrows and a magnified view of a 
plaque is visible in the top right corner. Quantification of (B) A! plaque number with Thioflavin S 
staining per µm2 and (C) plaque size of basal forebrain lesioned and control mice. Loss of basal 
forebrain cholinergic neurons has no effect of plaque number and size in the hippocampus. (D) 
Quantification of total A!42 levels by ELISA from hippocampal lysates of control and basal forebrain 
lesioned APP/PS1 mice. Loss of basal forebrain cholinergic neurons results in an increase in total A!42 
levels in the hippocampus. Data are presented as mean ± SEM, with sample size indicated in the bars. 
Unpaired t-test, *-p<0.05. 
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Figure 3.6     Hippocampal synaptophysin and GFAP levels are unchanged following loss of 
basal forebrain cholinergic neurons  
Representative western blots of hippocampal homogenates from naïve, control (IgG-saporin) and 
lesioned (p75-saporin) APP/PS1 amyloid transgenic mice probed for (A) synaptophysin and (B) glial 
fibrillary acidic protein (GFAP). Loss of basal forebrain cholinergic neurons does not change levels of 
expression of synaptophysin, a pre-synaptic protein marker, or GFAP, a marker of astrocytes. 
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Figure 3.7    Levels of soluble tau and hyperphosphorylated tau epitopes in the hippocampus are 
unaffected by loss of basal forebrain cholinergic neurons 
(A) Representative western blots of the soluble tau fraction of hippocampal homogenates from naive 
Tau knock out mice, and naïve, control (IgG-saporin) and basal forebrain lesioned (p75-saporin) 
APP/PS1 amyloid transgenic mice probed for the pan-tau marker Tau5 and tau hyperphosphorylation 
epitopes; AT8, AT180, AT270, pSer235, pSer262 and pSer422. Each tau band is compared to its 
respective GAPDH loading control band found underneath it.  
(B) Quantification of tau protein bands from the soluble tau fraction. No significant differences (two-
way ANOVA) in hyperphosphorylated tau epitopes were observed between naïve (grey bars), control 
(white bars) and basal forebrain lesioned (black bars) APP/PS1 mice. Bands were normalized to 
GAPDH loading control levels and levels are plotted relative to that of control APP/PS1 mice. Data are 
presented as mean ± SEM, with sample size indicated in the bars.  
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Figure 3.8     Levels of insoluble tau and hyperphosphorylated tau epitopes in the hippocampus 
are unaffected by loss of basal forebrain cholinergic neuron in APP/PS1 mice   
Representative western blots of the insoluble tau fraction of hippocampal homogenates from naive Tau 
knock out mice, and naïve, control (IgG-saporin) and basal forebrain lesioned (p75-saporin) APP/PS1 
amyloid transgenic mice probed for tau hyperphosphorylation epitopes AT180 and AT270. Each tau 
band of a particular hyperphosphorylated epitope is compared to its respective pan-tau marker (Tau5) 
and its GAPDH loading control band found underneath it.  
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Figure 3.9     Levels of soluble tau and hyperphosphorylated tau epitopes in the cortex are 
unaffected by loss of basal forebrain cholinergic neuron in APP/PS1 mice  
(A) Representative western blots of the soluble tau fraction of cortical homogenates from control (IgG-
saporin), basal forebrain lesioned (p75-saporin) APP/PS1 amyloid transgenic mice and a Tau knockout 
mouse, probed for tau hyperphosphorylation epitopes; AT8, AT180 and AT270, and the pan-tau 
marker Tau5. Each tau band is compared to its respective GAPDH loading control band found 
underneath it.  
(B) Quantification of tau protein bands in the cortex from the soluble tau fraction. No significant 
differences (two-way ANOVA) in hyperphosphorylated tau epitopes were observed between control 
(white bars) and basal forebrain lesioned (black bars) APP/PS1 mice. Bands were normalized to 
GAPDH loading control levels and levels are plotted relative to that of control APP/PS1 mice. Data are 
presented as mean ± SEM, with sample size indicated in the bars.  
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Figure 3.10     Trophic signalling and levels of the tau kinase, GSK3β , are unaffected by loss of 
basal forebrain cholinergic neurons and a reduction in hippocampal BDNF levels  
Representative western blots (A, C, E) and quantification (B, D, F) of total and phosphorylated 
ERK1/2 (A, B), Akt (C, D) and GSK3β (E, F) levels in hippocampal homogenates from naïve (gray 
bars), control (white bars) and basal forebrain lesioned (black bars) APP/PS1 amyloid transgenic mice. 
The band intensities were normalized to the GAPDH loading control levels and are shown relative to 
the levels in APP/PS1 control mice. Data are presented as mean ± SEM with the sample size indicated 
in the bars. 
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3.3    Discussion  	  
Basal forebrain cholinergic neuron degeneration is a major prodromal feature of AD. Loss of these 
neurons is associated with Aβ burden in the brain of AD patients and correlates with cognitive decline 
(Kerbler et al., 2015). In symptomatic mouse models of AD, inducing loss of BFCN results in an 
exacerbation of amyloid pathology and consequential cognitive impairment. However, the mechanisms 
underpinning the accelerated pathology are still unclear. The aim of this chapter was to reproduce this 
accelerated amyloid phenotype and cognitive changes in presymptomatic mice to determine if loss of 
BFCN innervation to the hippocampus was sufficient to trigger early changes to the disease process. 
Furthermore, we tested for other disease features that may underpin, or occur in parallel with, changes 
in amyloid pathology in the hippocampus, such as altered neurotrophic signalling, synaptic integrity 
and tau pathology. In the present work we found that loss of cholinergic neurons resulted in an increase 
in hippocampal Aβ levels and cognitive deficits that were specific for the combination of lesion and 
genotype. Additionally, we found a selective decrease in hippocampal BDNF protein following loss of 
BFCNs. However trophic signalling, synaptic integrity, glial response and tau pathology were not 
appreciably different. 
 
In the present chapter, we induced a partial cholinergic lesion in the basal forebrain resulting in a 
significant reduction in cholinergic neuron number as indicated by ChAT-positive neurons. 
Cholinergic neurons in the basal forebrain are the only cell type which express the p75NTR receptor in 
that brain area, and consistent with this, the p75-antibody conjugated saporin was selective in inducing 
cholinergic loss, with parvalbumin-positive neuronal number being unaffected following exposure to 
p75-saporin. Our lesion size and specificity is consistent with previous reports in which loss of BFCNs 
is sufficient to exacerbate pathology in susceptible, symptomatic mice (Gil-Bea et al., 2012, Laursen et 
al., 2013, Ramos-Rodriguez et al., 2013, Hartig et al., 2014). However, in contrast to previous studies 
achieving partial cholinergic degeneration through ICV infusion of p75-saporin, we injected p75-
saporin directly into the medial septum of AD transgenic mice. Our method achieves a selective loss of 
cholinergic neurons in the anterior basal forebrain without loss in neighbouring basal forebrain nuclei, 
such as the nucleus basalis (Boskovic, 2016). Moreover, our lesion of BFCNs resulted in a significant 
loss of ChAT protein in the hippocampus, further demonstrating the effectiveness of our lesion on the 
septal-hippocampal pathway. Therefore we conclude that we have achieved a working model of reduced 
cholinergic signalling from the basal forebrain to hippocampus in APP/PS1 amyloid transgenic mice in 
which to further investigate downstream degenerative pathways. 
	   65 
As hypothesized, we observed a significant decrease in BDNF protein levels following loss of BFCNs in 
our model. This is consistent with previous studies showing that a complete lesion of BFCNs in rats 
resulted in reduced BDNF mRNA in the hippocampus (Kokaia et al., 1996, Ferencz et al., 1997, 
Berchtold et al., 2002) and that cholinergic basal forebrain innervation of hippocampus is involved in 
the regulation of BDNF protein and mRNA (Lapchak et al., 1993, Gil-Bea et al., 2011). BDNF is 
synthesized, stored and released from dendrites of most excitatory neurons including pyramidal neurons 
in the hippocampus, in an activity-dependent manner (Hartmann et al., 2001). Furthermore, Gil-Bea 
et al., (2011) reported that cholinergic hypofunction leads to impaired muscarinic signalling in the 
hippocampus, resulting in decreased levels of BDNF protein and Arc protein.  
 
By contrast, we did not observe a decrease in NGF levels following basal forebrain lesion. NGF mRNA, 
but not BDNF mRNA, is expressed in GABAergic interneurons of hippocampus (Lauterborn et al., 
1993, Rocamora et al., 1996). Whereas pyramidal neurons of the hippocampus express BDNF mRNA 
(Lauterborn et al., 1993). Although cholinergic afferents target both cell populations, hippocampal 
interneurons that express NGF are preferential targets of the GABAergic septohippocampal pathway 
(Rocamora et al., 1996). Our findings of unchanged NGF may reflect that our cholinergic neuron 
lesion, which does not directly impact the GABAergic signalling, has less effect on interneuron activity 
than pyramidal neuron activity and thus has a milder affect on NGF synthesis. 	  
Given the significant decrease in levels of hippocampal BDNF protein, we expected to observe an 
equivalent reduction in hippocampal downstream neurotrophic signalling molecules. However, we 
found no differences in phosphorylation of ERK1/2 and Akt following a loss of BFCNs. This may be a 
result of compensatory signalling occurring in the hippocampus in order to negate the effects of 
reduced BDNF, as other neurotrophins such as NGF are unaffected. In contrast, Gil-Bea and 
colleagues (2011) reported reduced phosphorylation of ERK1/2 and Akt in hippocampal neurons by 
western blot analysis following lesion of BFCNs. This may reflect the difference in genotype, as 
APP/PS1 mice have increased numbers of reactive microglia surrounding plaques which have elevated 
levels of pERK1/2 signalling. We hypothesize that increased microglia-mediated pERK1/2 may explain 
why we do not see reduced trophic signalling in our APP/PS1 mice, compared to previous results in 
wildtype mice. 
 
The link between cholinergic dysfunction and impaired cognition is the basis of the cholinergic 
hypothesis of AD (Terry and Buccafusco, 2003). Moreover, current evidence links cholinergic 
degeneration with amyloid burden (Grothe et al., 2014, Teipel et al., 2014, Kerbler et al., 2015), which 
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in some studies correlates with greater cognitive impairment (Rodrigue et al., 2012), while the positive 
effects of neurotrophic signalling on memory, especially in the context of AD, are widely reported 
(Laske et al., 2011, Buchman et al., 2016). Thus we hypothesized that our BFCN lesioned APP/PS1 
mice with increased hippocampal Aβ levels and decreased BDNF protein, would demonstrate learning 
and memory impairments in a short term memory spatial navigation Y-maze paradigm and a 
hippocampal-dependent spatial navigation MWM task. 
 
To determine if reduced cholinergic signalling along with decreased BDNF and increased 
Aβ in the hippocampus of our presymptomatic APP/PS1 mice accelerated cognitive deficits, we tested 
them in a Y-maze paradigm. This paradigm tests hippocampal function in the form of spatial 
navigation and short term memory. Although our BFCN lesioned mice spend significantly less time in 
each of the maze arms compared to non-lesioned transgenic controls, we attribute this to their reduced 
velocity and distance travelled during the duration of testing. However, we can find no reason to 
explain this, as mice in subsequent behavioural testing show no differences in movement (Figure 
3.4F). The APP/PS1 mice therefore did not appear to be significantly impaired in the spatial memory 
aspect of this test. 
 
Next we tested long term spatial learning and memory in a MWM task to determine if loss of 
cholinergic signalling and its associated downstream consequences in APP/PS1 mice caused an 
acceleration in cognitive deficits resulting in poorer performance in the MWM task. We found that the 
6 month old APP/PS1 mice (regardless of basal forebrain status) have an equivalent escape latency 
learning curve to wildtype controls, indicating that at this age and in this context, they are 
presymptomatic. Lesioning of the basal forebrain in both wildtype and APP/PS1 mice resulted in 
slower escape latencies when platform location was changed on day 7. This deficit in memory updating 
is consistent with previous results (Hamlin et al., 2013), and is representative of cholinergic 
degeneration. Futhermore, in the probe trial we found that basal forebrain lesioned APP/PS1 spend 
significantly less time in the target quadrant, and make significantly fewer platform crossings compared 
to non-lesioned transgenic controls. This difference in performance is not observed in basal forebrain 
lesioned wildtype mice (compared to non-lesioned wildtype mice), indicating that loss of BFCNs in 
APP/PS1 mice caused an exacerbation in cognitive decline related to it genotype. This change in 
behaviour is consistent with exacerbation in older APP mice. Previous work by Ramos-Rodriguez et al. 
(2013) demonstrated a significant decrease in the time spent in the target quadrant in the probe trial by 
basal forebrain lesioned APP/PS1 mice compared to non-lesioned transgenic controls. Moreover, this 
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deficit was not observed in either basal forebrain lesioned or non-lesioned wildtype controls (Ramos-
Rodriguez et al., 2013). Therefore we conclude that the loss of BFCNs alone are insufficient to induce 
allocentric deficits, but that a combination of cholinergic hypofunction and exacerbated Aβ pathology 
can synergistically cause impairment in long term spatial learning and memory performance (Figure 
3.11B).  	  
We found an increase in total (soluble and insoluble) Aβ42 levels in the hippocampus as measured by an 
ELISA specific for human Aβ42 peptide, but no change in Aβ plaque number or size. This suggests an 
increase in soluble Aβ load. As human APP is driven by a transgene, it is unlikely the lesion would 
upregulate expression of APP, and therefore this result is indicative of either increased production or 
reduced clearance of Aβ. Moreover, this increase in soluble Aβ may be a prelude to subsequent 
increased Aβ deposition. However soluble Aβ oligomers are considered the more toxic species 
(Dahlgren et al., 2002, Benilova et al., 2012) and can induce neurotoxicity and memory deficits in mice 
(Brouillette et al., 2012). A widely supported hypothesis proposes that oligomeric Aβ induces the 
synaptic dysfunction and the spine loss that occurs in AD (Tu et al., 2014), and closely correlates with 
the severity of neurodegeneration (Terry et al., 1991, McLean et al., 1999). Synaptic loss mediated by 
Aβ is in turn dependent on N-methyl-D-aspartate receptor (NMDA-R) activity and mediated by 
dysregulated redox events, elevated cytoplasmic Ca2+ and tau hyperphosphorylation (Shankar et al., 
2007, Ittner et al., 2010, Tu et al., 2014). A parsimonious conclusion is that the BFCN-lesion induced 
increase in hippocampal Aβ levels is due to increased soluble Aβ which may cause synaptic transmission 
dysfunction and/or spine degeneration to result (either directly, or perhaps in combination with 
reduced ACh modulation) in MWM task memory retention impairments. 
 
As soluble Aβ is the main culprit in AD-related synapse loss (Tu et al., 2014), and we attribute our 
observed increase in Aβ levels to an increase in soluble Aβ, we assessed synaptic viability in the 
hippocampus by looking at levels of the presynaptic protein synaptophysin, however, no differences 
were found irrespective of increased Aβ levels. This may be due to insensitivity to mild synaptic 
degeneration, or that the Aβ was impairing synaptic transmission without (yet) resulting in spine 
degeneration. Future work may use electrophysiological methods to delve deeper into the mechanisms 
of action of soluble Aβ in this AD mouse model with cholinergic hypofunction, however, these 
methods are currently beyond the scope of our laboratory. 
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To determine if the increase in total Aβ resulted in an upregulation in immune response, we measured 
levels of the astrocyte marker, GFAP, a marker of inflammation, following loss of BFCNs. Reactive 
astrocytes and Aβ containing astrocytes are a common feature in an AD brain, particularly found 
accumulated around Aβ plaques, which possibly have Aβ clearing capacity (Thal, 2012). However we 
found no change in the levels of GFAP following basal forebrain lesion in APP/PS1 mice.  This likely 
reflects the fact that we did not observe an increase in amyloid plaque number or size, in which 
activated astrocytes are centered around. This result could also be considered consistent with a lack of 
synaptic degeneration induced by the increased Aβ levels.  
 
Despite inducing increased Aβ levels, no increase in tau or phospho-tau residues in APP/PS1 mice in 
either the cortex or hippocampus, was observed following the loss of BFCNs in APP/PS1 mice. 
Previous work has found an increase in the levels of a single hyperphosphorylated tau residue (AT8) in 
cortical tissue but not hippocampus, following an equivalent loss of BFCNs in 3 and 7 month old 
APP/PS1 mice. No cortical NFTs were observed (Ramos-Rodriguez et al., 2013). Similarly, increased 
tau phosphorylation at the AT270 residue in adult male WT rats with BFCN lesions was observed, 
with a corresponding decrease in phosphorylation (which corresponds to increased activity) of the tau 
kinase, GSK3β (Hawkes et al., 2005). This indicates that BFCN loss can regulate the 
hyperphosphorylation state of endogenous murine tau. In our mice, a reason why we do not see 
enhancement of tau pathology may be a result of the young age of our mice, as APP/PS1 mice do not 
develop tau pathology until later in life. Therefore, if reduced cholinergic signalling and increased Aβ 
levels do trigger pathological changes in tau (which is suggested in 3xTg-AD mice with cholinergic 
hypofunction) we may not have reached a critical level of pathology for this disease process to occur. 
One way to investigate this further is to induce cholinergic degeneration directly in tau transgenic AD 
mice to determine if cholinergic hypofunction can directly induce pathological changes in tau. We 
address this in the following chapter. 	  
We also assessed phosphorylation levels of the tau kinase GSK3β following loss of BFCNs, and no 
changes were observed. However, this is consistent with there being no observable increase in tau 
phosphorylation in our model. In contrast, Hawkes et al., (2005) show decreased phosphorylation of 
GSK3β following BFCN loss in adult WT rats both in the hippocampus and basal forebrain, as 
GSK3β colocalises with a subset of cholinergic neurons. However this decrease was transient and only 
significant 4 days post lesion, whereas by 14 days post surgery phosphorylated GSK3β levels have 
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returned to control levels (Hawkes et al., 2005). As we assessed mice 1 month post lesion it is not 
surprising that we did not replicate this loss of phosphorylated GSK3! following BFCN loss.
!
In conclusion, we successfully induced BFCN loss in presymptomatic APP/PS1 mice resulting in a 
significant reduction in ChAT levels in the hippocampus. Loss of cholinergic input to the hippocampus 
caused a reduction in hippocampal BDNF levels and increased the levels of total A!. As the 
combination of reduced cholinergic signalling and BDNF did not alone induce hippocampal-
dependent cognitive deficits in wildtype mice, elevated A! levels in this model appears to be required to 
induce spatial learning deficits in a MWM task (Figure 3.11). It remains to be determined whether this 
level of A! alone is sufficient to induce the cognitive decline, or whether the combination of deficits 
was required. As this model recapitulates a broader range of aspects of AD than just over expression of 
A!, namely neurotrophin and cholinergic dysregulation, it provides us with AD-relevant pathogenic 
pathways to manipulate in order to gain a better understanding of disease mechanisms. The first 
question is the role of cholinergic dysfunction in tau pathology which is addressed in the following 
chapter. Secondly, the remainder of the thesis focuses on the role of neurotrophins in AD. As such, the 
last two chapters investigated the role of low BDNF levels as a causative or contributing factor in the 
development of A! levels and cognitive decline, or whether BDNF levels fall as a consequence of 
disease processes.  
 
 
 
!
!
 
!
!
!
 
Figure 3.11     Schematic representation of a model of reduced cholinergic signalling in 
APP/PS1 mice 
Loss of cholinergic input to the hippocampus (reduced ACh) causes a reduction in BDNF levels and 
increases total A!. Reduced cholinergic signalling and BDNF alone do not induce cognitive deficits in 
wildtype mice indicating the requirement of increased A! in this model to negatively impact cognitive 
function. 
!
Reduced ACh
Reduced BDNF
Increased A!
Cognitive deficits
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4.1     Introduction 	  
4.1.1     Chapter overview 
In the previous chapter, loss of basal forebrain cholinergic neurons triggered pathogenic amyloidogenic 
processing, a decrease in BDNF protein and memory impairments in a MWM task. Together this 
resulted in an exacerbation of Aβ load early in disease course. Furthermore, others have reported that 
BFCN lesioning in symptomatic animals causes not only increased Aβ load but also increased plaque 
and tau pathology. The question therefore is, is this change in tau pathology a result of the BFCN 
lesion directly or subsequent to Aβ pathology?  In contrast to studies studying changes in tau in AD 
mouse models genetically predisposed to developing tau pathology, in the previous chapter we did not 
see any discernable tau phenotype following BFCN lesion in presymptomatic APP/PS1 mice. This may 
be due to APP/PS1 mice not developing tau pathology until late stages in the disease which would not 
be evident in the timeframe of the previous studies where lesioning was of presymptomatic mice, or it 
may be that reduced cholinergic and neurotrophic signalling do not affect tau directly. To address these 
questions, we recapitulated BFCN loss in a tau transgenic mouse strain called pR5 (P301L) mice, and 
assessed the downstream consequences on tau pathology and cognition following this lesion.  	  
4.1.2     Tau, cholinergic dysfunction and neurotrophins in Alzheimer’s disease 
Two hallmark histopathological lesions in the brains of Alzheimer’s disease patients are senile plaques 
composed of deposits of amyloid-β protein, and neurofibrillary tangles composed of 
hyperphosphorylated tau protein (Hardy and Selkoe, 2002). In order to model these features of AD, 
common genetically modified strains of mice express mutant human amyloid precursor protein and/or 
presenilin genes in the brain, resulting in increased production of Aβ protein, formation of plaques, and 
memory impairment (Jankowsky et al., 2004, Garcia-Alloza et al., 2006). Similarly, mice modeling tau 
pathology have been produced, e.g. pR5 transgenic mice that express the human tau isoform containing 
the P301L familial fronto-temporal dementia (FTD) mutation develop tau hyperphosphorylation, 
NFTs and impaired spatial reference memory from 6 months of age (Gotz et al., 2001, Pennanen et al., 
2006, Deters et al., 2008). Although Aβ and tau protein are neurotoxic through both separate and 
synergistic mechanisms (Nisbet et al., 2015), the causal factors that initiate these key pathogenic events 
in sporadic forms of the disease are unclear. Furthermore, most familial transgenic models fail to mimic 
the marked loss of basal forebrain cholinergic neurons characteristic of human AD.  
 
Cholinergic changes are observed prior to clinical manifestation of AD and are likely to directly 
underpin aspects of cognitive decline (Mesulam, 2004, Contestabile, 2011). Loss of BFCNs have also 
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been closely correlated with brain Aβ burden in human patients, potentially indicative of a causal 
relationship (Beach et al., 2000, Potter et al., 2011, Teipel et al., 2014, Kerbler et al., 2015). Although 
Aβ is neurotoxic to BFCNs (Sotthibundhu et al., 2008, Knowles et al., 2009), several groups have 
conversely demonstrated that lesioning these cells in Aβ-overproducing mice results in increased Aβ 
deposition, tau phosphorylation and memory impairment (Gil-Bea et al., 2012, Laursen et al., 2013, 
Ramos-Rodriguez et al., 2013, Hartig et al., 2014). Similarly, BFCN lesions in rats increase tau 
phosphorylation (Hawkes et al., 2005), suggesting that cholinergic denervation may trigger the 
generation of the Aβ and phosphorylated tau proteins which accumulate pathologically in AD.  
 
One mechanism to explain how reduced cholinergic function could regulate Aβ generation and tau 
phosphorylation is by altering the levels of neurotrophins in postsynaptic neurons of the cortex and 
hippocampus. Neurotrophins, including NGF and BDNF, regulate neuronal survival, maintenance and 
cell death through the Trk and p75NTR neurotrophin receptors (Kaplan et al., 1991). Neurotrophin 
deprivation of cultured hippocampal neurons results in overproduction of Aβ protein and concomitant 
apoptotic cell death (Matrone et al., 2008a, Matrone et al., 2008b), as well as increased tau 
phosphorylation due to increased Akt and GSK3β activity (Amadoro et al., 2011). GSK3β is a target of 
BDNF-mediated signaling, and a key tau kinase (Sperber et al., 1995, Mai et al., 2002). Both BDNF 
mRNA and protein are selectively decreased in the hippocampus and cortex of AD patients compared 
to normal aged controls (Phillips et al., 1991), and high BDNF levels predict slower cognitive decline 
in AD (Luthi et al., 1997). Furthermore, BFCN lesions can reduce BDNF (Gil-Bea et al., 2011) and 
increase GSK3β activity levels (Hawkes et al., 2005). Although the amyloid hypothesis of AD currently 
places tau hyperphosphorylation downstream of Aβ generation and oligomerization, here we used pR5 
tau transgenic mice to investigate whether degeneration of BFCNs, independent of an effect on Aβ 
generation, could cause or enhance tau phosphorylation and NFT pathology in vivo. 	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4.2     Results 	  
4.2.1     p75-saporin injection selectively lesions basal forebrain cholinergic neurons 
In order to test whether cholinergic neuronal degeneration causes tau hyperphosphorylation in 
genetically susceptible mice, we lesioned BFCNs in 2-month-old pre-symptomatic tau pR5 (P301L) 
tau transgenic mice using the toxin mu p75-saporin; p75NTR expression is restricted to BFCNs and 
endocytosis of the saporin-receptor complex induces cell death. Control mice were injected with IgG-
saporin. After one month, behavioral, histological and biochemical analyses were performed. Stereotaxic 
injection of p75-saporin into the medial septal area of the basal forebrain resulted in a 60% decrease in 
the number of ChAT-positive neurons compared to IgG-saporin injected mice (Figure 4.1A, B). This 
lesion also caused denervation of the BFCN projections to the hippocampus (not shown). The number 
of parvalbumin-positive neurons in the basal forebrain was unchanged following p75-saporin injection 
compared to control (Figure 4.1C), confirming the specificity of the lesion.  
 
4.2.2     Levels of BDNF and NGF are reduced following loss of basal forebrain cholinergic 
neurons innervation to the  hippocampus 
To determine whether loss of cholinergic innervation caused a change in the levels of neurotrophins in 
the hippocampus, we measured the amount of BDNF and NGF protein in hippocampal homogenates 
from p75-saporin- and IgG-saporin-injected pR5 tau transgenic mice, and their wildtype age- and 
gender-matched littermates. IgG-saporin-injected animals had equivalent levels of BDNF protein levels 
to their wildtype littermates (Figure 4.2A). In contrast, lesioning the BFCNs with p75-saporin 
reduced BDNF protein levels relative to unlesioned control levels (Figure 4.2A). This was considered 
biologically significant as mice with a heterozygous knockout of BDNF, had reduced BDNF protein 
levels in the hippocampus compared to wildtype mice (Figure 4.2A). Loss of BFCN projections had a 
similar effect on the levels of NGF protein in the hippocampus, with lesioned mice showing a 
significant decrease in NGF following p75-saporin injection compared to IgG-saporin injected controls 
(Figure 4.2B). 
 
4.2.3     Learning and memory are unaffected in a spatial navigation task following loss of 
basal forebrain cholinergic neurons  
To determine whether the loss of acetylcholine and/or the reduction of neurotrophins within the 
hippocampus was sufficient to induce a deficit in cognitive function, lesioned and control pR5 tau 
transgenic mice, together with their age- and gender-matched wildtype littermates, were tested in the 
Morris water maze hippocampal-dependent learning and memory paradigm. Animals underwent a 5 
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Figure 4.1     p75-saporin injection into the basal forebrain induces a selective loss of cholinergic 
neurons 
(A) Representative photomicrographs of coronal brain sections at the level of the basal forebrain, 
immunostained for a cholinergic neuron marker (α-ChAT) 1 month after microinjection of IgG-
saporin (control) or p75-saporin (lesion) into the medial septum. Location of photomicrograph 
indicated on schematic of coronal brain section in top right hand corner. Quantification of ChAT- (B) 
and parvalbumin-positive (C) neuronal numbers in the basal forebrain, demonstrating a selective loss of 
ChAT-positive neurons following p75-saporin lesion with parvalbumin-positive neuron numbers being 
unchanged. Data are presented as mean ± SEM. The number of animals per condition is indicated 
within the bars of the graphs. *** p<0.001, unpaired t-test. Scale bar represents 100µm. 
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Figure 4.2     Levels of BDNF and NGF are reduced following loss of basal forebrain cholinergic 
neuron innervation to the hippocampus 
Quantification of (A) BDNF and (B) NGF protein levels (pg protein/mg wet tissue) in hippocampal 
homogenates by ELISA in p75-saporin (lesion) and IgG-saporin (control) injected pR5 tau transgenic 
mice, their wildtype (WT) littermates, and BDNF heterozygous (BDNF +/-) mice. Data are presented 
as mean ± SEM. The number of animals per condition is indicated within the bars of the graphs. 
BDNF: One-way ANOVA with Tukey’s multiple comparisons test, **** p<0.0001. NGF: Unpaired t-
test, * p<0.05.  
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day learning schedule followed by a probe trial on the sixth day. Lesioned and control mice traveled 
equivalent distances in the maze arena and no mouse displayed obvious motor difficulties. No 
significant differences in escape latency between any of the groups were observed over the 5 days 
(Figure 4.3A). In the probe trial, when the hidden platform was removed from the arena, time spent in 
the target quadrant, latency to the platform quadrant and platform crossing frequency were assessed. 
Consistent with the evidence of robust learning by both groups of mice, no differences between 
lesioned and control mice were observed for these measures (Figure 4.3B-D). This demonstrates that, 
despite changes in cholinergic innervation and neurotrophin levels in the hippocampus, loss of BFCNs 
does not result in obvious impairment in allocentric navigation learning and memory. 
 
4.2.4     Tau hyperphosphorylation in the hippocampus is unaffected following loss of basal 
forebrain cholinergic neurons  
We next determined whether the cholinergic denervation of, and reduced neurotrophin levels in, the 
hippocampus precipitated the development of tau pathology. A range of tau phosphorylation epitopes 
that are considered to be markers of pathological hyperphosphorylation, and which are found in disease 
states, were analyzed in the hippocampal lysates of the lesioned and control pR5 tau transgenic mice by 
western blot. No difference was found in the level of either total human tau or the level of 
phosphorylation at any of the phospho-tau epitopes investigated, in either the soluble (Figure 4.4A 
and C) or insoluble lysate fractions (Figure 4.4B and D), between p75-saporin and IgG-saporin 
injected mice. This suggests that loss of BFCNs and neurotrophic dysregulation are not sufficient to 
induce tau phosphorylation, even in susceptible tau transgenic mice. 
 
4.2.5     Loss of basal forebrain cholinergic neurons in young pre-symptomatic mice does not 
affect tau hyperphosphorylation later in life 
Loss of BFCNs has been shown to exacerbate AD pathology in symptomatic mice carrying APP 
mutations. However, a loss of these neurons in our pre-symptomatic tau transgenic mice did not induce 
tau pathology. To determine whether a longer period of denervation might exacerbate existing tau 
pathology in pR5 mice, we again lesioned pre-symptomatic mice at 2 months of age, and then assessed 
the development of pathology 5 months later (in 7 month old animals). The level of phosphorylation at 
hyperphosphorylation epitopes was again measured by western blot analysis of hippocampal 
homogenates from lesioned and control mice. Consistent with the mice being of an age at which the 
transgene results in tau pathology, all aged transgenic mice had increased overall levels of total tau and 
increased expression of individual tau hyperphosphorylation epitopes, particularly in the soluble 
fraction (Figure 4.4A compared to Figure 4.5A) compared to the younger mice. However, consistent  
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Figure 4.3     Learning and memory are unaffected in a spatial navigation task following loss of 
basal forebrain cholinergic neurons 
 (A) Graph of the escape latency (time to find the hidden platform) averaged per day in a 5 day Morris 
water maze task of spatial learning. No significant differences between basal forebrain lesioned pR5 tau 
transgenic mice, control transgenic mice or their wildtype littermates were found. Two-way ANOVA 
with Bonferroni post-hoc test. Quantification of time spent in seconds (s) in target quadrant (B), 
latency to platform (C) and platform crossing frequency (D) during the probe trial on day 6. No 
significant differences were observed. Data are presented as mean ± SEM with sample size indicated in 
the bars. A one-way ANOVA was used for analysis of probe trial results. 
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Figure 4.4     Tau hyperphosphorylation in the hippocampus is unaffected following loss of basal 
forebrain cholinergic neurons  
(A) Representative western blots of the soluble tau fraction of hippocampal homogenates from naive 
wildtypes, and control (IgG-saporin) and lesioned (p75-saporin) pR5 tau transgenic mice probed for 
the tau hyperphosphorylation epitopes AT8, AT100, AT180, AT270 and Tyr18 or the pan-tau marker 
Tau5. (B) The insoluble tau fraction of hippocampal homogenates from naive wildtypes, and control 
(IgG-saporin) and lesioned (p75-saporin) tau transgenic mice was also probed for the  
hyperphosphorylated tau epitope AT270 and the pan-tau marker Tau5. No changes were observed 
following loss of basal forebrain cholinergic neurons.  
(C, D) Quantification of the phosphorylated human isoform tau bands from the soluble and insoluble 
(A and B, respectively) tau fractions. No significant differences in hyperphosphorylated tau epitopes 
were observed between control (white bars) and lesioned (black bars) pR5 mice. Bands were normalized 
to GAPDH loading control levels and levels are plotted relative to that of control pR5 mice. Data are 
presented as mean ± SEM, with sample size indicated in the bars. 
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with previous results, no change in total tau or phospho-tau in the soluble or insoluble lysate fractions 
was induced by BFCN lesioning (Figure 4.5). 
 
4.2.6     Downstream trophic signalling and levels of synaptophysin are unaffected following 
a reduction in hippocampal BDNF and NGF  
To determine whether the loss of BDNF and NGF in the hippocampus of lesioned mice resulted in a 
decrease in local downstream signaling, we first measured levels of phosphorylated ERK1/2 and Akt in 
the hippocampus. No differences in phosphorylated ERK1/2 or Akt, nor any changes in total ERK1/2 
or Akt were found by western blot (Figure 4.6A-D). Similarly, and consistent with the lack of change 
in phosphorylated Akt (a kinase upstream of GSK3β) and phospho-tau, western blot analysis revealed 
no change in either phospho-GSK3β levels or total GSK3β in the hippocampus of lesioned mice 
(Figure 4.6E-F) 
 
Finally, as increased BDNF has previously been correlated with an increase in hippocampal synaptic 
density (Blurton-Jones et al. 2009), we tested whether a BFCN lesion caused reduced synaptic 
connectivity by measuring the levels of the presynaptic protein synaptophysin by western blot. This 
analysis revealed no differences in total synaptophysin levels in the hippocampus following a decrease in 
BDNF induced by BFCN loss (Figure 4.6G-H). 
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Figure 4.5     Loss of basal forebrain cholinergic neurons in young pre-symptomatic mice does 
not affect tau hyperphosphorylation later in life  
(A) Representative western blots of the soluble tau fraction of hippocampal homogenates from 7-
month-old pR5 mice that underwent a control or basal forebrain cholinergic neuron lesion at 2 months 
of age probed for the tau hyperphosphorylation epitopes AT8, AT100, AT180 and AT270, and the 
pan-tau marker Tau5. (B) The insoluble tau fraction of hippocampal homogenates from naive 
wildtypes, and control (IgG-saporin) and lesioned (p75-saporin) pR5 tau transgenic mice was also 
probed for the hyperphosphorylated tau epitope AT270 and the pan-tau marker Tau5. No changes 
were observed following loss of basal forebrain cholinergic neurons.  
(C, D) Quantification of the human isoform tau bands from the soluble and insoluble (A and B, 
respectively) tau fractions. No significant differences in hyperphosphorylated tau epitopes were 
observed between control (white bars) and lesioned (black bars) pR5 mice. Bands were normalized to 
GAPDH loading control levels and levels are plotted relative to that of control pR5 mice. Data are 
presented as mean ± SEM, with sample size indicated in the bars. 	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Figure 4.6     Downstream trophic signalling and levels of synaptophysin are unaffected 
following a reduction in hippocampal BDNF and NGF  
Representative western blots (A, C, E, G) and quantification (B, D, F, H) of total and phosphorylated 
ERK (A, B), Akt (C, D), GSK3β (E, F) and synatophysin (G, H) levels in hippocampal homogenates 
from naive wildtype mice (gray bars), and control (white bars) and lesioned (black bars) pR5 transgenic 
mice. The band intensities were normalized to the GAPDH loading control levels and are shown 
relative to the levels in pR5 control mice. Data are presented as mean ± SEM with the sample size 
indicated in the bars. 
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4.3     Discussion 
 
BFCN loss is considered an early feature of AD, and basal forebrain degeneration correlates with Aβ 
burden in humans and can induce Aβ production and accumulation in genetically susceptible mouse 
models. The relationship between the second histological feature of AD, tau pathology, and BFCN 
degeneration is less well studied; however there are direct signaling pathways whereby BFCN loss, 
resulting in the downregulation of neurotrophic signaling, might cause tau hyperphosphoryation. Here 
we found that, although loss of the cholinergic neurons of the basal forebrain resulted in a decrease in 
hippocampal BDNF and NGF protein, trophic signaling, tau hyperphosphorylation and aggregation in 
the hippocampus, and hippocampal-dependent learning and memory, and synaptic integrity were 
unaffected. 
 
Our BFCN lesion was achieved by a direct medial septal injection of the p75-saporin immunotoxin, 
resulting in selective degeneration of BFCNs, with lesion extent and specificity being consistent with 
previous reports in which the toxin was injected into the ventricles bilaterally (Laursen et al., 2013, 
Ramos-Rodriguez et al., 2013, Hartig et al., 2014. In a number of previous reports, a BFCN lesion was 
sufficient to induce specific cognitive deficits and accelerate Aβ pathology in AD model mice (Laursen 
et al., 2013, Hamlin et al., 2013) This indicates that our lesion size was sufficient to reduce cholinergic 
innervation to the hippocampus and induce flow-on effects.  
 
Previous reports indicate that medial septum neurons of the basal forebrain which innervate the 
hippocampus are responsible for the regulation of normal hippocampal function and excitability, 
including regulating BDNF gene expression (Lindefors et al., 1992, Lapchak et al., 1993). Gil-Bea et al. 
(2011) further suggest that cholinergic hypofunction leads to impaired muscarinic signaling in the 
hippocampus that in turn decreases Arc and proBDNF levels. Consistent with this, several groups have 
previously reported reduced BDNF mRNA or protein in the hippocampus following a complete BFCN 
lesion in rats (Kokaia et al., 1996, Ferencz et al., 1997). It was therefore not surprising that cholinergic 
denervation induced a significant reduction in levels of BDNF and NGF in the pR5 mice, confirming 
the link between BFCN activity and neurotrophin availability in the hippocampus. 
 
It has been previously reported that, although BFCN lesioning in wildtype animals impairs uncued 
(idiothetic) maze tasks, it does not affect cued (allocentric) Morris water maze performance (Hamlin et 
al., 2013). Herein we hypothesized that a BFCN lesion would cause an impairment in hippocampal 
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memory due to the reduction in neurotrophin levels in combination with tau dysfunction in the 
hippocampus. However, no deficits in learning and memory were apparent in the hippocampal-
dependent spatial navigation task following loss of BFCNs in our study, and we did not observe any 
increase in tau hyperphosphorylation epitopes. In contrast, Ramos-Rodriguez et al., (2013) reported 
that 3-month-old APP/PS1 transgenic mice with BFCN lesions (but not controls) are mildly impaired 
in the acquisition phase of the Morris water maze task. This concurs with our findings that loss of 
BFCNs alone are insufficient to induce allocentric deficits, although a combination of cholinergic 
hypofunction and exacerbated Aβ pathology could synergistically cause impairment in spatial working 
memory performance.  
 
Our main hypothesis was that, like Aβ pathology, tau pathology would be exacerbated by BFCN 
degeneration. However, we found no evidence that a loss of BFCN innervation and the resulting 
decrease in BDNF and NGF in the hippocampus either induced or exacerbated the level of tau 
hyperphosphorylation at a variety of epitopes. This was the case even when mice harbored BFCN 
lesions for the majority of their life and were assessed at an age at which NFT pathology was already 
present. Consistent with this, we saw no change in the activation of tau or neurotrophic signaling 
kinases. In contrast, Hawkes et al., (2005) have reported that BFCN lesioning of adult male wildtype 
rats results in a transient decrease in phosphorylation (increase in the activation) of GSK3β and a minor 
increase in tau phosphorylation at the AT270 residue in the hippocampus between 4 and 14 days post-
lesion. It is possible that, at an intermediate time point between lesioning and analysis, tau 
phosphorylation (and GSK3β activity) was transiently increased in our animals. However, we reasoned 
that in the pR5 mice, in which the mutant human tau proteins have the propensity to aggregate, such a 
transient increase in tau phosphorylation could be sufficient to trigger a cascade effect resulting in 
NFTs. This idea is not supported by our data. Rather, the significant reduction in neurotrophins and 
cholinergic innervation in otherwise healthy animals over several months appears to have no overt 
adverse effect. This could be due to compensatory mechanisms, or the need for an additional molecular 
trigger. 
 
In contrast, comparable BFCN lesions in APP/PS1 mice result in an exacerbation in amyloid pathology 
(Laursen et al., 2013, Ramos-Rodriguez et al., 2013). Furthermore, in these mice tau 
hyperphosphorylation (but not NFTs) was induced in the cortex (Ramos-Rodriguez et al., 2013). Based 
on our results, we suggest that the reported increase in tau hyperphosphorylation is a downstream result 
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of the increased Aβ in BFCN lesioned APP/PS1 mice rather than a direct result of the lesion or the 
decreased neurotrophin levels.  
 
Aβ oligomers are toxic (Dahlgren et al., 2002, Benilova et al., 2012), and can cause mis-sorting of tau 
into dendrites, increased tau phosphorylation, and destabilization and damage of microtubules and 
spines (Zempel et al., 2010). A lack of neurotrophic activity to compensate for or reverse this effect 
could thereby trigger a disease cycle. Hyperphosphorylation of tau in the above APP models, and 
humans, may therefore require two “hits”: BFCN loss and the presence of Aβ oligomers. As rodent Aβ 
protein is structurally dissimilar to the human protein and does not form toxic aggregates, our pR5 
transgenic model may not possess the required amyloid pathology for the ‘second hit’ to induce tau 
phosphorylation. This idea is supported by in vitro data where neurotrophin starvation of hippocampal 
neurons resulted in an increased tau phosphorylation state that was temporally related to aberrant Aβ 
generation (Amadoro et al., 2011).  
 
Despite inducing robust cholinergic loss and a resultant significant reduction in neurotrophin levels in 
presymptomatic mice primed to develop tau pathology, altered signalling that resulted in changed tau 
phosphorylation did not result. We therefore suggest that, although BFCN degeneration is a risk factor 
for exacerbated Aβ pathology in genetically susceptible animals, associated tau pathology is likely to be 
mediated independently of/indirectly by BFCN degeneration and/or the resultant decrease in 
neurotrophin levels, albeit that these features may be essential contributing factors to disease etiology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 87 
!
!
!
!
!
!
!
!
!
!
!
 
 
 
 
 
Genetic knockdown of 
hippocampal BDNF: 
functional and 
pathological implications 
in an amyloid transgenic 
AD mouse model!
!
!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AAV-Synapsin-Cre-GFP  
expression in the hippocampus 
of a BDNF floxed mouse 
5 
	  88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   89 
5.1     Introduction 	  
5.1.1     Chapter overview 
In Chapter 3 we demonstrated that loss of BFCNs caused a reduction in BDNF protein levels, an 
increase in Aβ levels and corresponding cognitive impairments when tested in a MWM task. These 
results raised the question of whether the elevation in Aβ levels and cognitive impairment were a result 
of reduced hippocampal ACh, reduced BDNF protein, or a combination of both. In the present 
chapter, we tested whether direct knockdown of BDNF in the hippocampus affected Aβ levels and 
cognitive abilities. 	  
5.1.2      BDNF in AD. Causative, contributor or consequence? 
Growing evidence suggests the involvement of BDNF in AD pathogenesis (Fumagalli et al., 2006, 
Tapia-Arancibia et al., 2008). In human post-mortem tissue, BDNF mRNA and protein, as well as the 
pro-neurotrophin form pro-BDNF, its receptor TrkB and downstream signalling molecules such as 
CREB are all decreased (Phillips, 1991; Holsinger 2000; Peng 2005; Siegel and Chauhan, 2000; 
Yamamoto-Sasaki et al., 1999), as well as a decrease in serum BDNF levels (Yasutake et al., 2006). At 
the cellular level, neurons containing tau NFTs tend not to co-stain with BDNF labelling, whereas 
intensely BDNF-labelled neurons lack tau tangles (Murer et al., 1999). Futhermore, high levels of 
truncated TrkB (which cannot initiate survival signalling pathways) are found in senile plaques in the 
hippocampus of AD patients (Connor et al., 1996), indicating a dysfunction in BDNF signalling 
coincident with disease. These results suggest the involvement of reduced trophic signalling in AD, 
however whether this role is causative, contributive, or a consequence of the disease is still unclear. 
Nonetheless, the evidence for aberrant neurotrophic signalling has been substantial enough to prompt 
further investigation into neurotrophic factor-based therapeutics (Nagahara and Tuszynski, 2011, Lu et 
al., 2013), which we discuss further in Chapter 6. 	  
Longitudinal studies in humans suggest that low BDNF levels do not alone predispose people to AD 
(Carlino et al., 2013; Lim et al., 2013; Chen et al., 2014), however low BDNF significantly hastens 
disease progression and high BDNF levels are associated with slower cognitive decline (Laske et al., 
2011, Buchman et al., 2016). The association between BDNF signalling and AD in humans is 
particularly emphasized in studies investigating a single nucleotide polymorphism (SNP) in the BDNF 
gene, which produces an amino acid substitution of valine to methionine. This BDNF Val66Met 
polymorphism negatively affects activity-dependent secretion of BDNF and thus affects human 
memory and hippocampal function (Egan et al., 2003, Hariri et al., 2003, Chen et al., 2004b). 
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Although the frequency of the BDNF Val66Met polymorphism is significantly higher in AD patients 
compared to healthy controls, it itself does not appear to be a risk factor for development of AD (Feher 
et al., 2009, Lim et al., 2013, Lim et al., 2015). Yet, carriers of the BDNF Val66Met showed 
significantly greater impairment in memory functions compared to Val/Val homozygotes, and its 
presence significantly worsens the cognitive impairment in combination with the APOE ε4 allele. 
However interestingly, BDNF Val66Met genotype did not correlate with the amount of Aβ or to the 
rate of Aβ accumulation in AD subjects (Lim et al., 2015). Together these findings are suggestive of a 
contributive role in cognitive decline, without impacting pathology. 	  
The association between BDNF and AD has also been investigated in in vivo AD mouse models, where 
BDNF levels have been shown to be inversely correlated to Aβ levels in a number of amyloid transgenic 
mouse models of AD (Peng et al., 2009), mimicking human AD. As the mice were driven to produce 
Aβ, these results suggest that BDNF dysfunction is downstream of Aβ in these mouse models. 
Nonetheless, the contributive role of BDNF to AD pathology in in vivo AD mouse models has been 
investigated by Castello et al., (2012) by crossing triple transgenic AD (3xTg-AD) mice onto 
heterozygous BDNF knockout (BDNF-/+) mice. The authors of this work reported no increase in 
amyloid or tau pathology driven by the reduction of BDNF protein in these mice, however presynaptic 
markers such as synaptophysin were decreased (Castello et al., 2012). These results are supported by 
APP/PS1 x BDNF +/- mice which similarly showed no alteration in amyloid pathology but displayed 
exacerbated memory impairments in a Morris water maze task (Rantamaki et al., 2013). Interestingly, 
the latter study reported a possible mechanism by which Aβ might induce BDNF reduction - through 
BDNF protein sequestration into amyloid plaques (Rantamaki et al., 2013). Together these results 
suggest that the reduced BDNF levels found in AD are a consequence of AD pathology, yet they do 
contribute to impairments in memory. As these studies were performed on mice with reduced levels of 
BDNF since birth, there are interpretive confounds. For example, compensatory neurotrophic 
signalling may have occured over the course of a BDNF -/+ mouse’s life which might mitigate any 
impact of the reduced BDNF on AD features. Indeed, this idea is supported by the demonstration that, 
despite the mice having reduced BDNF levels, they did not have changes in BDNF-related signalling 
(Castello et al., 2012, Rantamaki et al., 2013). Therefore, while it appears that BDNF plays a 
contributory role in cognitive deficits in AD mice, it is as yet too early to conclude that BDNF does not 
have a causative role. 
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In vitro evidence has demonstrated that BDNF dysfunction can be a consequence of AD pathology. Aβ 
protein causes a decrease in BDNF mRNA by downregulation of specific transcripts in human 
neuroblastoma cells (Garzon and Fahnestock, 2007) and disruption of BDNF axonal transport in 
cultured hippocampal neurons (Ramser et al., 2013). Conversely, interruption of BDNF and NGF 
signalling can induce amyloidogenic processing and apoptotic cell death in cultured hippocampal 
neurons, suggesting a causative role for the neurotrophins in AD (Matrone et al., 2008a). Moreover, 
some in vitro results also indicate that enhancing BDNF signalling early in disease may have the ability 
to be disease modifying – that is, reduce Aβ production or enhance clearance (Arancibia et al., 2008) 
and dephosphorylate tau protein (Elliott et al., 2005), suggestive that lowered BDNF might exacerbate 
Aβ levels. 	  
In summary, although dysfunctional BDNF signalling is strongly associated with AD, whether it is 
causative, a contributor to, or a consequence of various AD features such as amyloid burden is still 
being debated. Data from human studies suggest that although dysfunctional BDNF signalling is not 
causative of amyloid burden, it does contribute to cognitive impairments (Lim et al., 2015). Results 
from mouse models suggest that dysfunctional BDNF signalling also contributes to cognitive decline, 
but indicate that reduced BDNF levels are most likely a consequence of AD pathology such as amyloid 
burden, as there is no exacerbation of Aβ pathology found in AD models with reduced BDNF. Results 
of in vitro experiments indicate that BDNF dysfunction can be a consequence of AD pathology, but 
that it may also cause pathology, and additionally demonstrate that enhancing BDNF signalling may 
reduce Aβ levels. It is important to continue to distinguish between these possibilities both to 
understand the disease process and in order to understand what features of AD neurotrophic based 
treatments might be effective upon. 	  
5.1.3     Chapter aims 
In Chapter 3, our model of reduced cholinergic signalling in APP/PS1 mice caused a reduction in 
BDNF and an increase in Aβ, which coincided with the mice displaying cognitive deficits in a MWM 
task. This memory impairment was concluded to be a result of the combination of three AD features 
(reduced cholinergic signalling, decreased BDNF levels and increased Aβ), as an equivalent reduction in 
cholinergic signalling with BDNF dysfunction in wildtype mice (with no Aβ load) did not cause the 
same cognitive impairment (Figure 5.1A). However the exact role that lowered BDNF plays in the 
associated features of AD in this model are uncertain. In this chapter we tested whether reduced BDNF 
protein (without a parallel reduction in cholinergic signalling) could directly cause an elevation in total 
Aβ and cognitive deficits that were observed in Chapter 3 (Figure 5.1B).  
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Figure 5.1     Schematic representation of the aim of this chapter: Can selective reduction of 
BDNF directly cause increases in A! and the resulting cognitive deficits in AD transgenic mice?  
(A) Mechanism of degeneration by BFCN lesion of APP/PS1 mice (based on Chapter 3) resulting in 
reduced acetylcholine (ACh) signalling and culminating in cognitive deficits, through reduced BDNF 
and increased A!. (B) The question addressed by this chapter: does selective reduction of BDNF by 
viral knockdown (in APP/PS1 transgenic mice with intact BFCNs) cause an increase in A! and 
cognitive impairment? 
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5.2      Results 	  
5.2.1.1     Virus recombination and expression of a GFP construct in the hippocampus 
following intrahippocampal injections of an AAV-Cre into BDNF floxed mice  
To achieve a specific decrease in BDNF protein, we used a line of mice which express loxP sites 
flanking the BDNF gene coding region, in which a bilateral intrahippocampal injection of a adeno-
associated virus expressing cre-recombinase from the synapsin promoter would knockdown BDNF gene 
expression specifically in neurons of the hippocampus. An initial pilot study was conducted in order to 
determine if this technique worked. These results are presented below as results for BDNF fl/wt and 
fl/fl mice. Following this pilot study, this line of mice was crossed onto APP/PS1 amyloid transgenic 
mice, to provide us with a model in which we could experimentally knockdown BDNF gene expression 
in a defined location (the hippocampus) at a defined time point, to determine if reduced neurotrophin 
levels exacerbated Aβ load and cognitive impairment in genetically susceptible AD model mice. We 
used heterozygous (rather than homozygous) mice with the rationale being to mimic the reduction 
(rather than complete loss) of BDNF as measured in our earlier work (Chapters 3 and 4) and BDNF 
down regulation in human AD. This strategy was also expeditious in terms of breeding, as APP/PS1 
mice are hemizygous, and neither strain breeds well, so using heterozygous mice saves one generation 
and large numbers of breeding stock required to generate the required mice for use in behavioural 
cohorts. 	  
5.2.1.2     Decreased hippocampal BDNF protein levels in homozygous, but not heterozygous, 
BDNF floxed mice and weight loss in all genotypes following intrahippocampal injection of 
an AAV-Cre   
One month following AAV-Synapsin-Cre-GFP infusion into the hippocampus of BDNF fl/fl and fl/wt 
mice, mice were sacrificed and GFP expression in the hippocampus was evaluated qualitatively by 
histological analysis to assess virus spread across the cohort. GFP-positive cells, representative of virus-
infected neurons, were observed in the dentate gyrus (Figure 5.2A-B).  	  
To determine whether the viral expression of Cre recombinase was able to reduce levels of BDNF 
protein in these mice, we performed a BDNF ELISA on anterior hippocampal homogenates. We found 
that levels of BDNF protein in the hippocampus were significantly reduced in homozygous BDNF flox 
(fl/fl) mice following injection of AAV-Cre. However, although the tissue used for these assays was 
restricted to the anterior portion of the hippocampus, where GFP expression was predominantly found, 
levels of BDNF protein in heterozygous BDNF flox (fl/wt) mice compared to wildtype were equivalent 
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to that of naïve BDNF flox control mice (Figure 5.3A), indicating BDNF levels were not significantly 
reduced in this area of the brain in the heterozygous mice.  	  
An unexpected consequence of AAV-Cre injection into the hippocampus of BDNF floxed mice, was a 
significant loss of body weight one month following surgery that was not observed in saline-injected 
controls (Figure 5.3B). Furthermore, this decrease in weight was observed in all virus-injected mice, 
regardless of heterozygous or homozygous flox status. One explanation is that although no decrease in 
overall BDNF protein levels were measured by BDNF ELISA in heterozygous floxed mice, that a 
neuronal-specific decrease in BDNF protein levels occurs that is functionally significant, as exemplified 
by the loss of weight following injection of AAV-Cre.  	  
Although a significant change in BDNF protein levels following injection of the virus into the 
hippocampus of heterozygous BDNF fl/wt mice was not detected, the results we obtained from 
homozygous BDNF fl/fl mice suggest that the virus was able to knockdown BDNF gene expression in 
the hippocampus. Moreover, the expression of the virus in the fl/wt mice was predominantly localised 
to the dentate gyrus, indicative of a more restricted knock down, and the subsequent loss of body 
weight of the mice one month following surgery, supports evidence of functional changes. Therefore, 
we reasoned that examining the affect of acute BDNF reduction in APP/PS1 x BDNF fl/wt mice (while 
awaiting the generation APP/PS1 homozygous BDNF fl/fl mice) could be informative. 	  	  
5.2.2.1      Reduction in BDNF protein and loss of body weight following intrahippocampal 
injections of an AAV-Cre into BDNF fl/wt mice crossed onto APP/PS1 amyloid transgenic mice  
The BDNF floxed line of mice was crossed with APP/PS1 amyloid transgenic mice to generate 
APP/PS1 transgene positive BDNF fl/wt mice that were used for the following experiments. For these 
experiments, we used two cohorts of mice at different ages (7 months and 9 months at sacrifice, n= 2 
and 3, saline and virus, respectively for the 7 month old cohort. n=4 and 5, saline and virus, respectively 
for the 9 month old cohort) the results of which were quantified separately; however where no 
significant differences were found between the ages, data were pooled and further analyses were 
conducted with the combined cohort.  
 
Based on the virus expression in the above pilot study being restricted to the dentate gyrus subregion of 
the hippocampus, we altered the injection site in the APP/PS1 x BDNF fl/wt cohort reducing the 
depth of the needle within the hippocampus. This resulted in a much larger spread of the virus in the 
CA1/CA2 region of the hippocampus (Figure 5.4A).  	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Figure 5.2     Virus recombination and expression of a GFP construct in the hippocampus 
following intrahippocampal injections of an AAV-Cre into BDNF floxed mice  
(A) Schematic of a mouse coronal brain section at the level of the hippocampus. Green lines represent 
the sites of injection of the neuron specific, cre recombinase-carrying adeno-associated virus (AAV-
Synapsin-Cre-GFP) into the hippocampus.  
(B) Representative fluorescent image of a BDNF fl/wt mouse coronal brain section at the level of the 
hippocampus 4 weeks following injection of AAV-Synapsin-Cre-GFP. Outline of the hippocampus is 
represented by the dotted white line. Green immunohistochemical staining is for GFP, which is 
expressed together with cre recombinase, is restricted to the dentate sub region of the hippocampus in 
these pilot experiments 
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Figure 5.3     Decreased hippocampal BDNF protein levels in homozygous, but not 
heterozygous, BDNF floxed mice and weight loss in all genotypes following intrahippocampal 
injection of an AAV-Cre   
(A) Quantification of BDNF protein levels (pg protein/mg total protein) in hippocampal homogenates 
by ELISA in control saline injected (cre negative) BDNF flox mice (pooled data from one BDNF fl/fl 
and two BDNF fl/wt mice), and AAV-Synapsin-Cre-GFP (Virus) injected BDNF heterozygous (fl/wt) 
and homozygous (fl/fl) floxed mice. Data are presented as mean ± SEM. The number of animals per 
condition is indicated within the bars of the graphs. One-way ANOVA with Tukey’s multiple 
comparisons test, * p<0.05. (B) Quantification of the weight change in grams (g) of BDNF fl/wt and 
fl/fl mice one month following bilateral intrahippocampal injections of AAV-cre compared to saline 
injected transgenic controls.  Data are presented as mean ± SEM. The number of animals per condition 
is indicated within the bars of the graphs. Unpaired t-test, ** p<0.01. Statistical significance for BDNF 
fl/fl mice was unable to be determined as the saline group has n=1.  
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To determine if injection of AAV-Cre into the hippocampus of APP/PS1 x BDNF fl/wt at these new 
coordinates caused a change in BDNF protein levels, we performed BDNF ELISAs on anterior 
hippocampal lysates. Injection of the AAV-Cre into the hippocampus resulted in a significant reduction  
(25%) in BDNF protein levels in comparison to saline injected transgenic controls and naïve APP/PS1 
mice (Figure 5.4B). A decrease in body weight was also observed with APP/PS1 x BDNF fl/wt mice 
showing a 8.9% reduction in body weight one month following surgery compared to saline-injected 
transgenic controls which exhibited an increase in body weight of 3% (Figure 5.4C).  
 
5.2.2.2     Trophic signalling in the hippocampus is unchanged following bilateral 
intrahippocampal injections of an AAV-Cre into APP/PS1 x BDNF fl/wt  
To investigate whether the reduction in BDNF protein levels in the hippocampus of virus-injected 
APP/PS1 x BDNF fl/wt mice affected trophic signalling, the levels of total and phosphorylated forms of 
signalling proteins downstream of the BDNF receptor, namely, ERK1/2 and Akt, were measured in 
hippocampal lysates. No differences in the levels of phosphorylated ERK1/2 or Akt, nor any changes in 
the levels of total ERK1/2 or Akt were found by western blot of lysates of hippocampus of virus 
injected APP/PS1 x BDNF fl/wt mice compared to saline-injected controls (Figure 5.5) 
 
5.2.2.3     Memory and movement are unchanged following intrahippocampal injections of an 
AAV-Cre into APP/PS1 x BDNF fl/wt mice  
To test the hypothesis that any disturbance in BDNF signalling could negatively regulate AD 
pathocascades and thus cognitive performance, virus-injected APP/PS1 x BDNF fl/wt were assessed for 
changes in movement using an activity monitoring box (Figure 5.6), anxiety-like behaviour in an 
elevated plus maze (Figure 5.7) and learning and spatial memory in a Y-maze paradigm (Figure 5.8); 
unfortunately animal numbers were not sufficient for analysis by MWM which in our hands requires 
N≥8 mice per condition for a power of 0.8. In the activity monitoring box, over the course of the 20 
minute testing time, mice were assessed for velocity, time at rest, the number of ambulatory episodes, 
frequency of centre zone entries, number of rears and the number of revolutions (Figure 5.6). In the 
elevated plus maze, over the 10 minute testing period mice were assessed based on their preference for 
the open or closed arm of the maze. The time in each arm, frequency of alternation, frequency of arm 
entries, distance travelled, and velocity was measured (Figure 5.7). Finally, in a Y-maze paradigm, mice 
were assessed on the time spent and number of entries into each of the maze arms, as well as distance 
travelled, average velocity and the time spent immobile (Figure 5.8). Based on all the above measured 
parameters in the each of the paradigms, the virus-injected APP/PS1 x BDNF fl/wt group displayed no 
difference in behaviour and movement to the saline-injected transgenic control animals.  
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Figure 5.4     Reduction in BDNF protein and loss of body weight following intrahippocampal 
injections of an AAV-Cre into BDNF fl/wt mice crossed onto APP/PS1 amyloid transgenic 
mice  
(A) Representative fluorescent image of a coronal section at the level of the hippocampus following an 
infusion of AAV-Synapsin-Cre-GFP into the hippocampus of an APP/PS1 x BDNF fl/wt mouse. 
Green immunohistochemical staining represents recombination of the virus and fluorescing of GFP in 
cells and is labelled by an anti-GFP antibody, whereas blue staining is the total cell nuclei marker 
DAPI. 
(B) Quantification of BDNF protein levels (ng protein/mg total protein) in hippocampal homogenates 
by ELISA in naïve APP/PS1 mice, and saline and AAV-Synapsin-Cre-GFP (virus) injected APP/PS1 x 
BDNF fl/wt mice. Injection of virus caused a significant reduction in the levels of BDNF protein 
measured compared to saline injected mice and naïve APP/PS1 mice used as a control. Data are 
presented as mean ± SEM. The number of animals per condition is indicated within the bars of the 
graphs. Unpaired t-test, ** p<0.01. 
(C) Quantification of the weight change in grams (g) of APP/PS1 x BDNF fl/wt mice one month 
following injection of saline control or AAV-cre into the hippocampus. Hippocampal injection of the 
AAV-cre results in a significant loss of body weight compared to saline injected controls. Data are 
presented as mean ± SEM. The number of animals per condition is indicated within the bars of the 
graphs. Unpaired t-test, ** p<0.01.  
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Figure 5.5     Trophic signalling in the hippocampus is unchanged following bilateral 
intrahippocampal injections of an AAV-Cre into APP/PS1 x BDNF fl/wt  
Representative western blots (A, C) and quantification (B, D) of total and phosphorylated ERK (A, B) 
and Akt (C, D) levels in hippocampal homogenates from saline-injected (white bars) and AAV-Cre-
injected (black bars) APP/PS1 x BDNF fl/wt transgenic mice. The band intensities were normalized to 
their respective GAPDH loading control levels and are shown relative to the levels in (control) saline-
injected mice. Data are presented as mean ± SEM with the sample size indicated in the bars. 	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Figure 5.6     No displays of abnormal behaviour or movement in an activity monitoring box 
following local reduction in BDNF protein by intrahippocampal injections of an AAV-Cre into 
APP/PS1 x BDNF fl/wt mice  
Assessment of movement and behaviour parameters in an activity monitoring box. Quantification of 
(A) velocity (centimetres per second), (B) time at rest in seconds (s), (C) the number of ambulatory 
episodes, (D) frequency of centre zone entries, (E) rearing count and (F) number of revolutions (both 
clockwise and anticlockwise). In all parameters, APP/PS1 x BDNF fl/wt mice that had bilateral 
injections of AAV-Synapsin-Cre-GFP into their hippocampi performed comparably to saline-injected 
controls.  
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Figure 5.7     No anxiety-like behaviour in APP/PS1 x BDNF fl/wt mice following local 
reduction in BDNF protein by intrahippocampal injections of an AAV-Cre in an elevated plus 
maze paradigm 
Assessment of movement and behaviour parameters in an elevated plus maze. Quantification of (A) 
time in arms in seconds (s), (B) frequency of alternations, (C) frequency of arm entries, (D) distance 
travelled measured in centimetres (cm) and (E) velocity measured in centimetres per second (cm/s). In 
all parameters, APP/PS1 x BDNF fl/wt mice that had bilateral injections of AAV-Synapsin-Cre-GFP 
into their hippocampi performed comparably to saline-injected controls.  
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Figure 5.8     No learning or memory impairments in a Y-maze paradigm following local 
reduction in BDNF protein by intrahippocampal injections of an AAV-Cre into APP/PS1 x 
BDNF fl/wt mice  
(A) Graph of the percentage of total time that AAV-cre injected and saline injected APP/PS1 x BDNF 
fl/wt mice spent in familiar and novel arms of the Y-maze. Hippocampal injection of AAV-cre into 
these BDNF floxed mice did not affect the proportion of time spent in the novel or familiar arms of the 
Y-maze compared to saline injected controls. (B) Total number of arm entries made by saline-injected 
and AAV-Cre injected APP/PS1 x BDNF fl/wt mice into the home, familiar and novel arms. Both 
groups of mice showed no preference for any arm, regardless of novelty. Quantification of (C) distance 
travelled in centimeters (cm), (D) average velocity (centimeters per second) and (E) time in seconds 
spent immobile. No differences between saline-injected and AAV-Cre injected APP/PS1 x BDNF fl/wt 
mice were observed in any of these parameters. Data are presented as mean ± SEM with sample size 
indicated in the bars.  
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5.2.2.4     No change in total hippocampal Aβ42 levels or amyloid pathology following local 
reduction in BDNF protein by injection of AAV-Cre into APP/PS1 x BDNF fl/wt mice 
hippocampi 
To determine if the reduction in BDNF levels in hippocampal neurons resulted in amyloidogenic 
processing in the hippocampus, we measured total levels of Aβ42 by ELISA and assessed amyloid 
pathology by immunohistochemistry. We performed Aβ42 ELISAs on lysates of anterior hippocampus 
and compared the results between virus and saline injected APP/PS1 x BDNF fl/wt mice. We found no 
changes in the levels of total Aβ42 in the hippocampus of virus-injected transgenic compared to saline-
injected transgenic controls (Figure 5.9). Amyloid pathology was assessed by staining hippocampal 
sections with an anti-Aβ antibody and analysing Aβ plaque number in the CA1/CA2 and dentate gyrus 
sub regions, on brain sections that displayed positive immunostaining for GFP (i.e. viral cre-GFP 
expression). Although a difference was observed between APP/PS1 mice between ages, no difference in 
plaque number per mm2 was observed between AAV-Cre injected transgenic mice or saline injected 
transgenic controls in any of the subfields of the hippocampus (Figure 5.10). This indicates that a 
reduction in BDNF protein is insufficient to cause local changes in levels of Aβ.
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Figure 5.9     No change in total hippocampal Aβ42 levels following local reduction in BDNF 
protein by injection of AAV-Cre into APP/PS1 x BDNF fl/wt mice hippocampi 
Quantification of Aβ42 protein levels (ng protein/mg total protein) in hippocampal homogenates by 
ELISA in saline-injected and AAV-Cre (virus)-injected APP/PS1 x BDNF fl/wt transgenic mice. 
Hippocampus infusion of the virus did not cause a change in Aβ42 levels compared to control saline-
injected transgenic mice. Data are presented as mean ± SEM. The number of animals per condition is 
indicated within the bars of the graphs.  
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Figure 5.10     No change in the number of A!  plaques in the CA1/CA2 and dentate gyrus 
subregions of the hippocampus following local reduction in BDNF protein by injection of AAV-
Cre into APP/PS1 x BDNF fl/wt mice hippocampi 
Representative fluorescent images of amyloid plaques in the hippocampus of an APP/PS1 x BDNF 
fl/wt mouse injected with (A) saline or (B) an AAV-Synapsin-Cre-GFP. An equivalent number of 
amyloid plaques  are visible in the CA1/CA2 and dentate gyrus subregions of the hippocampus, despite 
infusion of an AAV-Cre virus (green cells and neurites) in the CA1/CA2.
Quantification of A! plaques (plaque per µm2) in (C, E) CA1/CA2 and (D, F) dentate gyrus 
subregions of the hippocampus of (C, D) 7 month old and (E, F) 9 month old mice, following control 
saline injections or AAV-Cre (virus) injections into the hippocampus of APP/PS1 x BDNF fl/wt 
transgenic mice. Data are presented as mean ± SEM. The number of animals per condition is indicated 
within the bars of the graphs. As older mice have a greater number of amyloid plaques, amyloid burden 
in the hippocampus following virus or saline injection was separated into age groups and presented in 
separate graphs.  
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5.3     Discussion 
 
The identification of dysregulated BDNF signalling in human AD patients has led to wider 
investigation into the role of BDNF in AD pathogenesis. In particular, whether BDNF dysfunction is 
causative, contributes to, or occurs as a consequence of the disease, is still being determined. Our results 
in Chapter 3 highlighted the potential involvement of reduced hippocampal BDNF in causing an AD 
phenotype. In the present chapter, we tested the role of reduced BDNF levels in causing elevation of 
total Aβ and cognitive deficits. 
 
In order to acutely reduce BDNF levels in the hippocampus of AD mice (in contrast to previous studies 
which use BDNF +/- mice) we injected an AAV which expresses a cre-GFP fusion protein from the 
neuron specific synapsin promoter. GFP expression was evident in immunostained anterior 
hippocampal sections indicting successful infection of a significant number of neurons with the virus. 
In cells in which recombination was successful, one allele of the BDNF gene would be excised, reducing 
BDNF expression by ~50%. Indeed, a significant decrease in BDNF levels was measured in both 
BDNF fl/fl mice and APP/PS1 x BDNF fl/wt mice, indicating recombination of the loxP sites flanking 
the BDNF gene by the cre-recombinase had occurred, validating this method. In APP/PS1 x BDNF 
fl/wt mice this results in a 25% decrease in hippocampal BDNF compared to a previously reported 
43% reduction in BDNF protein in heterozygous BDNF knockout mice (Castello et al., 2012). 
Moreover, as expected, this reduction is less than the 50% decrease in hippocampal BDNF  that we 
report in Chapter 3.  
 
An unexpected finding in the present study is the loss of body weight that accompanied injection of 
AAV-Cre into the hippocampus. In the APP/PS1 x BDNF fl/wt mice, we recorded a 9% loss of body 
weight compared in saline injected control transgenics (who exhibit a 3% increase in body weight). 
This weight loss is particularly relevant as BDNF regulation of body weight has been widely described 
and BDNF+/- mice often display overeating behaviour and are obese compared to wildtype mice 
(Kernie et al., 2000). Although we report the opposite of this, it may be a result of our virus having an 
effect on local BDNF signalling in the hippocampus. Alternatively, it may represent an immunological 
response to the AAV generated by the mice that results in loss of weight, although the recombinant 
AAV used in the present chapter has low immunogenicity and an absence of cytotoxic responses in 
mice (Herzog, 2007, Aschauer et al., 2013). Moreover, this and other AAVs have been used by other 
members of the Coulson laboratory without observable weight, loss suggesting this phenotype is related 
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to the genotype rather than virus. However, in future experiments using AAV-encoded cre as a method 
to knockdown BDNF gene expression in the hippocampus should include injection of a control AAV. 	  
Extensive literature exists of multiple transgenic mouse lines with increased or decreased BDNF 
signalling and behavioural phenotypes as models of various mood disorders (reviewed in Lindholm and 
Castren, 2014), demonstrating a tight link between BDNF levels and cognitive processes. Moreover, an 
exacerbation of memory impairments in a Morris water maze has been reported in APP/PS1 mice with 
a global decrease in BDNF (BDNF +/- mice) (Rantamaki et al., 2013). However in the present chapter, 
we demonstrated that knockdown of hippocampal BDNF in APP/PS1 mice did not result in a change 
in Y-maze performance compared to saline-injected transgenic controls. Other studies have 
demonstrated lower discrimination ratios (preference for novel arm over the start arm and other arm) in 
a Y-maze paradigm in BDNF+/- mice compared to wildtype controls, however these mice have a global 
knockdown of BDNF, unlike our selective decrease of BDNF in the hippocampus (Wu et al., 2015).  
APP/PS1 mice also have changes in Y maze performance as an early indicator of cognitive function 
(Holcomb et al., 1998). Indeed both saline and AAV-injected APP/PS1 BDNF fl/wt mice showed no 
preference for the familiar or novel arms of the maze, indicating that these mice may already have mild 
cognitive impairment. However, there was no exacerbation of this decline in memory evidence in the 
AAV-injected mice, indicating the reduction in BDNF did not affect this behaviour. We also found no 
abnormal behaviour of AAV-injected mice compared to saline-injected controls in activity or anxiety-
like behaviours. This is consistent with results of Adachi et al., (2008) who show that selectively 
knocking down BDNF gene expression in the CA1 or DG regions of the hippocampus does not alter 
locomotor activity, anxiety-like behavior, fear conditioning, or depression-related behaviours. 
Unfortunately, we lacked the animal numbers required to robustly test performance in the MWM 
paradigm as we had done in Chapter 3, in which saline-injected APP/PS1 mice may have performed as 
well as wildtype animals, and an effect on the lowered BDNF levels may have been evident. Future 
work may investigate this further, but we nonetheless conclude that the 25% loss of BDNF in the 
anterior hippocampus was not sufficient to induce additional short-term memory changes in 7-9 month 
old APP/PS1 mice  
 
We next tested whether the reduction of BDNF was able to increase Aβ levels. Using biochemical and 
histological methods, we found no detectable impact on Aβ pathology or Aβ levels. This is in line with 
findings by Castello et al., (2012) that, despite a significant reduction in BDNF protein levels in triple 
transgenic AD BDNF-/+ mice, levels of Aβ and tau pathology were comparable to that of transgenic 
controls.  In contrast to these findings, Matrone et al (2008) demonstrate in vitro that withdrawal of 
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BDNF from hippocampal neurons results in an increase in Aβ production. This finding may be 
representative of the inherent differences of in vivo vs. in vitro methodology, or, of the degree of BDNF 
knockdown achieved. Matrone et al (2008) attain a complete withdrawal of BDNF with the use of a 
blocking antibody, whereas in contrast, Castello (2012) report a 43% reduction in BDNF protein in 
the cortex, equivalent to BDNF loss in human AD (Tapia-Arancibia et al., 2008), and see no impact on 
pathology. Our results are in line with results by Castello et al (2012) and further supports the idea of 
dysfunctional BDNF signalling in AD is not sufficient to cause Aβ accumulation and is rather a 
possible consequence of Aβ pathology.  	  
ERK and Akt are important downstream mediators of BDNF signalling (Reichardt, 2006), and despite 
measuring a 25% decrease in BDNF levels, we found no change in total or phosphorylated forms of 
ERK1/2 and Akt. In agreement with these findings, previous research has reported no differences in 
downstream trophic signalling in BDNF-/+ (as homozygous BDNF knockouts are lethal (Ernfors et al., 
1994)), crossed onto AD transgenic mice, despite reporting 40-50% decreases in BDNF protein levels 
(Castello et al., 2012, Rantamaki et al., 2013), nor changes in TrkB phosphorylation (Rantamaki et al., 
2013). This suggests that BDNF signalling may have an adaptive capacity with built in compensation 
(e.g. upregulation of TrkB levels), or ERK and Akt activity levels are dominated by non BDNF-
mediated signalling pathways. It is possible that because the signalling levels were not significantly 
reduced, there was no subsequent effect on Aβ levels or cognitive processes. However in Chapter 3 
where BDNF levels are low, signalling was similarly unchanged but Aβ was increased and cognition was 
impaired. Therefore, the conclusion that low BDNF is not sufficient to drive Aβ accumulation remains 
valid. 
 
Our results indicate that dysfunctional BDNF signalling is not a cause, and is therefore likely to be a 
consequence, of AD disease processes with little direct impact on cognitive function given that selective 
BDNF knockdown alone did not accelerate amyloidogenic processing or cognitive impairments 
(Figure 5.11A). Rantamäki et al (2013) suggest that reduced BDNF may be a result of being 
sequestered into amyloid plaques. An alternative, but not mutually exclusive, possibility is that BDNF 
levels are decreased due to BFCN dysfunction (Chapter 3; Gil Bea et al., 2011). Nonetheless, we also 
cannot rule out a role for deficits in BDNF signalling as a contributor to pathology or cognitive 
impairment in our mice in Chapter 3, in the context of reduced cholinergic signalling (Figure 5.11B). 
Findings from both human studies (Lim et al., 2015) and in vivo AD mice studies (Rantamaki et al., 
2013), report that reduced BDNF plays a role in worsening cognition in AD, which is in contrast to 
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our results. This disparity may be due to the spatially restricted knockdown of BDNF in our model, 
compared to the generalized reduction in BDNF in human AD patients and heterozygous BDNF mice. 
!
In conclusion, we report that selective reduction of BDNF protein in the hippocampus of APP/PS1 
mice failed to significantly alter A! accumulation or exacerbate memory performance in APP/PS1 mice 
with intact basal forebrains. This suggests that BDNF does not play a causative role in the development 
of A! pathology or cognitive impairment. Rather, dysfunctional BDNF signalling most likely results as 
a consequence of reduced cholinergic signalling and/or increased A! in our model in Chapter 3. 
However, we cannot exclude reduced BDNF as a contributing factor in association with high 
A! in cognitive impairment. Futhermore, as previous research suggests, this does not discount the 
possibility that enhancement of BDNF signalling could provide therapeutic benefit, which is explored 
in the following chapter. 
!
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Figure 5.11     Schematic of disease pathways  
(A) Schematic representation of the findings of this chapter. Selective BDNF expression knockdown in 
APP/PS1 mice, does not result in increased A! and cognitive deficits (in mice with intact basal 
forebrains). 
(B) Schematic representation of disease pathways following reduced cholinergic innervation to the 
hippocampus. The pathway culminates in cognitive deficit via the combination of reduced BDNF and 
increased A!. 
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6.1     Introduction 	  
6.1.1     Chapter overview 
Performed in parallel to Chapter 5, this chapter aimed to test whether enhancing neurotrophic 
signalling could rescue or prevent memory impairments and/or increased Aβ levels caused by the loss of 
basal forebrain cholinergic signalling in APP/PS1 mice (as induced in Chapter 3).  
 
6.1.2     Neurotrophin based AD therapy 
Given their wide-ranging role in supporting neuron survival and function, the use of neurotrophins or 
mimetics as supportive therapy in neurodegenerative diseases to slow cellular death and support 
function in remaining neurons has long been advocated (Lu et al., 2013). Moreover, aberrant 
neurotrophic signalling appears to be an early event in AD and, as discussed in earlier chapters, could be 
directly involved in disease processes resulting in characteristic pathology, and is a further rationale for 
research into neurotrophic factor-based therapeutics (Nagahara and Tuszynski, 2011, Lu et al., 2013). 
Although human longitudinal studies suggest that low BDNF levels do not alone predispose people to 
AD (Carlino et al., 2013, Lim et al., 2013, Chen et al., 2015) low BDNF significantly hastens disease 
progression; treatment would therefore merely slow an inevitable process. However, in vitro evidence 
indicates that enhancing neurotrophic signalling early in disease may have the ability to be disease 
modifying – that is reduce Aβ production or enhance clearance (Arancibia et al., 2008). It remains 
unclear therefore whether neurotrophic treatments would best act to overcome damage or to be given 
early in disease with the aim of preventing further disease progression. 
 
Several neurotrophin-based therapies have been clinically tested, with positive proof of principle 
outcomes. However, these trials also revealed a number of issues including poor systemic delivery of 
neurotrophins to the brain due to neurotrophins being relatively large molecules that do not readily 
cross the blood-brain barrier. Alternate approaches, such as gene therapy have been tested, however, 
these approaches have also met with significant adverse effects such as weight loss, dysaesthesias and 
migration and/or proliferation of Schwann cells in the subpial space (Nagahara and Tuszynski, 2011). 
Therefore, alternative approaches to neurotrophin-based interventions such as small molecule 
neurotrophin mimetics or agonists have been pursued more recently.  
 
To date, numerous neurotrophin mimetic therapies for AD have been tested, including selective small 
molecule agonists of NGF, BDNF, TrkA, TrkB and p75NTR (Longo and Massa, 2005, 2013). One 
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example is a small molecule BDNF mimetic developed by Massa and colleagues (2010), a 
pharmacophore based on a loop domain of BDNF that binds to the TrkB receptor. This compound is 
able to increase cultured hippocampal neuron survival with the similar efficacy to BDNF, and 
importantly, does not bind the p75NTR which mediates cell death signalling and the pain-promoting 
effect of BDNF, and prevents cognitive deficits in an AD mouse (Massa et al., 2010, Knowles et al., 
2013). Correspondingly, a different small molecule TrkB agonist was able to rescue memory deficits in 
a Y-maze task and restored deficient TrkB signalling in vivo in an AD mouse model (Devi and Ohno, 
2012).  
 
These neurotrophin-based therapies highlight the potential for neurotrophin mimetics in the treatment 
of AD, however a drawback of this is the broad activation of TrkB signalling, and thus the lack of 
signalling selectivity that is characteristic of the neurotrophin signalling system. For example in the case 
of BDNF, gene expression, activity-dependent release and signalling, and post-translational 
modifications including its conversion from pro-neurotrophin to the mature form, is tightly controlled 
(Nagahara and Tuszynski, 2011, Park and Poo, 2013). This tight regulation of BDNF signalling is 
responsible for the wide range of BDNF actions, including neuronal survival, regulation of dendritic 
branching and spine morphology and enhancement of synaptic transmission (such as LTP), which 
underpin neuronal development and cognitive dysfunction (Korte et al., 1995, Figurov et al., 1996, 
Horch and Katz, 2002, Kovalchuk et al., 2002, Minichiello, 2009, Park and Poo, 2013). 
Unsurprisingly, dysfunction or improper regulation of BDNF thus results in a range of neurological 
conditions, such as anxiety, depression (Minichiello et al., 1999, Egan et al., 2003, Liu et al., 2004, 
Nagahara and Tuszynski, 2011). Therefore, broad activation of TrkB by BDNF or mimetics will fail to 
recapitulate the precisely regulated endogenous supply, which is reduced in neurodegenerative 
conditions, and is required for correcting synaptic deficits.  
 
6.1.3      c29 peptide as an enhancer of neurotrophic signalling 
In this chapter, we explore the use of an alternative to small molecule agonists, focusing instead on a 
therapeutic that amplifies receptor affinity to the reduced supply of endogenous neurotrophic ligands. 
This can be used to test in our basal forebrain lesioned APP/PS1 mice whether enhancing neurotrophic 
signalling could be disease modifying or alternatively help overcome cognitive decline, possibly only 
temporarily, by masking disease processes by enhancing synaptic signalling. 	  
A candidate therapeutic compound which enhances neurotrophic signalling of the Trk receptors has 
been developed in the Coulson laboratory. This peptide, called c29 peptide, is a 29 amino acid peptide 
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derivative of the cytoplasmic juxtamembrane region of the p75NTR, fused to TAT-like protein 
transduction domain (PTD) so that it can cross the blood brain barrier and enter cells (Ho et al., 
2001). Determining the physiological function of p75NTR has been the focus of many laboratories over 
the past two decades. Advances in the understanding of the pro-survival functions of p75NTR have led to 
the development of this peptide. One of the mechanisms by which p75NTR can mediate survival 
signalling is based on its ability to associate with Trk receptors, forming a complex that has a higher 
ligand-binding affinity for neurotrophins than either receptor alone (Mahadeo et al., 1994). This 
complex appears to be dependent on the regulated intramembrane proteolysis of p75NTR (Sykes et al., 
2012, Matusica et al., 2013, Kraemer et al., 2014). This process generates functionally active cleaved 
fragments of p75NTR that mediate signal transduction, and appears to be required for many of its 
functions (Davies et al., 1993, Lee et al., 1994, Skeldal et al., 2011)  
 
p75NTR undergoes two sequential proteolytic cleavage events (Jung et al., 2003; Kanning et al., 2003; 
Figure 6.1): the first of these is a shedding event mediated by the α-secretase tumour necrosis factor-α 
converting enzyme/a disintegrin and metallopeptidase domain (TACE/ADAM) 17 (Jung et al., 2003, 
Kanning et al., 2003), resulting in cleavage at the transmembrane domain and liberation of the 
extracellular domain fragment. The remaining membrane-bound carboxyl-terminal fragment (CTF) of 
p75NTR is then further processed by a presenilin-dependent γ-secretase, giving rise to a soluble 
intracellular domain fragment (Jung et al., 2003, Kanning et al., 2003). A splice variant of p75NTR 
lacking the neurotrophin-binding region of the ECD can regulates NGF binding to the TrkA receptor, 
demonstrating that specific p75NTR fragments can be functionally significant (Murray et al., 2003).  	  
The initial proteolytic processing of p75NTR by α-secretase into the membrane tethered CTF, is 
proposed as a key regulating step of cell death (Underwood and Coulson, 2008). CTF mediation of cell 
death was first described by Coulson et al., (2000) who showed that the death regulating function of 
the CTF could be ascribed to the 29 amino acid juxtamembrane domain named “Chopper”. Following 
this, Sotthibundhu et al., (2008) demonstrated that neuronal death is correlated with an increase of 
CTF in cells, mechanistically mediated by an inhibition of γ-secretase cleavage of the CTF into the 
ICD fragment. Moreover, CTF has been found to activate G-protein-coupled inwardly rectifying 
potassium (GIRK) channels which mediate neuronal death through potassium efflux allowing for 
formation of apoptosomes and thus activation of caspases (Coulson et al., 2000). More recently Vicario 
et al., (2015) has also reported CTF can mediate cell death when it accumulates, such that ICD is not 
produced.  
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Figure 6.1     Regulated intramembrane cleavage of p75NTR 
Schematic representation of regulated intramembrane cleavage of the transmembrane pan-neurotrophin 
receptor, p75NTR. Proteolytic cleavage of the full length p75NTR occurs in two steps. The initial cleavage 
at the membrane by the #-secretase tumour necrosis factor-# converting enzyme/a disintegrin and 
metallopeptidase domain (TACE/ADAM) 17 to release the extracellular domain (ECD), followed by 
cleavage of the remaining membrane bound carboxy-terminal fragment (CTF) by a presenilin-
dependent $-secretase to release the intracellular domain (ICD). 
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The ICD has been associated with mediating both neuronal survival and death signalling (Casademunt 
et al., 1999, Kenchappa et al., 2006, Coulson et al., 2009, Ceni et al., 2010, Matusica et al., 2013, 
Vicario et al., 2015, Matusica et al., 2016). Survival signalling of the ICD fragment has been reported 
to occur through formation of a signalling complex with a member of the Trk receptor family and 
initiation of neurotrophin-induced ERK and Akt signalling and thus enhancement of Trk survival 
signalling (Ceni et al., 2010, Matusica et al., 2013, Matusica et al., 2016). It is from this ICD fragment 
that the soluble peptide mimic, c29, was derived. Work from the Coulson laboratory has shown that 
c29 peptide can act as a dominant-negative inhibitor of p75NTR death signalling as well as enhancing 
NGF survival signalling by interaction with its cognate receptor, TrkA (Coulson et al., 2000, Matusica 
et al., 2013). More recently, Matusica et al., (2016) showed that c29 peptide promoted motor neuron 
survival in vitro and in vivo in SOD1 mice, a model of motor neuron disease by facilitating TrkB 
signalling. C29 peptide is therefore a promising candidate for promoting synapse-specific trophic 
signalling in low neurotrophin concentrations as occurs in AD generally, and specifically in the context 
of BFCN dysfunction in mouse models. 	  
6.1.4      Supporting evidence for the use of c29 peptide in AD 
In parallel to my work, a post-doc in the laboratory, Dr Lei Qian, tested whether an acute treatment of 
c29 peptide had an affect on the memory of 8 month old (unlesioned) APP/PS1 mice. A 5 mg/kg 
intraperitoneal injection of c29 peptide was given to mice 30 minutes before being placed in the MWM 
arena, and this dosage schedule was continued every day of behavioural testing. The following results 
are unpublished data courtesy of Dr. Lei Qian.  
 
APP/PS1 mice treated with c29 or SC control peptides were compared to age and gender matched 
wildtype control mice. Mice underwent a five day learning schedule including a probe trial on the sixth 
day where the platform was removed.  No significant differences in escape latency between any of the 
groups were observed over the 5 days learning schedule (Figure 6.2A). Also, no significant differences 
between groups were observed when assessing the latency to platform location or the time spent in the 
target quadrant on test. However, APP/PS1 mice treated with SC made fewer platform crosses than 
their wildtype controls whereas c29 peptide treatment APP/PS1 mice made the same number of 
platform crosses as the wildtype controls, and platform crossing frequency was significantly higher than 
the SC control group (Figure 6.2B-D). This indicated that the c29 peptide treated group displayed 
more precise spatial memory for the platform location than control treated APP/PS1 mice, supporting 
the idea that c29 peptide (and thus enhanced neurotrophic signalling) might promote cognitive  	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Figure 6.2     Rescue of memory performance in a Morris water maze task following acute c29 
peptide administration 30 minutes prior in aged APP/PS1 mice 
(A) Graph of the escape latency (time to find the hidden platform) averaged per day in a 6 day Morris 
water maze task of spatial learning. Aged APP/PS1 mice were administered c29 peptide or its scrambled 
(SC) control every day of behavioural testing, 30 minutes prior to testing began. No significant 
differences between mice treated with c29 or SC peptide, or age-matched wildtype control mice were 
observed during the initial 5-day learning schedule.  
Quantification of latency to platform (B) in seconds (s), time spent in target quadrant (C), and 
platform crossing frequency (D) during the probe trial on day 6, between aged APP/PS1 mice treated 
with c29 peptide or its SC control, and wildtype control mice. APP/PS1 mice treated with c29 peptide 
have a significantly higher platform crossing frequency than SC peptide treated APP/PS1 mice. Data 
are presented as mean ± SEM with sample size indicated in the bars. Unpaired t-test, **=p<0.01. 
 
[Data for this figure kindly provided by Lei Qian, PhD]  	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function of mice with A!-induced cognitive impairment. In this experiment, it was unlikely that c29 
peptide was altering the A! burden over the acute 6 day treatment, and therefore the peptide treatment, 
if truly efficacious, would more likely be acting by over coming A!-induced synaptic impairment. 
 
6.1.5      Chapter aims  
The over arching aims for this chapter were two fold:  
1.  To test whether an acute c29 peptide treatment could enhance cognition of APP/PS1 mice 
with BFCN lesions (a more humanised AD mouse model), with the hypothesis that treatment 
would overcome BFCN-induced A! mediated synaptic dysfunction (Chapter 3). I.e. could 
acute treatment with c29 peptide overcome the memory impairments caused by A! in a context 
of low BDNF levels (Figure 6.3A). 
$%  To test whether chronic c29 peptide treatment could enhance cognition of APP/PS1 mice with  
BFCN lesions, by reversing the effects of BFCN-induced low neurotrophin levels, and 
preventing A! generation and thus A!-mediated synaptic dysfunction. i.e. can c29 peptide 
treatment modify disease progression and prevent further impairment? (Figure 6.3B). 
This chapter describes pilot studies beginning to address these questions. 
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
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Figure 6.3     Schematic demonstrating possible mechanisms of cognitive rescue by c29 peptide in 
basal forebrain lesioned APP/PS1 mice 
Hypothetical modulation of degenerative pathway by acute (A) and chronic (B) treatment with c29 
peptide, resulting in cognitive rescue either directly by acute treatment or indirectly, via a reduction in 
A! levels, by chronic treatment. 
!
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6.2      Results 
 
6.2.1     Basal forebrain cholinergic neuron loss induced by p75-saporin injection is not 
mitigated by treatment with c29 peptide 
The experiments in this chapter were performed in 6 month old basal forebrain lesioned APP/PS1 mice 
(5 months old at time of lesion) with either acute or chronic treatment of c29 peptide and its scrambled 
peptide control. Although BFCN lesions are induced by a ribosome-arresting toxin, as these neurons 
express p75NTR and Trk receptors, we first had to confirm that c29 peptide had no effect on the loss of 
neurons induced by p75-saporin injection. The following data is pooled from acute and chronic c29 
peptide treatment experiments as statistical analysis confirms there are no differences between treatment 
schedules.  
 
As observed in previous chapters, stereotaxic injection of p75-saporin into the medial septal area of the 
basal forebrain resulted in a significant (62%) decrease in the number of ChAT-positive neurons 
compared to IgG-saporin (control) injected mice (Figure 6.4A and B). Consistent with our 
hypothesis, treatment with c29 peptide either by acute intraperitoneal injections or chronic 
subcutaneous osmotic mini pump neither mitigated or enhanced this loss. Furthermore, the number of 
parvalbumin-positive neurons in the basal forebrain was also unchanged following p75-saporin 
injection and treatment with c29 peptide or its scrambled control (Figure 6.4C).  Therefore any effects 
of c29 peptide treatment are due to modifications downstream of BFCN lesioning, and not as a result 
of peptide-induced changes in the lesion. 	  
6.2.2.1     Levels of total Aβ42 in the hippocampus were not decreased following acute c29 
peptide administration in basal forebrain lesioned APP/PS1 transgenic mice 
To address our first question of whether c29 peptide treatment could be effective as treatment to 
overcome memory impairment by enhancing neurotrophic signalling in the context of Aβ-induced 
dysfunction, such as that exhibited by basal forebrain lesioned mice (Chapter 3), we lesioned BFCNs in 
APP/PS1 mice with p75-saporin injections into the medial septum. One month after basal forebrain 
lesion, 5 mg/kg intraperitoneal injections of c29 peptide or its scrambled control was given to mice 30 
minutes before being placed in the Morris water maze arena, and this dosage schedule was continued 
every day of behavioural testing. At the end of testing, mice were sacrificed and Aβ42 ELISAs were 
performed on hippocampal homogenate to determine if acute administration of c29 peptide had an  	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Figure 6.4     Basal forebrain cholinergic neuron loss induced by p75-saporin injection, is not 
mitigated by treatment with c29 peptide 
(A) Representative photomicrographs of coronal brain sections at the level of the basal forebrain, 
immunostained for a cholinergic neuron marker (anti-ChAT) 1 month after microinjection of p75-
saporin (lesion) into the basal forebrain of APP/PS1 mice and treatment with c29 peptide or its 
scrambled (SC) control. Location of photomicrograph indicated on schematic of coronal brain section 
in top right hand corner. Quantification of (B) ChAT- and (C) parvalbumin (PARV)-positive neuronal 
numbers in the basal forebrain of lesioned mice treated with c29 peptide or SC control, and compared 
to unlesioned (IgG-saporin) control transgenic mice. ChAT-positive neuron numbers are decreased 
following p75-saporin lesion, but are unaffected by c29/SC peptide treatment. Parvalbumin-positive 
neuron numbers are not affected by c29 peptide or its scrambled control. Data are presented as mean ± 
SEM. The number of animals per condition is indicated within the bars of the graphs. * p<0.001, one-
way ANOVA. 
!
!
!
!
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effect on total Aβ42 levels. Aβ levels were equivalent to that of lesioned mice in Chapter 3 indicating 
they were enhanced above non-lesioned transgenic controls. As expected, we found that acute treatment  
with c29 peptide did not change total Aβ42 levels in the hippocampus of basal forebrain lesioned 
APP/PS1 mice compared to control transgenic mice treated with SC peptide (Figure 6.5). This 
suggests that c29 peptide in this context is not disease modifying and we can next test its potential to 
overcome resultant cognitive impairment. 	  
6.2.2.2     No rescue of memory performance in a Morris water maze following acute 
administration of c29 peptide in basal forebrain lesioned APP/PS1 mice  
To determine if the acute administration of c29 peptide was able to rescue cognitive impairments 
induced by loss of BFCNs in presymptomatic mice APP/PS1 mice, basal forebrain lesioned APP/PS1 
mice were acutely treated with c29 or SC peptide then tested in the MWM paradigm. No significant 
differences in escape latency between groups treated with c29 peptide or its scrambled control peptide 
were observed over the 5 days learning schedule (Figure 6.6A). During the probe trial on the sixth day, 
the latency to the platform quadrant, the time spent in the target quadrant, and platform crossing 
frequency were assessed. No significant differences were observed between basal forebrain lesioned 
APP/PS1 mice treated with c29 peptide or its scrambled control (Figure 6.6B-D). This suggests that 
acute c29 peptide is insufficient to overcome impairment in basal forebrain-lesioned APP/PS1 mice. 
However, an alternative interpretation of these data is that neither the c29 nor SC peptide treated mice 
displayed cognitive impairment, and there was therefore no impairment to rescue with treatment.  	  	  
6.2.3.1     Decreases in hippocampal BDNF protein induced by BFCN loss are unaffected by 
chronic c29 peptide administration   
To address the second aim, we tested whether mice treated with c29 peptide in parallel to p75-saporin 
lesions could restore neurotrophic signalling sufficiently following loss of BFCN loss to prevent the 
increase in Aβ levels and thus prevent memory impairments one month later. To achieve this, 
immediately following lesion surgery, mini-osmotic 28-day pumps were implanted subcutaneously 
(Matusica et al., 2016) to provide a constant infusion of 5 mg/kg/day of c29 peptide or its scrambled 
control over the 28 day period following the surgery. At the end of this treatment period, mice were 
tested for cognitive ability in the MWM paradigm then sacrificed for further biochemical and 
histochemical analysis.  	  
To determine if chronic, 29 day administration of c29 peptide affected hippocampal BDNF protein 
levels previously shown to be reduced in the context of reduced cholinergic signalling in the  
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Figure 6.5     Levels of total Aβ42 in the hippocampus are not decreased following acute c29 
peptide administration in basal forebrain lesioned APP/PS1 transgenic mice 
Quantification of total Aβ42 levels (pg/mg) by ELISA from hippocampal lysates of basal forebrain 
lesioned APP/PS1 mice treated with a single intraperitoneal dose of c29 peptide or its scrambled (SC) 
peptide control for 6 days prior to sacrifice. Data are presented as mean ± SEM, with sample size 
indicated in the bars.  
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Figure 6.6    No rescue of memory performance in a Morris water maze following acute 
administration of c29 peptide in basal forebrain lesioned APP/PS1 mice 
(A) Graph of the escape latency (time to find the hidden platform) averaged per day in a 5 day Morris 
water maze task of spatial learning. APP/PS1 mice had undergone basal forebrain lesioning one month 
prior and were administered c29 peptide or its scrambled (SC) control every day of behavioural testing, 
30 minutes prior to testing began. No significant differences between basal forebrain lesioned APP/PS1 
transgenic mice treated with c29 peptide or SC peptide were observed during the initial 5-day learning 
schedule.  
Quantification of (B) latency to platform in seconds (s), (C) time spent in target quadrant and (D) 
platform crossing frequency during the probe trial on day 6, between basal forebrain lesioned mice 
treated with c29 peptide or its SC peptide control. Treatment with c29 peptide or its SC peptide 
control has no effect on any of these criteria. Data are presented as mean ± SEM with sample size 
indicated in the bars.  
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hippocampus, we measured BDNF levels in hippocampal homogenate by BDNF ELISA. As previously 
reported, p75-saporin injection into the basal forebrain caused a reduction in BDNF protein in the  
hippocampus compared to IgG-saporin injected transgenic controls (Figure 6.7). Furthermore, 28 days 
of c29 peptide treatment did not affect this decrease in BDNF protein and levels are comparable to SC 
peptide treated control mice (Figure 6.7). 	  
6.2.3.2     Learning and memory performance are unaffected by chronic c29 peptide 
treatment in basal forebrain lesioned APP/PS1 mice in a Morris water maze paradigm 
c29 peptide acts in vitro and in the spinal chord of motor neuron disease model mice by facilitating 
neurotrophic signalling (Matusica et al., 2013, Matusica et al., 2016). We hypothesized that this 
mechanism of action may prevent cognitive decline by preventing generation of Aβ, and thus Aβ-
induced cognitive deficits. We therefore compared the performance of control non-lesioned APP/PS1 
transgenic mice with age- and gender-matched lesioned APP/PS1 mice treated for 28 days with c29 
peptide or its scrambled peptide control in the MWM paradigm. Note that drug treatment had 
finished before behavioural testing began. Animals then underwent a five day learning schedule 
followed by a probe trial on the sixth day where the platform was removed.  
 
No significant differences in escape latency between any of the groups were observed over the first 5 
days (Figure 6.8A), as expected based on results from Chapter 3. Furthermore, no significant 
differences between groups were observed in the probe trial in measures of latency to the platform 
quadrant, the time spent in the target quadrant, and platform crossing frequency (Figure 6.8B-D). 
Importantly, although there was a trend for basal forebrain lesioned APP/PS1 mice (irrespective of 
treatment) to perform worse in all three measures than their non-lesioned APP/PS1 controls, this was 
not statistically significant, therefore there was no cognitive deficit compared to non-lesioned control 
animals that could be rescued by c29 peptide treatment. Indeed, there were no significant differences 
between c29 peptide treated basal forebrain lesioned APP/PS1 mice compared to scrambled peptide 
treated animals (Figure 6.8B-D). As we did not see a cognitive deficit following basal forebrain lesion 
in the mice compared to non-lesioned APP/PS1 mice (in contrast to chapter 3), we did not have a 
phenotype to rescue with peptide treatment, and thus these results are inconclusive. 	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Figure 6.7     Decreases in hippocampal BDNF protein induced by BFCN loss are unaffected by 
chronic c29 peptide administration 
Quantification of BDNF protein levels (pg BDNF/mg wet tissue) in hippocampal homogenates by 
ELISA in IgG-saporin (control) and p75-saporin (lesion) injected APP/PS1 amyloid transgenic mice 
with 1 month of c29 peptide administration or its scrambled (SC) control. Loss of basal forebrain 
cholinergic neurons resulted in a decrease in hippocampal BDNF levels that are unaffected by 
treatment with c29 peptide or its SC control. Data are presented as mean ± SEM. The number of 
animals per condition is indicated within the bars of the graphs. One-way ANOVA with Tukey’s 
multiple comparisons test, *= p<0.05.  
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Figure 6.8     Learning and memory performance are unaffected by chronic c29 peptide treatment 
in basal forebrain lesioned APP/PS1 mice in a Morris water maze paradigm 
 (A) Graph of the escape latency (time to find the hidden platform) averaged per day in a 5 day Morris 
water maze task of spatial learning of basal forebrain lesioned APP/PS1 mice treated with 1 month of 
c29 peptide or its scrambled (SC) and their non-lesioned (IgG-saporin) transgenic controls. No 
significant differences between basal forebrain lesioned APP/PS1 transgenic mice treated with c29 
peptide or SC peptide, or their unlesioned transgenic controls, were observed during the initial 5-day 
learning schedule.  
Quantification of latency to platform (B) in seconds (s), time spent in target quadrant (C), and 
platform crossing frequency (D) during the probe trial on day 6, between basal forebrain lesioned mice 
treated with c29 peptide or its SC control, and non-lesioned transgenic mice. No significant differences 
between basal forebrain lesioned mice and control non-lesioned mice were observed. Furthermore, 
treatment with c29 peptide or control SC peptide of basal forebrain lesioned APP/PS1 did not result in 
any significant changes. Data are presented as mean ± SEM with sample size indicated in the bars.  
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6.2.3.3     Amyloid plaque size and number are not reduced in the hippocampus of basal 
forebrain lesioned APP/PS1 mice following chronic treatment of c29 peptide 
One of our primary measures in the above experiment was to determine whether 28 days of treatment 
with c29 peptide prevented the increased levels of Aβ in basal forebrain lesioned APP/PS1 mice. 
Unfortunately, after performing the neurotrophin ELISA assays, we had insufficient hippocampal 
lysates to conduct the analysis of total Aβ42 by ELISA. Therefore as a secondary method, we analysed 
hippocampal sections by immunohistochemical staining. Amyloid plaque deposition in the 
hippocampus of basal forebrain lesioned APP/PS1 mice was assessed by counting the number and 
measuring the size of thioflavin S-positive plaques in the hippocampus of unlesioned APP/PS1 control 
mice and lesioned APP/PS1 mice treated for 28 days with c29 or SC peptide. As reported in chapter 3, 
there were low levels of Aβ plaque pathology in both lesioned and non lesioned APP/PS1 mice. 
Furthermore, no differences in amyloid plaque number or size were observed between lesioned c29 and 
SC treated animal groups (Figure 6.9) This result indicates that c29 treatment can not prevent Aβ 
plaque deposition over the 1 month treatment period, but we can not make a conclusion regarding 
whether BFCN lesion-induced soluble Aβ levels can be mediated by c29 treatment. 	  
6.2.4     Trophic signalling remains unchanged following a single dose of c29 peptide in aged 
wildtype or APP/PS1 transgenic mice  
Our laboratory has reported that a single intraperitoneal injection of c29 peptide can enhance low levels 
of trophic signalling in the spinal cord of SOD1 mice, a model of motor neuron disease (Matusica et 
al., 2016). To test whether a single intraperitoneal injection of c29 peptide could similarly effect 
downstream trophic signalling in the brains of APP/PS1 mice, we injected 16 month old wildtype and 
APP/PS1 mice with a single dose of c29 or SC peptide one hour prior to sacrifice. Western blot analysis 
was performed on hippocampal homogenates and levels of total and phosphorylated ERK1/2 and Akt 
were assessed. Surprisingly, given the age and cognitive deficits in 16 month old animals (Edwards et 
al., 2014) and in contrast to what we had hypothesized, no deficit in trophic signalling was observed in 
naïve APP/PS1 mice when compared to age-matched wildtypes (Figure 6.10A-B). In addition, no 
differences in phosphorylated ERK1/2 or Akt, or in total ERK1/2 or Akt were found by western blot 
following injection of c29 peptide or its scrambled control in either wildtype mice or age-matched 
APP/PS1 mice (Figure 6.10). These results indicate that measuring levels of phosphorylated ERK1/2 
and Akt in hippocampal lysates may not be the most appropriate indicators of changes to neurotrophic 
signalling, as further discussed below.
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Figure 6.9     Amyloid plaque size and number are not reduced in the hippocampus of basal 
forebrain lesioned APP/PS1 mice following chronic treatment of c29 peptide 
Quantification of (A) Aβ plaque number with Thioflavin S staining per µm2 and (B) plaque size of 
basal forebrain lesioned (p75-saporin) APP/PS1 mice treated for 1 month with c29 peptide or its 
scrambled (SC) control, and control (IgG-saporin) APP/PS1 mice. Loss of basal forebrain cholinergic 
neurons and treatment with c29 peptide or SC has no effect of plaque number and size in the 
hippocampus. Data are presented as mean ± SEM, with sample size indicated in the bars.  	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Figure 6.10     Trophic signalling remains unchanged following a single dose of c29 peptide in 
aged wildtype or APP/PS1 transgenic mice 
Representative western blots (A, B) and quantification (C, D) of total and phosphorylated ERK (A, C) 
and Akt (B, D) in hippocampal homogenates from aged wildtype and APP/PS1 transgenic mice 
following intraperitoneal injection of c29 peptide (black bars) or its scrambled peptide control (SC; 
white bars) one hour prior to sacrifice. The band intensities are normalized to the GAPDH loading 
control intensity and are shown (C, D) relative to levels of SC (control) treated mice. Data are 
presented as mean ± SEM with the sample size indicated in the bars.  
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6.3     Discussion 
Enhancement of neurotrophic signalling as a therapeutic strategy for the treatment of 
neurodegenerative diseases has broad potential given the wide-ranging role of neurotrophin signalling in 
supporting neuron survival and function. Moreover, neurotrophic dysfunction is widely reported in a 
range of diseases, highlighting their involvement in disease processes (Nagahara and Tuszynski, 2011, 
Longo and Massa, 2013, Lu et al., 2013). Potential neurotrophin-based therapies for AD have been 
clinically tested (Longo and Massa, 2005), however significant adverse effects and issues regarding the 
delivery of neurotrophins to the brain has impeded progress. Neurotrophic mimetics also have 
specificity issues to be overcome (Nagahara and Tuszynski, 2011). In this chapter, we evaluated c29 
peptide that acts post synaptically to enhance low neurotrophin signalling, as a candidate therapeutic 
for rescuing or preventing memory impairments and increased Aβ42 load caused by reduced basal 
forebrain cholinergic signalling in APP/PS1 mice and the subsequent reduction in BDNF protein. c29 
peptide is a p75NTR-derived trophic peptide which enhances neurotrophic signalling by facilitating Trk 
receptor ligand binding and enhancing endogenous signalling. This mechanism circumvents potential 
problems innate to broad, agonist-induced receptor activation and preserves signalling selectivity that is 
characteristic of the neurotrophin signalling system. Moreover, we used c29 peptide as a tool to 
enhance neurotrophic signalling induced by loss of BFCNs to help define the degenerative pathways 
which follow the loss of these neurons, i.e. is it the loss of BDNF signalling or the cholinergic deficit 
which results in increased Aβ.  
 
In the present work we demonstrate that a series of acute doses of c29 peptide administered at the time 
of behavioural testing, does not rescue learning and memory deficits caused by lesion of BFCNs in 
APP/PS1 mice. Moreover, as we hypothesized, this acute treatment schedule has no effect on Aβ levels. 
Unfortunately however, we lack non-lesioned transgenic controls as a comparison for cognitive testing. 
Although we cannot conduct statistical analyses on behavioural tests performed at different times, when 
these results are compared to chronic c29 peptide treatment experiments, our basal forebrain lesioned 
APP/PS1 mice (irrespective of treatment) demonstrate comparable latency to platform, time in target 
area and platform crossing frequencies to non-lesioned transgenic control mice. Consequently, there 
may be no cognitive deficit caused by basal forebrain lesions in these mice to rescue with c29 peptide 
treatment, which is in contrast to what we report in Chapter 3. Alternatively, the results may indicate 
that c29 peptide is ineffective in this context, as there is no statistical difference between c29 and SC 
peptide treated mice in the MWM paradigm and Aβ42 levels are comparable to those of lesioned mice 
in Chapter 3, which do show memory impairments. If our hypothesis is correct, elevation of Aβ (in 
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combination with loss of cholinergic signalling) causes memory impairments, and c29 peptide is unable 
to overcome this impairment to rescue resultant cognitive decline. However, as this result raises the 
need for additional controls, we have insufficient evidence to draw a conclusion on the effectiveness of 
this peptide.  
 
Futhermore, we demonstrate that chronic treatment with c29 peptide immediately following basal 
forebrain lesions in APP/PS1 mice did not rescue amyloid pathology or cognitive deficits.  Again this 
may indicate that c29 peptide treatment is ineffective at enhancing cognitive abilities in this context. 
However, in this case, our basal forebrain lesion did not cause significant cognitive deficits in these 
mice, and thus there is no impairment to be rescued by long term treatment with c29 peptide. 
Additionally, we lack measurements of total Aβ42 levels by ELISA (which were increased following 
BFCN loss in Chapter 3), to suggest that chronic c29 peptide treatment does not alleviate the increase 
in Aβ levels. Consequently, our results testing whether chronic c29 peptide treatment can be disease 
modifying is inconclusive. However previous findings from the Coulson laboratory demonstrate subtle 
cognitive rescue of aged APP/PS1 mice acutely treated with c29 peptide, suggest that c29 peptide in the 
treatment of AD is worth pursuing.  
 
Previous research has shown that an acute dose of c29 peptide is sufficient to activate BDNF-mediated 
survival signalling in the spinal cord of SOD1 mice. Matusica et al., (2016) reported a significant 
increase in phosphorylated TrkB, ERK1/2, Akt and CREB in spinal cord tissue following c29 peptide 
treatment in comparison to SC peptide treated SOD1 mice. However our study did not to replicate 
this, with no increase in the levels of total or phosphorylated ERK1/2 and Akt 1 hour after IP injection 
in APP mice. However, it is important to note that the SOD1 mice had significantly less activation of 
these signalling molecules compared to wildtype mice, with c29 peptide only partially rescuing this 
deficit. Surprisingly, by contrast, the levels of total or phosphorylated ERK1/2 and Akt in 16 month 
old APP/PS1 mice were not significantly reduced compared to age-matched wildtype mice. Therefore, 
it is possible that the assays are not measuring neurotrophin-mediated signalling, that there is 
compensation in trophic signalling from support cells such as microglia, or that there is no 
neurotrophin deficit in these animals. As such, investigation into a more specific downstream signalling 
molecule of BDNF is warranted. If it is a result of trophic compensation, ERK1/2 and Akt signalling 
may be at maximal levels and thus leaving little room for enhanced signalling in the presence of c29 
peptide treatment. Indeed, in vitro c29 peptide only affects Trk activity in sub threshold BDNF 
concentrations (Matusica et al., 2016). Additionally, direct investigation of neurotrophin levels in these 
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aged mice may be necessary. Again a redesign of methods to demonstrate that systemic administration 
of c29 peptides to mice can affect brain Trk signalling is necessitated. We suggest the use of a 
heterozygous BDNF knockout mouse to test c29 peptide rescue of TrkB signalling in a model of 
downregulated BDNF signalling, or measuring changes in proteins such as Arc which are directly 
regulated by BDNF signalling (Gil-Bea et al., 2011). 
 
We consider that the aims of this chapter are still worth pursuing using c29 peptide treatment but that 
improvements in experimental design are required in future studies to robustly answer the posed 
questions. Our first issue was not having robust cognitive changes in the lesioned APP/PS1 mice. In 
contrast to Chapter 3 where a significant difference is observed, animal numbers in the cohorts used in 
this chapter were almost half of what we used. Unfortunately, our numbers in this chapter were limited 
to what was available in the time frame of the thesis. Moreover, as demonstrated by previous results in 
our laboratory on studies of 8 month old APP/PS1 mice, the cognitive changes observed are subtle. 
Therefore future experiments would require larger cohorts as prescribed by the guidelines for preclinical 
testing.  
 
The second complexity is the peptide treatment itself. c29 peptide is an unmodified peptide and is 
known to have a short serum half-life. Nonetheless, it, and other TAT-fused peptides, can cross the 
blood brain barrier (Matusica et al., 2016; Ho et al., 2001). The encouraging behavioural results 
reported in this chapter’s introduction and other studies from our laboratory suggest that c29 peptide 
can affect cognitive processes and therefore can cross the blood brain barrier. The results using i.p 
injections of c29 peptide in unlesioned, aged APP/PS1 mice may reflect an administration which best 
allows c29 peptide to act – a high concentration bolus rather than a slow infusion. Clearly both these 
administration strategies require further testing, and improvements to the biostability of c29 are a 
current focus of the Coulson laboratory.  
 
Alternatively, the effectiveness of c29 peptide in previous results from the Coulson laboratory compared 
to the results in this chapter may reflect the differences in the mice themselves. Previous experiments in 
the lab used APP/PS1 mice with intact basal forebrains compared to the basal forebrain lesioned 
APP/PS1 mice that we used in this chapter. This may suggest that there is too much damage from the 
combination of reduced cholinergic signalling along with increased Aβ, for c29 peptide to rescue and 
that loss of cholinergic signalling plays a vital role, in combination with increased Aβ, in the observed 
cognitive decline. This may explain why current anti-Aβ treatments in human AD patients only 
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modestly rescue cognitive decline, despite lowering Aβ levels (Lemere and Masliah, 2010). It is also 
possible that c29 peptide is acting by enhancing BFCN function in the intact APP/PS1 mice, which is 
not possible in lesioned mice (or humans with BFCN atrophy). 
 
This thesis explores the impact of reduced cholinergic signalling in the context of an AD transgenic 
mouse line. Results from previous chapters show that loss of BFCNs causes a reduction in BDNF levels 
in the hippocampus. This coincides with increased hippocampal Aβ levels and cognitive deficits. 
Memory impairments in the Morris water maze in Chapter 3 suggest this pathway to cognitive deficit is 
a result of the combination of loss of BFCN and increased Aβ, as an equivalent reduction in cholinergic 
signalling with BDNF dysfunction in wildtype mice (with no Aβ) did not cause cognitive impairment. 
Successful cognitive rescue by one of our two methods of administration would have further teased 
apart the core steps in the pathway to cognitive deficit in our basal forebrain lesioned mice. If acute c29 
peptide treatment resulted in successful cognitive rescue with no change in Aβ levels, it would have 
provided evidence that enhancing neurotrophic signalling (above normal levels) was able to overcome 
Aβ increases without affecting memory harming-Aβ directly, and would be a viable therapeutic avenue 
for relief of AD symptoms (Figure 6.3A). Alternatively, if chronic c29 peptide treatment was able to 
reduce amyloid pathology which consequently rescued memory impairments, it would highlight a role 
for the rescue of neurotrophic signalling as an candidate for disease modifying treatment of AD (Figure 
6.3B). Moreover, it would have demonstrated that changes in neurotrophin signalling are (at least 
partially) causative. 
 
In conclusion, we found that both chronic and acute administration of c29 peptide did not significantly 
alter amyloidogenic processing/Aβ accumulation or alter baseline memory performance in APP/PS1 
mice in which BFCNs had been lesioned. This lack of rescue is in contrast to the apparent rescue of 
behavioural deficits of aged but unlesioned APP/PS1 mice by acute c29 peptide treatment 
demonstrated in the Coulson laboratory. We conclude that although c29 peptide may provide some 
cognitive benefit, at this stage there is no evidence that c29 can either be disease modifying or overcome 
a combination of Aβ load and BFCN loss. However, a different dose or treatment schedule, the use of a 
more biostable peptide or more directly targeted delivery still warrants further investigation. Likewise, 
the use of c29 peptide as an adjuvant therapy may prove to provide additional benefit to currently used 
therapeutics or Aβ lowering drugs currently in clinical trials. 	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7.1      Cholinergic hypofunction as a trigger for AD degenerative 
pathways 	  
During the course of this thesis, we demonstrated that the loss of basal forebrain cholinergic neuron 
innervation to the hippocampus in presymptomatic APP/PS1 transgenic mice triggers pathogenic 
changes, including a reduction in hippocampal BDNF, an increase in total Aβ levels, and cognitive 
decline. As the combination of reduced cholinergic signalling and reduced BDNF did not induce 
cognitive deficits in wildtype mice, these results suggest that an increase in Aβ is required for spatial 
learning deficits in this model. Albeit that reduced cholinergic signalling and/or reduced BDNF levels 
likely contribute to this decline. These results demonstrate that loss of BFCNs is a mechanism by which 
Aβ load can be induced early in disease etiology. 
 
Our results are supported by previous in vivo findings in which equivalent losses in cholinergic 
innervation to the hippocampus in a range of AD transgenic mouse models, resulted in acceleration of 
amyloidogenic processing and/or a reduction in amyloid clearance and cognitive deficits in one or more 
tests of learning and memory (Gil-Bea et al., 2012, Laursen et al., 2013, Ramos-Rodriguez et al., 2013, 
Hartig et al., 2014, Laursen et al., 2014). However the majority of these changes were measured in AD 
mice which were already symptomatic, such that the BFCN lesion resulted in an acceleration of the 
already present pathology. Futhermore, we are the first to investigate changes specifically in 
neurotrophic signalling in an AD mouse model triggered by cholinergic degeneration. Recent findings 
using MRI in human AD patients show that basal forebrain loss is significantly greater in AD and MCI 
patients compared to age-matched controls (Hall et al., 2008, Muth et al., 2010, Grothe et al., 2012, 
Kerbler et al., 2015), and atrophy of the basal forebrain is correlated to Aβ burden (Grothe et al., 2014, 
Teipel et al., 2014, Kerbler et al., 2015). As our model of BFCN lesioning inducing Aβ levels replicates 
the human etiology, our model is a better model of sporadic disease than other currently available 
mouse AD models.  	  
Along with reduced cholinergic signalling and amyloid plaques, post-translational modifications of the 
protein tau are a main feature of AD. As a tau phenotype was not observed in our APP/PS1 cholinergic 
hypofunction model possibly due to the immaturity of the disease process, we induced equivalent 
BFCN lesions in pR5 (P301L) tau transgenic mouse in order to directly investigate a possible 
association between cholinergic signalling and tau pathology. As no change in tau pathology was found 
following the loss of cholinergic signalling in mice predisposed to tau hyperphosphorylation, this 
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suggests that tau pathology is unlikely to be directly regulated by BFCN degeneration or the 
corresponding decrease in hippocampal neurotrophin levels, although these features may still contribute 
to disease etiology. Rather, we propose that amyloid pathology, which is not present in pR5 (P301L) 
transgenic mice, is required, perhaps in combination with reduced cholinergic signalling to induce 
pathological changes in tau, as exemplified by cholinergic denervation in transgenic mice with both 
amyloid and tau mutations (Hartig et al., 2014). We therefore suggest that, although BFCN 
degeneration is a risk factor for exacerbated A! pathology in genetically susceptible animals, associated 
tau pathology is likely to be mediated indirectly by BFCN degeneration and/or the resultant decrease in 
neurotrophin levels, albeit that these features may be essential contributing factors to disease etiology 
(Figure 7.1).  
 
 
!
!
!
!
Figure 7.1     Regulation of AD pathology by reduced cholinergic signalling 
Schematic representation of the proposed downstream neurodegenerative pathways following reduced 
cholinergic signalling. Reduced BDNF and increased A! lead to cognitive deficits mediated by tau 
pathology. 
 
7.2     Role of BDNF in AD degeneration 
!
The involvement of neurotrophins in AD has been widely documented (Fumagalli et al., 2006, Tapia-
Arancibia et al., 2008). However whether the role they play is causative, contributive, or a consequence 
of the disease in still being debated. Results from Chapter 3 highlighted the association of dysfunctional 
BDNF signalling with increased amyloidogenic processing and cognitive deficits in our cholinergic 
hypofunction AD mouse models. Therefore in Chapter 5 we investigated this further by selectively 
knocking down BDNF gene expression in the hippocampus of APP/PS1 mice, mimicking the spatially 
restricted decrease in BDNF protein attained in Chapter 3, but in the absence of cholinergic 
hypofunction. We found that selective reduction of BDNF protein in the hippocampus of APP/PS1 
mice did not significantly alter A! accumulation or baseline memory performance in APP/PS1 mice 
with intact basal forebrains. At face value, this suggests that lowered BDNF levels are not sufficient to 
cause the development of A! pathology or cognitive impairment in presymptomatic mice predisposed 
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to Aβ production. However, we cannot exclude reduced BDNF, particularly over a wider brain area, as 
a contributing factor to increased amyloid and cognitive deficits.  
 
Indeed the conclusion that lowered BDNF contributes to cognitive decline and possibly amyloid 
burden is consistent with studies in human which suggest that dysfunctional BDNF signalling is not 
causative of AD, but contributes to cognitive impairments without impacting on levels of Aβ pathology 
(Laske et al., 2011, Carlino et al., 2013, Lim et al., 2013, Lim et al., 2015).  Futhermore, transgenic 
AD mouse models place dysfunctional BDNF signalling as a consequence of AD disease processes, with 
no exacerbation of pathology found in AD mouse models with globally reduced BDNF levels (Castello 
et al., 2012, Rantamaki et al., 2013). In vitro results have pointed to BDNF dysfunction as a cause, a 
contributor and a consequence of AD pathology (Elliott et al., 2005, Garzon and Fahnestock, 2007, 
Arancibia et al., 2008, Matrone et al., 2008a, Ramser et al., 2013) and therefore do not help this 
debate. Despite this, dysfunctional BDNF signalling is a major feature of AD, and although it may not 
cause pathology, enhancement of BDNF signalling remains as a major therapeutic opportunity.  
 
7.3     Enhancing neurotrophic signalling in AD  
Given their wide-ranging role in supporting neuron survival and function, and their reduction in AD 
disease progression, the use of neurotrophin mimetics as supportive therapy in AD to slow cellular 
death and support function in remaining neurons has long been advocated (Lu et al., 2013). In Chapter 
6 we tested a p75NTR-based peptide mimetic, c29 peptide, which promotes synapse-specific trophic 
signalling in the context of low neurotrophin concentrations, as occurs in AD generally, and specifically 
in the context of our BFCN lesioned AD mouse model. We evaluated c29 peptide as a candidate 
therapeutic in our cholinergic hypofunction APP/PS1 mice with low BDNF levels, with two different 
treatment strategies, which also aimed to test specific roles for trophic signaling in disease processes.  
 
The first strategy was an acute treatment administered in parallel to behavioural testing (one month 
after induced loss of BFCNs) to determine if enhanced neurotrophic signalling could overcome 
Aβ/BFCN lesion-induced impairments and rescue cognitive function. The second was a chronic 
treatment schedule, administered by osmotic pump over the 28 days following stereotaxic surgery to 
lesion the BFCNs (Figure 7.2). The aim of this second strategy was to determine whether enhancing 
neurotrophic signalling from day one could be disease modifying and thus prevent an increase in Aβ, 
and therefore the subsequent cognitive decline. We found that both acute and chronic treatment 
strategies for administration of c29 peptide did not significantly alter Aβ accumulation or alter memory 
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performance in basal forebrain-lesioned APP/PS1 mice. We conclude that although c29 peptide may 
provide some cognitive benefits, as evidenced by rescue of selective behavioural deficits in aged but 
unlesioned APP/PS1 mice by c29 peptide in our lab (Qian, unpublished) at this stage there is 
insufficient evidence to conclude that c29 can either be disease modifying or overcome a combination 
of A! load and BFCN loss. However based on the preliminary findings and the strong support for 
neurotrophic therapy in the literature (Tapia-Arancibia et al., 2008, Lu et al., 2013), pursuit of this line 
of study is warranted. Future work should treat larger cohorts, use a more biostable peptide or more 
directly targeted delivery in order to determine the effectiveness of enhancing neurotrophic signalling to 
treat AD degenerative pathways with this peptide. Based on the work in this thesis we predict that the 
most efficacious effect of c29 peptide would be overcoming impairment, with minimal if any effect on 
A! even in the context of reduced cholinergic support (Figure 7.2A). 
!
This project adds insight into the role of reduced cholinergic signalling, a feature of AD, in the etiology 
of the disease. Inducing loss of BFCNs in AD mouse models recapitulates certain key features of the 
disease, including reduced neurotrophic signalling, and triggers early amyloidogenic processing and 
cognitive decline. Moreover, this model has provided us with a platform to further investigate the role 
of BDNF in AD neurodegeneration. In agreement with current research, we show that dysfunctional 
BDNF signalling is most likely a consequence of AD disease processes, although it may also contribute 
to cognitive decline. Futhermore, enhancing neurotrophic signalling early in disease development may 
prove a viable treatment opportunity as an adjuvant therapy for AD.  
!
 
!
!
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Figure 7.2     Projected changes in neurodegenerative pathways following treatment with c29 
peptide  
Hypothetical modulation of degenerative pathway by acute (A) and chronic (B) treatment with c29 
peptide, resulting in cognitive rescue either directly by acute treatment or indirectly, via a reduction in 
A! levels, by chronic treatment. 
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Appendix I 
 
The following work represents the initial direction of my PhD in which my aim was to understand, at 
the molecular level, how post-translational modifications of p75NTR affect its function and mediate the 
switching between pro-survival to apoptotic signalling. In order to investigate this dual role of p75NTR, 
we first needed to establish an in vitro assay of cultured sympathetic neurons in which the in vivo 
developmental scenario of NGF signalling survival (through a TrkA:p75NTR complex) and BDNF 
signalling inducing death (through p75NTR alone) is replicated. We hypothesized that cultured superior 
cervical ganglion (SCG) neurons that were grown in defined, serum-free culture conditions would 
enable NGF-mediated survival as well as robust BDNF-mediated death.   
 
Unfortunately, upon continuing the use this primary culture system to answer further questions 
regarding post-translational modifications of p75NTR, we ran into replication issues when inducing 
apoptotic death of neurons with treatment with BDNF, namely, that BDNF no longer induced death 
in the defined conditions. Following several months of troubleshooting sources of NGF, BDNF and 
media, we came to the conclusion that the culture assay did not infact represent a robust, reproducible 
assay and discontinued the project. This resulted in a complete change of direction of my PhD which 
culminated in the previous chapters of this thesis. However for the sake of prosperity, I have included 
in this appendix the results from my initial project. 	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In vitro culturing of neurons isolated from 
dissociated superior cervical ganglia (SCG) has 
been essential for advancing our understanding 
of neurotrophin biology including the 
mechanisms by which neurons survive and die 
during development. Such cultures still serve as 
the best in vitro model for the study of 
functional interactions and competition  
between the TrkA receptor and the p75 
neurotrophin receptor (p75NTR) in response to 
!
!
!
!
!
!
!
!
!
!
!
!
!
!
the neurotrophins nerve growth factor (NGF) 
and brain derived neurotrophic factor (BDNF), 
which occurs in vivo during developmental 
programmed sympathetic neuronal death. 
However, functional assays reported in the 
literature have been performed using a range of 
mediums resulting in inconsistency in the 
outcome of BDNF treatment of SCG cultures 
maintained with NGF. Our objective was to 
find the best defined serum-free culture 
medium and conditions to assay murine 
superior cervical ganglion neurons, for studying 
the competing signaling events between NGF-
induced Trk-mediated survival and BDNF-
induced p75NTR-mediated apoptosis during 
sympathetic neuronal development. 
Comparison of various media types in this 
study shows that maintenance of sympathetic 
neurons in serum-free Neurobasal media 
supplemented with 0.2% B-27 provides 
optimal culture conditions for both NGF-
mediated survival and BDNF-induced 
apoptosis of established sympathetic neurons. 
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8.1     Introduction 
 
Developmental cell death of neurons is an essential adaptive process required for the establishment of 
appropriate neural circuitry (Oppenheim, 1991). This programmed cell death is responsible for the 
shaping and maintenance of a functional nervous system (Oppenheim, 1991) and is regulated by 
growth factors produced in limiting amounts by target tissues (Davies, 1994, Huang and Reichardt, 
2001).  Neurotrophins are the classical growth factors that regulate neuronal survival, maintenance and 
cell death during development and adulthood (Friedman and Greene, 1999). The neurotrophin family 
consists of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 
(NT-3) and neurotrophin-4 (NT-4) (Friedman and Greene, 1999). Cellular responses to neurotrophins 
are mediated by two classes of transmembrane receptor; the tyrosine kinase receptor family of Trks 
(Johnson et al., 1986, Radeke et al., 1987) and the pan neurotrophin receptor p75NTR (Kaplan et al., 
1991, Klein et al., 1991).  
 
Dissociated sympathetic neurons from the superior cervical ganglia (SCG) are a neuronal population 
well characterized regarding their dependence on neurotrophins and are widely used for investigation of 
neurotrophin signalling (Weskamp and Reichardt, 1991, Ibanez et al., 1992, Clary and Reichardt, 
1994, Bamji et al., 1998, Kohn et al., 1999, Majdan et al., 2001). Sympathetic neurons are dependent 
on NGF for their survival and differentiation, and express the tyrosine kinase receptor TrkA, and the 
pan-neurotrophin receptor p75NTR (Johnson et al., 1986, Radeke et al., 1987, Kaplan et al., 1991, Klein 
et al., 1991). During development, sympathetic neurons send out neuritic processes to compete for 
limited quantities of NGF secreted by target tissues. Binding of NGF to the TrkA receptor mediates the 
selective survival of a proportion of sympathetic neurons as they innervate their target tissues (Levi-
Montalcini, 1987;Clary et al., 1994; Ibanez et al., 1992; Weskamp and Reichardt, 1991), and failure to 
compete for NGF results in elimination of approximately 50% of these neurons during development 
(Oppenheim, 1991). 
 
Activation of the p75NTR by BDNF also plays a role in regulating survival of sympathetic neurons. TrkA 
activation by NGF in sympathetic neurons stimulates secretion of BDNF onto neighboring neurons, 
which acts to inhibit axonal growth and promote apoptosis (Aloyz et al., 1998, Bamji et al., 1998, 
Deppmann et al., 2008). The importance of BDNF-mediated death signaling through p75NTR in vivo 
has been demonstrated in genetic studies of BDNF and p75NTR knockout mice in which naturally 
occurring sympathetic neuron death does not occur (Bamji et al., 1998). Thus programmed cell death 
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and appropriate developmental innervation appears to be due to competition between NGF activation 
of TrkA and BDNF activation of p75NTR (Belliveau et al., 1997, Aloyz et al., 1998, Bamji et al., 1998, 
Kohn et al., 1999, Majdan et al., 2001, Deppmann et al., 2008). However, the molecular mechanisms 
underlying the functional antagonism of NGF-induced survival and BDNF-mediated death signaling 
in SCG sympathetic neurons are not yet fully understood. 
 
Studies of neurotrophin action on SCG neurons have demonstrated the need for a defined culture 
system with minimal variables, which can be widely used to standardize investigation of survival and 
death signalling of neurotrophins. For example across the major labs involved in neurotrophin research, 
media and serum conditions vary widely, from Ultraculture medium or Leibovitz’s L-15 medium 
supplemented with 3% fetal bovine serum (FBS) or 3% rat serum (Aloyz et al., 1998; Bamji et al., 
1998; Vaillant et al., 1999; Edwards et al., 1991; Edwards et al., 1994; Kohn et al., 1999; Majdan et 
al., 2001), to Hams F-14 medium supplemented with 5% fetal calf serum (FCS) (Palmada et al., 2002) 
and Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS (Ham et al., 1995, Tsui-Pierchala 
and Ginty, 1999, Kuruvilla et al., 2000, Ye et al., 2003, Deppmann et al., 2008, Kristiansen et al., 
2010). Furthermore, serums contents are inconsistent with variability in animals and batch numbers, 
and contain undefined growth factors that may interfere with normal neurotrophin receptor activity. 
An alternative to serum is the use of defined, serum-free neuronal supplements.  
 
As a result of the variability in culture conditions, a range of NGF concentrations have been used to 
sustain survival of sympathetic neurons in vitro. The most widely used is 10 ng/ml of NGF, which is 
generally sufficient to sustain >80% of neurons for 48 hours ( Aloyz et al., 1998; Bamji et al., 1998; 
Vaillant et al., 1999; Ye et al, 2003; Majdan et al., 2001), however 5 ng/ml of NGF has also been 
reported capable of eliciting maximal survival of these neurons (Kohn et al., 1999). Moreover, reports 
of NGF sustained neuronal survival across different concentrations are inconsistent. 1 ng/ml of NGF 
has been reported to sustain survival in 82% of sympathetic neurons (Deppmann et al., 2008) while 2.5 
ng/ml of NGF has been reported to sustain survival in approximately 30% or 55% of neurons (Bamji et 
al., 1998, Vaillant et al., 1999). Similarly, 5 ng/ml of NGF has been reported to support survival in 
approximately 50%, 85% or all sympathetic neurons (Bamji et al., 1998, Kohn et al., 1999, Vaillant et 
al., 1999). 	  
Reports of BDNF-induced death of sympathetic neurons are similarly variable. A reduction in NGF 
concentration or complete removal of NGF from the media and replacement with KCl to stimulate 
depolarization-dependent survival, are the two most commonly used strategies in assays investigating 
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BDNF induced apoptosis (Aloyz et al., 1998, Bamji et al., 1998, Palmada et al., 2002, Deppmann et 
al., 2008). However, due to differences in methodology and data representation, the amount of BDNF 
required to induce adequate death i.e. neuronal death of more than 50%, in sympathetic neurons is still 
unclear. It has been reported that in the presence of 1 ng/ml of NGF, 75-80% of sympathetic neurons 
survive after 36 hours of 100 ng/ml of BDNF treatment (Deppmann et al., 2008). Conversely in 
another study, 100 ng/ml of BDNF in the presence of 2.5 ng/ml of NGF results a reduced survival of 
43% of SCG neurons compared to 10 ng/ml of NGF only after 48 hours (Bamji et al., 1998). 
Comparably, an 87% increase in sympathetic neuron apoptotic nuclei was observed following BDNF 
treatment for 48 hours in the presence of KCl (Palmada et al., 2002).  
 
In previous studies investigating NGF and BDNF in developmental cell death of sympathetic neurons, 
a range of different media, media supplements and animal serums have been used, resulting in 
inconsistent reports of NGF-mediated survival and BDNF-induced death of these neurons. A 
standardised and defined serum-free culture system with minimal variables enables a clear delineation of 
survival and death signalling in SCG neurons which would further our understanding of the molecular 
mechanisms behind neurotrophin signalling. The aim of the present study was to establish such a 
method for growing dissociated SCG neurons in NGF such that treatment with BDNF causes robust 
apoptosis, mimicking the in vivo scenario. 
 
  
 
 
 
 	  
	   165 
8.2     Materials and Methods 
 
8.2.1     Dissociation and culture of SCG neurons 
SCGs were dissected from c57Bl6 postnatal day 3-5 mouse pups, with approval from the University of 
Queensland Animal Ethics Committee. Isolation of mouse SCGs was adapted from a previously 
published protocol for the dissection of rat sensory sympathetic neurons (Zareen and Greene, 2009). 
Briefly, pups were anesthetized by being placed on ice for 5 minutes, then rapidly decapitated with 
sharp scissors and the head drained of blood. The ganglia were dissected out and cleaned of carotid 
artery, fat and other tissue. Individual ganglia were then pooled and then digested in 1 ml of 0.25% 
trypsin for 30 minutes at 37˚C. Digestion was stopped by adding 2 ml of medium containing 10% 
fetal bovine serum (FBS) to the trypsin solution. The ganglia were centrifuged at 800 xg, re-suspended 
in 1 ml of media and then mechanically dissociated using a sterile glass-polished pipette. Dissociated 
cells were centrifuged at 400 xg for 10 minutes, re-suspended into single cell solutions, and relative cell 
viability assessed based on 0.4% trypan blue dye exclusion. Cells were then plated onto dishes coated 
with 0.0015% poly-L-ornithine (Sigma-Aldrich) and mouse laminin (3.5 µg/ml; Invitrogen). The 
dissociated SCG neuron cultures were grown in various culture media at 37˚C in a 5% CO2 
humidified atmosphere.  
 
8.2.2     Culture medium preparations 
Six commonly used media were screened for the ability to maintain viable SCG neuronal cultures: 
Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco) supplemented with 10% FBS 
(Thermo Fischer Scientific), Neurobasal medium (Gibco) with 1% N-2 supplement (Gibco), 
Neurobasal medium with 1% B-27 serum-free supplement (Gibco), Neurobasal medium with 0.2% B-
27 serum-free supplement, Dulbecco’s modified Eagle’s medium (DMEM) (Gibco) with 1% 
Monomed supplement (SAFC Biosciences) and 1% FBS, and DMEM with 1% Monomed 
supplement.  
 
All media were additionally supplemented with 1% non-essential amino acids (NEAA) and 1% L-
glutamine (Gibco). The antimitotic agents uridine (Sigma-Aldrich) and 5-fluoro-5’-deoxyuridine (5-
FDU) (Sigma-Aldrich) were made up in sterile H2O, filter sterilized and added at the time of plating at 
a final concentration of 2.5 mM. 
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8.2.3     NGF survival assays 
To establish NGF dependent survival in the six media described above, single-cell suspensions were 
plated in an initial volume of 100 µl at a cell density of 2,500 – 3,500 cells per well of Greiner 4-well 
(10 mm round wells inside 35 mm) culture dishes (Interpath Services). Each well was manually etched 
with a 5 x 5 grid using a sterile 21-gauge needle. The plates were then incubated at 37˚C with 5% CO2 
for 1 hour to allow for cell attachment before being flooded with medium containing 0.1, 1 or 10 
ng/ml nerve growth factor (NGF) (Biosensis). An initial cell count of viable cells within 4 random 
regions of interest (ROIs) was then performed. Cell counts were then repeated 48 hours later using the 
same ROIs to calculate the percentage of neuronal survival. Cell counts were used to determine the rate 
of survival. Counting was performed using an Olympus phase-contrast light microscope with a 20x 
objective. At time=0, live cells were phase bright and predominantly spherical in shape, or exhibited a 
short neuritic extension. Established neurons were considered viable if they exhibited robust neurite 
outgrowth, were phase bright with a smooth membrane and displayed non-fragmented nuclei 
(Whitfield et al., 2004). Non-neuronal cells identified by their flattened or triangular morphology and 
lack of extensive neurites were counted in some established cultures. 
 
Alternatively, rates of neuronal survival were determined using an acid phosphatase assay which involves 
the conversion of p-nitrophenyl phosphate to p-nitrophenol by cytosolic acid phosphatase produced by 
functional mitochondria (Yang et al., 1996).  Dissociated SCGs were plated in pre-coated 96-well 
plates at a density of 5,000 cells per well in 200 µl of either RPMI medium containing 10% FBS or 
Neurobasal medium containing 0.2% B-27 supplemented with 0.1, 1 or 10 ng/ml NGF and cultured 
for 48 hours. Cells were then gently washed 3 times in ice-cold phosphate buffered saline (PBS), after 
which 100 µl of reaction buffer containing 0.1 M sodium acetate, 5 mM p-(4) nitrophenyl phosphate 
and 0.1% v/v Triton-X100, pH 5 was added to each well, and the plate was incubated for 45 minutes 
at 37˚C. The enzymatic reaction was stopped by the addition of 10 µl of 1 M NaOH to each well, 
before measuring absorbance with optical density (O.D) at 405 nm on a plate reader.  
 
8.2.4     BDNF-induced apoptosis assays  
In experiments assessing the BDNF-mediated apoptosis of neurons in the presence of competing NGF-
induced survival, SCG cultures were first allowed to grow for 48 hours in the presence of 10 ng/ml 
NGF. After this 48 hour incubation in the appropriate medium containing NGF, the cultures were 
washed for 15 minutes with NGF-free medium and then incubated in fresh medium containing 10 
ng/ml NGF and 0, 50, 100 or 200 ng/ml BDNF (PeproTech). The numbers of surviving neurons were 
counted 24 hours following the addition of BDNF, and are expressed as a percentage of neurons 
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counted prior to the addition of BDNF. In experiments investigating BDNF-induced cell apoptosis in 
non-established cultures that have not yet initiated neurite outgrowth, dissociated neurons were plated 
into poly-L-ornithine and laminin coated wells and immediately flooded with medium containing 10 
ng/ml NGF and 0, 50, 100 or 200 ng/ml of BDNF. Viable neurons were counted 24 hours later. 
 
8.2.5     Immunohistochemistry  
Activated caspase-3 immunohistochemistry was used for the detection of cells undergoing neuronal 
apoptosis induced by BDNF. Dissociated SCG neurons were plated at a density of 5,000 cells per well 
onto glass cover slips coated with 0.0015% poly-L-Ornithine in sterile H20, 1:45 bovine collagen in 
PBS (Stem Cell Technologies) and 3.5 µg/ml mouse laminin. Neurons were cultured for 48 hours in 
Neurobasal medium containing 0.2% B-27, 1% NEAA, 1% L-glutamine, Uridine (2.5 mM), 5-FDU 
(2.5 mM) and 10 ng/ml NGF at 37˚C in 5% CO2. Following 48 hours in culture, the medium was 
replaced with fresh medium containing 100 ng/ml BDNF and NGF.  Neurons were fixed for 20 
minutes on ice in PBS containing 4% paraformaldehyde at 0, 12 and 24 hour time points following 
BDNF administration. Neurons were then blocked in 3% BSA for 1 hour and stained overnight with 
an anti-βIII-tubulin antibody (1:2,000; Promega), washed for 30 min in PBS and followed by a anti-
mouse 3 hour incubation with an Alexa-Fluor 488 secondary antibody (1:20,000; Invitrogen). Anti-
activated caspase-3 antibody (1:500; Cell Signaling) was detected with an anti-rabbit Alexa-Fluor 594 
secondary antibody (1:20,000; Invitrogen) to visualize apoptotic cells. Fluorescence microscopy and 
image acquisition were performed using a Zeiss LSM 510 META inverted confocal microscope with 
Zeiss ZEN 2009 software. 
 
8.2.6     Statistical analysis 
All data are expressed as mean ± SEM. Statistical significance was assessed using a one-way ANOVA 
with a Tukey’s post-hoc test unless indicated otherwise. The level of significance was set at p<0.05. 
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8.3     Results 
 
8.3.1     NGF mediates better survival in Neurobasal and B-27 supplemented media 
In this study we aimed to establish an in vitro assay that models BDNF-mediated apoptosis of 
sympathetic SCG neurons while in the presence of NGF observed in vivo. We therefore first established 
the rates of neuronal survival of dissociated SCG neurons cultured for 48 hours in the presence of 0.1, 
1 or 10 ng/ml of NGF in each of six different media. Neurons were counted 2 h after plating, giving 
them sufficient time to adhere, and counted again 48 hours later to determine the percentage neuronal 
survival. Greater than 75% survival of neurons was observed in all media containing 10 ng/ml of NGF 
after 48 hours of culture, except for neurons cultured in DMEM with 1% Monomed in which less than 
35% of neurons were viable (Figure 8.1E). Greater than 75% survival of neurons was also observed 
when cultured in 1 ng/ml of NGF in three media: RPMI with 10% FBS, Neurobasal supplemented 
with 1% B-27 and Neurobasal supplemented with 0.2% B-27. Survival of between 25-50% of 
sympathetic neurons was seen at this NGF concentration in the other three media. The majority of 
neurons cultured in 0.1 ng/ml of NGF died within 24 hours regardless of media composition (Figure 
8.1A-H).  
 
In order to determine the proportion of neurons that die by a method other than cell counts we 
measured neuronal viability using the acid phosphatase enzymatic assay. We used RPMI medium 
supplemented with 10% FBS as a representative of serum-containing media and Neurobasal medium 
with 0.2% B-27 neuronal supplement as a representative of serum-free media due to their robust 
survival under a range of NGF concentrations. For both media, the greatest rate of neuronal survival 
was observed at 10 ng/ml of NGF, followed by 1 ng/ml of NGF then the lowest rate of survival was 
seen in neurons cultured in 0.1 ng/ml of NGF (Figure 8.1G, H). Thus the percent survival of neurons 
measured by acid phosphatase assay mirrored the survival of neurons cultured in the same conditions 
but determined by cell counting, therefore confirming the validity of our cell count methods. 
 
8.3.2     BDNF-mediated death in the presence of NGF is optimal in Neurobasal with 0.2% B-27 
Next we determined whether BDNF could induce death of cultured SCG neurons in the different 
media in the presence of optimal NGF. Dissociated SCGs were cultured in the four media in which 
>75% neuronal survival was observed when cultured in 10 ng/ml of NGF, except for Neurobasal with 
1% N2. These media are: RPMI with 10% FBS, Neurobasal with 1% B-27, Neurobasal with 0.2% B-
27 and DMEM with 1% Monomed and 1% FBS (Figure 8.2C-F). SCG neurons were cultured in 10 
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Figure 8.1     Quantification of NGF mediated survival in dissociated SCG cultures in various 
compositions of media 
Graph showing percentage survival of neurons after 48 hours culture with 0.1, 1 or 10 ng/ml of NGF 
and cultured in (A) RPMI with 10% FBS, (B) Neurobasal with 1% N2, (C) Neurobasal with 1% B-27, 
(D) Neurobasal with 0.2% B-27, (E) DMEM with 1% Monomed or (F) DMEM with 1% Monomed 
and 1% FBS. Graph of acid phosphatase quantification of neuronal survival after treatment of neurons 
with 0.1, 1 or 10 ng/ml of NGF for 48 hours in (G) RPMI with 10% FBS or (H) Neurobasal with 
0.2% B-27. Number of experiments per condition is noted on each graph bar. Values are mean ± SEM; 
one-way ANOVA with Tukeys post-hoc. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. O.D, 
optical density. 
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ng/ml of NGF and one of the four media for 48 hours, which allowed the neurons to develop neuritic 
connections with neighboring neurons. Cultures were then treated with 0, 50, 100 or 200 ng/ml of 
BDNF in fresh media containing 10 ng/ml of NGF. In media in which neuronal death was observed 
24 hours later, neurons exposed to BDNF began contracting and fragmenting their neurites after 12 
hours (Figure 8.2A, B). Viable neurons were counted before and after treatment with BDNF to 
calculate the percent neuronal survival. 
 
No change in neuronal survival was observed in RPMI with 10% FBS and Neurobasal with 1% B-27 
after 24 hours of treatment with BDNF, compared to when cultured in NGF only (Figure 8.2C, D). 
In contrast, rates of neuronal survival were significantly reduced in cultures treated with 100 or 200 
ng/ml of BDNF while in the presence of 10 ng/ml of NGF in both Neurobasal media with 0.2% B-27 
and DMEM supplemented with 1% Monomed and 1% FBS  (Figure 8.2E, F). No effect on neuronal 
survival was observed when treated with 50 ng/ml of BDNF in Neurobasal with 0.2% B-27, however 
neuronal survival was reduced to less than 15% when cultured in 100 and 200 ng/ml of BDNF for 24 
hours (Figure 8.2E). While BDNF induced neuronal death in DMEM with 1% Monomed and 1% 
FBS, the rate of neuronal death was not high as in Neurobasal supplemented with 0.2% B-27. 56% 
and 37% of neurons remained viable after 24 hours when cultured in 100 and 200 ng/ml of BDNF, 
respectively (Figure 8.2F). These findings indicate that Neurobasal media with 0.2% B-27 is a suitable 
media for NGF-mediated survival and BDNF-induced death of cultured sympathetic SCG neurons. 
 
8.3.3     Activated caspase-3 is visible in the cell at 12 and 24 hours post BDNF 
To determine whether BDNF-induces death via apoptotic mechanisms in cultured SCG neurons we 
used activated caspase-3 immunohistochemistry as a marker of apoptosis. Sympathetic neurons were 
grown for 48 hours in NGF and then switched to a BDNF-containing media. Double-labeled 
immunohistochemistry for the neuronal marker bIII-tubulin and activated caspase-3 was used and 
compared to control conditions that were not cultured in BDNF. We observed significant activated 
caspase-3 immuno-staining present in neurons 12 and 24 hours following treatment with BDNF 
(Figure 8.3A-C). Immunoreactivity of the active caspase-3 antibody was present in the neuronal soma, 
as well as extensive distribution throughout the neurites of dying neurons. 
 
8.3.4     Non-neuronal cell contamination is less in SCG cultures grown in Neurobasal media 
with B-27 supplement 
To explain why BDNF-induced death of neurons did not occur when cultured in RPMI supplemented 
with 10% FBS we hypothesized that serum-containing media may support increased numbers of non-
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Figure 8.2     BDNF-induced death in the presence of NGF 
Photomicrographs of cultured sympathetic neurons under phase-contrast (magnification at 20x) before 
(A), and 24 hours after (B), BDNF in Neurobasal medium with 0.2% B-27 neuronal supplement. 
Graphs representing % survival of neurons after a 48 hour incubation in 10 ng/ml of NGF followed by 
24 hours in 10 ng/ml of NGF and 0, 50, 100 or 200 ng/ml of BDNF. Cultured in (C) RPMI with 
10% FBS, (D) Neurobasal with 1% B-27, (E) Neurobasal with 0.2% B-27 or (F) DMEM with 1% 
Monomed and 1% FBS. Number of experiments per condition is noted on each graph bar. Values are 
mean ± SEM; one-way ANOVA with Tukeys post-hoc. *=p<0.05, **=p<0.01, ***=p<0.001.  
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Figure 8.3     Immunofluorescence staining of βIII-tubulin and cleaved caspase-3 in dissociated 
SCG neurons 
(A) before and (B) 12 or (C) 24 hours after exposure to 100 ng/ml of BDNF. Neurons were cultured 
for 48 hours in 10 ng/ml of NGF and Neurobasal with 0.2% B-27 neuronal supplement prior to 
BDNF treatment. 
Cleaved Caspase-3ßIII-Tubulin Merge
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neuronal cells and thus SCG neurons may receive additional trophic support from these cells. 
Therefore, to determine if serum-containing media had an effect on the number of non-neuronal cells 
in our cultures, dissociated SCG neurons were grown for two days in 10 ng/ml of NGF and our 
representative serum and serum-free media; RPMI with 10% FBS and Neurobasal media with 0.2% B-
27 neuronal supplement, respectively. We then counted cells with non-neuronal cell morphological 
features under a phase contrast microscope and expressed them as a percentage of non-neuronal cells 
out of a total cell count. We found greater non-neuronal cell numbers (10.5 ± 2.3%, n=5; Figure 
8.4A) in SCG neuron cultures grown in RPMI and 10% FBS, compared to those cultured in 
Neurobasal with 0.2% B-27 supplement (4.1 ± 1.1%, n=4), despite both media containing the anti-
mitotic agents 5-FDU and Uridine. This suggests that BDNF-induced death in serum-containing 
cultures may be mitigated by increased numbers of non-neuronal cells providing additional trophic 
support to SCG neurons. 
 
8.3.5     BDNF-induced death does not occur in immature SCG cultures 
To determine if there was a neuronal culture maturity-dependent factor in BDNF-induced neuronal 
death in SCG cultures, we added BDNF to immature cultures grown for less than two hours. 
Dissociated SCG neuron cultures were plated at 0DIV and immediately exposed to 10 ng/ml of NGF 
and 0, 50, 100 or 200 ng/ml of BDNF in Neurobasal medium supplemented with 0.2% B-27 neuronal 
supplement. BDNF-induced death of these immature cultures did not occur despite a range of 
concentrations (Figure 8.4B) and in contrast to its effects in more established cultures grown under the 
same media conditions. Indeed, freshly isolated neurons in the presence of BDNF proceeded to develop 
healthy neurites and morphology identical to neurons not exposed to BDNF (Figure 8.4C, D). This 
observation suggests that there is a time- and maturity-dependent component in the ability of BDNF to 
promote death of sympathetic neurons in vitro. 
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Figure 8.4     Non-neuronal cell presence in sympathetic neuron cultures in serum-containing 
and serum-free media 
(A) Graph depicting the % of non-neuronal cells in dissociated SCGs cultures grown in RPMI with 
10% FBS or Neurobasal with 0.2% B27 for 48 hours. Unpaired two-tailed t-test. (B) BDNF-induced 
neuronal death in immature sympathetic neuron cultures. Graph of the % survival of dissociated SCG 
neurons after 24 hours of 10 ng/ml of NGF and 0, 50, 100 or 200 ng/ml of BDNF treatment to 
neurons cultured for less than 2 hours. Photomicrographs of cultured sympathetic neurons under 
phase-contrast (magnification at 20x) 24 hours after culture in (C) 10 ng/ml of NGF treatment and 
(D) 10 ng/ml of NGF and 100 ng/ml of BDNF in Neurobasal medium with 0.2% B-27 neuronal 
supplement. Values are mean ± SEM; one-way ANOVA with Tukeys post-hoc. *=p<0.05, **=p<0.01, 
***=p<0.001, ****=p<0.0001. 	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8.4     Discussion 
 
Here we have identified a serum-free media in which the addition of BDNF to NGF sustained cultures, 
results in the majority of neurons dying within 24 hours. As these culture conditions mimic in vivo 
programmed cell death, they provide a defined paradigm for the further study of underlying survival 
and death signals. We have standardized a method for culturing dissociated, NGF-dependent 
sympathetic neurons in defined serum-free media and can induce robust BDNF-mediated apoptosis in 
these neurons, mimicking the in vivo scenario. Such conditions provide a paradigm for the study of 
competing survival and death signals, with minimal interference from undefined growth factors 
contained in media types supplemented with serum.  
 
In this study, we compared NGF-mediated survival in various media types, both serum-supplemented 
and serum-free, that are commonly used to culture sympathetic neurons isolated from SCG. We found 
that NGF-mediated survival of sympathetic neurons is optimal in Neurobasal medium with B-27 
neuronal supplement. Survival rates for media types supplemented with serum enabled maximal 
survival and were comparable to rates of survival mediated by 10-50 ng/ml of NGF reported in other 
studies (Belliveau et al., 1997, Aloyz et al., 1998a, Bamji et al., 1998, Kohn et al., 1999, Majdan et al., 
2001, Palmada et al., 2002b). However, only media containing 10% FBS or serum-free media 
supplemented with B-27 were capable of maintaining the survival of sympathetic neurons above 75% 
in 1 ng/ml NGF, in agreement with Deppmann et al., (2008), but an NGF concentration considered 
sub-optimal in other reports (Aloyz et al., 1998a, Bamji et al., 1998, Majdan et al., 2001). This 
indicates that serum-free media supplemented with at least 0.2% B-27 is sufficient to provide ideal 
culture conditions for studying NGF-dependent survival of SCG neurons. Moreover, Neurobasal 
medium and B-27 neuronal supplement are both widely accessible and easily used, we believe that it 
should be the standard media used for investigation of neurotrophin signalling in sympathetic neurons.  
 
BDNF-induced death of sympathetic neurons is an important developmental process resulting in 
apoptosis of about 50% of neurons in vivo (Oppenheim, 1991, Bamji et al., 1998). In this study, we 
demonstrate that induction of BDNF-mediated death in the presence of optimal NGF concentration 
(10 ng/ml) occurs in serum-free media supplemented with 0.2% B-27, but not 1% B-27 or 10% FBS 
media. This is consistent with previous reports that in serum-supplemented media, 100 ng/ml of 
BDNF is unable to induce death when optimal NGF is present (Bamji et al., 1998, Kohn et al., 1999). 
Hence, past studies that report BDNF-mediated cell death of SCG neurons have required one of two 
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culture conditions for BDNF-induced neuronal death to occur: a reduction of NGF concentration to 
suboptimal concentrations, or complete removal of NGF followed by a switch to a KCl containing 
medium to mediate survival through chronic depolarization (Aloyz et al., 1998b, Bamji et al., 1998, 
Palmada et al., 2002a, Kenchappa et al., 2006, Deppmann et al., 2008). Reduction or removal of NGF 
is unnecessary under our culture conditions, which suggests that BDNF-mediated cell death might be 
inhibited by the presence of factors within the serum.  
 
The number of non-neuronal cells found in culture may be a factor in why BDNF-induced neuronal 
death is variable across cultures conditions as they may be providing an additional source of trophic 
support for cultured sympathetic neurons. We found that a serum-containing culture (RPMI 
supplemented with 10% FBS) contains more non-neuronal cells than our defined serum-free culture 
(Neurobasal medium with 0.2% B-27 neuronal supplement). This is consistent with previous studies 
that report a decrease in non-neuronal cells when grown in a serum free environment, compared to one 
containing serum (Bottenstein et al., 1980, Ahmed et al., 1983). Therefore, as non-neuronal cell 
numbers are reduced under serum-free conditions, cultured neurons may be receiving less trophic 
support from these support cells and are more likely to undergo apoptosis when treated with BDNF.  
 
As previously reported, BDNF-induced death of sympathetic neurons has required either a reduction of 
NGF concentration, or complete removal of NGF followed by a switch to a KCl containing medium to 
mediate survival through chronic depolarization (Bamji et al., 1998, Kenchappa et al., 2006). KCl 
administration mimics the effects of naturally occurring electrical activity in neurons (Franklin and 
Johnson, 1992, Franklin et al., 1995), however we have previously shown that potassium efflux is 
induced and required for rapid apoptosis induced by p75NTR  (Coulson 2008). This death-signalling 
pathway is active even in optimal growth factor signalling conditions but is inhibited by high 
extracellular KCl, which prevents potassium efflux along its concentration gradient (Coulson et al., 
Underwood et al., 2008). Thus we suggest that KCl-mediated survival in sympathetic neurons is an 
inappropriate method to sustain survival in SCG cultures. 
 
Finally, to determine if there was a neuronal culture-maturity dependent factor in BDNF-induced cell 
death, we treated immature cultures (<2 hours in culture) with NGF and BDNF. Under these 
conditions, the sympathetic neurons attached and extended neurites over 24 hours in the same manner 
as neurons plated in NGF only. We found that BDNF was not able to induce apoptosis in these 
immature cultures as there was no difference in survival rates when treated with NGF and BDNF, 
compared to NGF alone. This observation supports previous studies showing that BDNF-p75NTR 
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ligand-receptor complexes necessary for death signalling require axonal retrograde transport (Hibbert et 
al., 2006). These signalling complexes may not be not be found in our immature cultures as neurons 
may not have yet established the required neurite connections for retrograde transport. Interestingly, a 
previous study reported that the apoptotic signalling induced by BDNF via p75NTR was generated at the 
cell body in compartmentalized SCG neurons (Deppmann et al., 2008). Future comparison of receptor 
expression levels and locations between culture conditions permissive for and resistant to BDNF-
induced apoptosis may reveal new molecular mechanisms that control competition between BDNF and 
NGF in SCG neurons. 
 
In conclusion, we recommend that Neurobasal media supplemented with 0.2% B-27 is an ideal serum-
free culture condition to be used as a standardized method for growing dissociated SCG neurons in 
optimal NGF concentration, such that treatment with BDNF causes robust apoptosis, mimicking the 
in vivo scenario of programmed cell death in development. 
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